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Abstract 
This dissertation covers a variety of the genetic and molecular abnormalities of lung adenocarcinoma 
with an emphasis on STK11 loss and its implications on immunotherapy response.  Given that lung 
cancer is the leading cancer killer, novel therapies are in great demand.  In particular, immunotherapy 
has shown some of the most promise in the last decade but remains limited due to nearly 80% of 
patients not significantly responding.  This dissertation aims to molecularly characterize lung 
adenocarcinoma while attempting to explain the reason why patients with STK11 loss do not respond to 
immunotherapy. 
In the first chapter we discuss the relationship between ancestry and mutational frequency in lung 
adenocarcinoma.  We performed next generation sequencing on over 100 tumors from Hispanic 
patients.  From whole blood, we calculated ancestry using a panel of single nucleotide polymorphisms. 
Our analysis revealed that Indigenous American ancestry is highly associated with an increased rate of 
EGFR mutations despite smoking status.  Further studies will be needed to determine whether this 
change in frequency can be attributed to the environment or if polymorphisms associated with this 
ancestry can predispose patients to the acquisition of lung cancers driven by EGFR. 
Chapter 2 is focused on the classification and characterization of patients with mutations in STK11. First, 
we developed a novel signature for the prediction of STK11 loss of function in lung adenocarcinoma 
patients.  We further describe the inverse relationship of the polyamine pathway with gene expression 
markers of immune response suggesting that polyamines may be the result of immune suppression in 
patients with STK11 loss of function.  Finally, using LC-MS we show that patients with loss of function in 
STK11 upregulate putrescine and GABA amongst other metabolites.  This reveals that not only do 
xii 
 
patients upregulate genes regulating polyamine metabolism (ODC1) but that the metabolites 
downstream of its control are upregulated.  These data also suggest a non-canonical utilization of 
putrescine for the synthesis of GABA.  
Chapter 3 highlights the limitations of studying STK11 loss in vitro through its impact on cell lineage 
identity.  We reveal that cell line, mouse models, and patient derived xenografts of STK11 loss 
unanimously lose their marker of cell lineage (NKX2-1).  In addition to this loss in cell lineage, a small 
subset of patient tumors that lose NKX2-1 also lose hallmarks of immune modulation through 
inflammatory signaling and polyamine metabolism.  These patient tumors that lack NKX2-1 have similar 
genetic changes as ex vivo models of STK11 loss suggesting that we are not accurately studying STK11 
loss as it occurs in a majority of patients.   
Chapter 4 is a description of in vitro experiments performed using cell lines with a small report of in vivo 
biomarkers of STK11 loss.  We restore STK11 expression in 3 cell lines lacking STK11 function: A549, 
NCIH1437, and NCIH1944.  We confirm that the addition of STK11 to these cell lines did not alter ODC1 
expression or other patient specific biomarkers of STK11 loss. We further attempted to recapture the 
patient tumor phenotype of STK11 loss through the modification of metabolic stress.  Other 
experiments focused on sensitivities or resistance as a result of STK11 loss.  We conclude by displaying 
that KIT can be used as a biomarker for STK11 loss in vivo. 
Chapter 5 is a molecular characterization of lung adenocarcinoma.  We performed untargeted LC-MS on 
123 patients from our MLOS cohort for proteins and metabolites.  We analyzed the relationship 
between networks of protein, metabolite, and gene expression. We then molecularly characterized this 
cohort by mutations in STK11, EGFR, KRAS, TP53, and KEAP in addition to by two immune signatures for 
inflammatory and interferon gamma response.  Finally, using the overall survival data in this cohort we 
xiii 
 
identified novel metabolite, protein, and gene expression networks that can be used in patient 
prognosis.
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Introduction 
 
Lung Cancer Epidemiology and Statistics  
As of 2018, lung cancer is the leading killer amongst all cancer types and the second most commonly 
occurring [1] (Figure I.1). Global estimates of lung cancer cases in 2012 were over 1.8 million new cases 
year and 1.6 million deaths in the same year, increasing from 1.6 million cases and 1.4 million deaths in 
2009.  In 2018 in the United States it is estimated that 234,030 people will be diagnosed, 121,680 men 
and 112,350 women.  In the same year it is estimated to account for 25% of all cancer related deaths 
and has one of the worst survival rates.  5-year overall survival for all combined stages increased only 
from 12% in 1975 to 18% in 2003.  Advanced stages have a 5-year survival of roughly 5% [2].  These data 
highlight the importance and urgency for the discovery of novel therapies for the treatment of this 
malignancy.  
Lung cancer is more commonly associated with old age with the median diagnosis for both men and 
women being 70 years of age [1, 2]. Only 10 percent of lung cancer diagnoses are found in patients of 
less than 55 years and are likely attributed to genetic predisposition [1, 2].  Data suggests that non-
smoking related cases of cancer are elevated in woman compared to men, with women harboring 
significantly higher rates of EGFR mutations [3, 4].  Tobacco smoke is by far the greatest single risk factor 
for lung cancer with over 90% of all lung cancers being caused by smoking.  
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Figure I.1 Cancer incidence and mortality by gender 
Lung Pathological and Molecular classification 
Pathologic diagnosis is of great importance for proper cancer treatment and care.  Histological subtyping 
allows for more personalized treatment through the classification of lung cancer into distinct subtypes 
based upon their cell of origin.  Our increase in knowledge about these subtypes has given insight into 
the prognosis, genetic drivers, and likelihood of various treatment responses.  Lung cancer histological 
subtypes include adenocarcinoma, squamous cell carcinoma, small cell carcinoma, and large cell 
carcinoma [1]. The first tier of lung cancer classification divides lung cancer into either non-small cell or 
small cell, with non-small cell encompassing squamous, adenocarcinoma, and large cell carcinoma [5].  
The most common subtype of lung cancer is adenocarcinoma, comprising roughly 40% of all lung 
cancers.  Squamous cell carcinoma makes up roughly 30% followed by small cell and large cell carcinoma 
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at 15% and 5% respectively (Figure I.2).  To further the complexity of this classification even further, 
each histological subtyping of lung cancer can be classified by driver mutations or pathway aberration. 
 
Figure I.2 Frequency of pathological subtypes of lung cancer 
Adenocarcinoma 
Lung Adenocarcinoma is the most commonly occurring histological subtype of lung cancer, and even 
more enriched in frequency among non-smokers [6, 7].  The cell of origin of lung adenocarcinoma is the 
type II pneumocyte or alveolar type II cell [8, 9]. These cells are responsible for mediating gas exchange 
and response to lung injury through the secretion of pulmonary surfactants.  Pathologically they are 
characterized by having high expression of the marker NKX2-1 also known as thyroid transcription factor 
1 (TTF1).  Similarly to squamous cell carcinoma the most commonly occurring mutation is TP53 at a rate 
of 65%. However, unlike squamous cell cancers most tumors harbor mutations at high frequency in 
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oncogenic drivers KRAS (35%) or EGFR (25%) with KRAS being most common amongst smokers and EGFR 
most common amongst non-smokers [10].  Other mutations in tumor suppressors such as STK11 also 
occur at a high rate of 30% and KEAP1 (20%).  Most patients have a mutation in one of the preceding 
genes, making lung adenocarcinoma more readily classifiable, but nonetheless a challenging one to 
treat. Targeted molecular therapy exists for mutations in EGFR but other mutations have proven to be 
much less actionable [11, 12].  There have been several attempts at targeted therapy for KRAS pathway 
activation [13-15]. Increased understanding into these genetic drivers of cancer initiation and 
progression will be crucial in increasing patient survival. 
Squamous cell carcinoma 
Squamous cell carcinoma is characterized by the expression of cytokeratins and formation of keratin 
pearls [1]. Most commonly associated with being a central lung tumor, these cells have basal like 
properties and commonly express the genetic markers TP63, KRT5, and SOX2 [16].  The most commonly 
occurring somatic mutation in squamous cell carcinoma is the tumor suppressor TP53 which occurs at a 
frequency of 65%. DNA level amplifications are seen in genes: FGFR1, SOX, PIK3CA, MDM2, PDGFRA, and 
MET. Other important somatic mutations that occur at a  1-10% frequency include: MDM2, PDGFRA, 
MET, NRF2, PTEN, EPHA2, STK11, AKT, EGFR, DDR2, and PTEN [17].   Due to the fact that many different 
mutations occur at low frequency in squamous cell carcinoma, it is much more difficult to classify these 
tumors into straightforward treatment regimes, as in the case adenocarcinoma.  However, attempts 
have relied on the utilization of gene expression as a representation of downstream signaling in order to 
target pathways rather than specific somatic mutations [17, 18].   
Small Cell Carcinoma 
Small cell carcinoma is an extremely aggressive cancer accounting for roughly 15% of all lung cancers.  5-
year overall survival is between 5% and 8% [1].  These cells are also thought to originate from 
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neuroendocrine cells.  The most common genetic alterations occur in TP53, RB1, PTEN, and many others 
[19].  This histology is often associated with MYC activation, and expresses master regulators ASCL1 and 
NEUROD1.  
Large Cell Carcinoma  
Large cell carcinoma is the rarest subtype found at a frequency of roughly 5% of all lung cancers.  Large 
cell carcinoma is most commonly diagnosed when no other diagnosis can be made [1].  A subset of large 
cell carcinomas is classified as large cell neuroendocrine carcinoma, and arises from neuroendocrine 
cells.  In general, not as much is known about this subtype of lung cancer. 
Alveolar type I and II pneumocytes 
Type I pneumocytes (ATI) also populate the lung, but they are not capable of self-replication as they lack 
cellular organelles. They represent roughly 8% of the total cells by number, yet make up almost 90-95% 
of the lung surface. Type II pneumocytes (ATII) on the other hand, comprise only 5% of the lung alveolar 
surface but 15% of the total cell number [9].  These cells are both functionally and metabolically 
differentiated epithelium. It has been noted that dedifferentiation and loss of the ATII phenotype to an 
ATI phenotype has occurred when studied in vitro [9, 20].  This provides a severe limitation to the study 
of relevant lung biology, especially in the context of oncology [20].  
The ATII cell lineage gives rise to lung adenocarcinoma and are characterized by the expression of (TTF1 
or NKX2-1) [21].  These cells have unique metabolic characteristics, as they produce and secrete lipid 
surfactants, mediate the innate immunity, and control inflammation and repair of the lung [8].   
Surfactants (gene symbols SFTP A-D) allow for low surface tension and optimal gas exchange in the lung, 
and have been shown to mediate inflammation and fight infection in the lung.  In response to infection 
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ATII cells can secrete cytokines and chemokines capable of recruiting and activating immune cells such 
as IL1, TNF, IL-6, CXCL1, CXCL5, CXCL8, and even type I interferons.  
NKX2-1 
The NKX2-1 transcription factor is a lineage distinguishing biomarker of lung adenocarcinoma[21].  Much 
controversy surrounds this gene as it has been described as both an oncogene and tumor suppressor 
dependent upon context [22, 23]. A publication highlighted the ability of NKX2-1 to function as a 
repressor of malignant progression in KRAS/TP53 double mutant mouse models [24]. Mutations in 
NKX2-1 result in a condition known as brain-lung-thyroid disease, a rare familial disorder descriptive of 
the organs in which NKX2-1 expression is abundant [25].  Patients with this condition have learning 
difficulty, psychosis, chorea, dystonia, and developmental delay.    
NKX2-1 in the lung 
In the lung, NKX2-1 has been shown to regulate the transcription of pulmonary surfactants [26].  Other 
studies have displayed the duality of NKX2-1 to regulate inflammatory signaling through NF-kappaB in a 
TP53 dependent manner [27]. Further, NKX2-1 has a role in repressing latent gastric differentiation in 
lung adenocarcinoma, suggesting that the lung lies further down the embryonic lineage tree from the 
gastric endoderm [28].  These gastric enzymes were regulated by the transcription factors FOXA1 and 
FOXA2 in the absence of NKX2-1, as NKX2-1 is a repressor to their functionality [29].  Other studies have 
elucidated NKX2-1’s role in determining the shape of the immune microenvironment through the 
balance of the expression of SOX2 and NKX2-1 in lung cells [30]. 
Neuroendocrine cells 
Neuroendocrine cells are a very rare and innervated epithelial cell type. In fact, they are the only 
innervated cell type in the lung airway, and release a number of neuropeptides, amines, and 
neurotransmitters in response to changes in oxygen availability and other stimuli [31].  They often are 
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found in clusters rather than single cell populations called neuroepithelial bodies [32].  Several diseases 
have been linked to aberration in these cell types such as: chronic obstructive pulmonary disease, cystic 
fibrosis, and asthma [33, 34].  Neuroendocrine cells upregulate calcitonin related gene peptides such as 
CALCA and can have significant impact on immune cell recruitment and function. In fact, these cell types 
have been described as rheostats of the airway, capable of translating environmental stimulus into 
immune responses.    
Immunotherapy 
Immunotherapy has shown some of the most promising results in modern day cancer therapy, 
increasing the survival rate of a number of different cancers [35].  Given the high mutation burden and 
subsequently high quantity of neo-antigens in lung cancer, immunotherapy has shown efficacy in this 
cancer type. However, this efficacy remains limited, as only 20% of all patients respond [36, 37]. The 
main function of immunotherapy is to activate an otherwise anergic immune response, often an end 
product of a tumors adaptive ability to evade the immune system.  Mechanistically-informed 
immunotherapy focuses on inactivation of either inhibitory receptors on the immune cells, or inhibitor 
ligands on the tumor.  The most common receptor-ligand pairs that are inactivated include CTLA4, which 
binds the CD80 costimulatory receptor, or programmed cell death receptor/ligand PD-1/PD-L1 [38] 
(Figure I.3).  Anti PD-1 therapeutic antibodies include Nivolumab and Pembrolizumab, while anti PD-L1 
antibodies include Durvalumab, Atezolizumab, and Avelumab.  These receptors are most commonly 
found of CD8+ cytotoxic T lymphocytes, which are attributed to having the largest anti-tumor immune 
response. While some tumors overexpress inhibitory ligands, others find novel ways of evading the 
immune response by undiscovered mechanisms.  Source for figure below explaining T-cell activation and 
suppression [37]. 
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Figure I.3 T-cell activation and effector function suppression through PD-1 and PD-L1 
STK11 Function 
STK11 (serine threonine kinase 11), also known as LKB1 (liver kinase B1), is located on the p13 arm of 
chromosome 19. STK11 forms a complex with two additional proteins: STRAD and MO25, who when 
bound, re-localize from the nucleus to the cytoplasm [39]. The two most common histological subtypes 
for STK11 mutations are large cell neuroendocrine carcinoma and lung adenocarcinoma, both with a 
frequency of around 30% of tumors [40]. STK11 is most commonly known for its kinase activity and 
ability to phosphorylate and activate AMPK [41].  In addition to its role in the phosphorylation of AMPK, 
it has also been shown to activate over 14 other downstream kinases.  Previously, STK11 has been linked 
to the regulation of cell polarity [42], metabolic response [43, 44] , methylation [45], apoptosis [46], and 
metastatic potential .  Only recently has STK11 been found to be associated with a decrease in immune 
infiltration and response to immunotherapy [47-49].  Interestingly, mutations in STK11 occur in other 
cancers such as ovarian, breast, skin, and gastrointestinal but none of them occur at rates exceeding 5%. 
Even amongst lung cancers it is only lung adenocarcinoma and neuroendocrine large cell carcinoma with 
mutation rates above 5% frequency. This strongly suggests that there is a favorable selective pressure 
for STK11 loss in cells that give rise to these cell lineages.   
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Figure I.4 STK11 function and signaling 
Heterozygous loss of STK11 also gives rise to a condition known as Peutz-Jeghers syndrome (PJS) [50, 
51].  Interestingly, those affected by this condition are likely to develop hamartomatous polyps in the 
gastrointestinal tract.  In addition to GI polyps, children will often develop dark colored spots on the lips 
and inner mouth.  People with heterozygous loss of STK11 are also at a much greater risk of cancer.   
Genetically, mutations in STK11 have significant co-occurrence with mutations in KRAS (Kirstein Rat 
Sarcoma viral oncogene) and KEAP1 (Kelch like ECH associated protein).  KRAS is an oncogene capable of 
constitutively activating MYC and proliferative signaling [52-54]. KEAP1 functions as a binding partner to 
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NRF2 and serves as a repressor of NRF2 nuclear localization and transcriptional activity [55, 56]. NRF2 
transcription results in activation of the oxidative stress response.  Additionally, STK11 has been shown 
to serve as a suppressor of MYC activity [57-60]. Activation of KRAS with loss of STK11 could potentially 
result in the synergistic upregulation of MYC.    
STK11 and metabolic control 
STK11 functions as a mediator of metabolic stress through the activation and phosphorylation of (AMP 
active protein kinase) AMPK [44]. Reduced energy availability shifts the balance of this signaling 
pathway through an increase in AMP/ATP ratio.  Activation of AMPK results in the induction of 
autophagy and energy sensing pathways, inhibiting Mechanistic Target of Rapamycin mTOR (Figure I.4).  
These two pathways shift metabolic signaling between catabolic (AMPK) and anabolic (mTOR).  
Deficiency in STK11 allows tumors to eliminate stress signaling and allow for more rapid, anabolic 
growth even under periods of limited nutrient availability. Additionally, during periods of prolonged 
starvation or autophagic signaling, apoptotic signaling can occur [43]. Other studies have focused on 
STK11’s ability to upregulate carbamoyl phosphate synthetase 1 (CPS1), the first rate limiting step of the 
urea cycle [61, 62].  CPS1 knockdown resulted in reduced growth and nucleic acid biosynthesis, 
suggesting alterative mechanisms of biomass generation during metabolic stress.  STK11 deficiency has 
also been linked to glutamine addiction, one of the most abundant amino acids [44, 63, 64].  STK11 loss 
of function may allow for a shift in energy utilization while sequestering growth inhibitory signaling that 
would normally be the result of metabolic stress. 
STK11 and immune suppression  
Perhaps the most recently discovered impact of STK11 loss lies in its relationship to the immune system.  
Patient tumors harboring a mutation in STK11 have been shown to have significantly reduced levels of 
PD-L1 [47, 65]. Gene expression studies have also elucidated a decrease in inflammatory and interferon 
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related signaling.  Additionally, these same tumors also have shown reductions in T-cell lineage markers 
through gene expression and immunohistochemistry, specifically in the CD4+ helper and CD8+ cytotoxic 
subtypes [53, 66]. Taken together, this suggests that PD-L1 is absent in these tumors due to an 
alternative evasion of the immune response by way of cytotoxic immune cell recruitment.  Not only do 
these tumors show a decrease in immune response but they also show little to no response to 
immunotherapy [48, 49]. Novel therapies for the molecular targeting of tumors with STK11 loss is of 
great need, especially in the context of the reactivation of the immune response.  The direct cause of 
STK11 mediated immune suppression remains to be known. 
STK11, NKX2-1, and their impact on differentiation through TP53 
Mechanistic studies have revealed that STK11 is directly upregulated through TP53 signaling mediated 
by NKX2-1[67].  However, in cells with mutated TP53 the opposite was true. In this context, STK11 was 
downregulated by NKX2-1 through the inhibition of SP1 binding to the STK11 promoter. This highlights 
the intricate role that TP53 signaling plays in the cross talk between NKX2-1 and STK11.  Prognosis of 
patients in TP53 wildtype tumors was worse for low NKX2-1/low STK11 compared to high NKX2-1/high 
STK11.  In patients with TP53 mutant tumors, worse prognosis was for patients with high NKX2-1/low 
STK11 compared to low NKX2-1/high STK11.  This suggests the intricate role and cross talk of STK11 in 
the context of TP53 function and cell lineage transcription factor NKX2-1. 
Polyamines 
Polyamines are positively charged organic compounds that contain more than two amino groups [68].  
Found in all forms of life, they are known to bind to DNA and impact a number of cellular processes such 
as transcription, translation, autophagy, oxidative stress, and inflammation [69-72].  Due to this, they 
are one of the most delicately and intricately regulated of all mammalian pathways and their regulatory 
genes have transcriptional and translational half lives in the range of 10-30 minutes.  In fact, ODC1 is 
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regulated through the complex balance of antizymes and antizyme inhibitors, which target ODC1 for 
degradation through the 26S proteasome.  Additionally, they have also been known to play a role in ion 
channel regulation and synaptic transmission through the NMDA and AMPA receptors.  In addition to 
their neurological role they have also been known to protect the cell in periods of oxidative stress by 
serving as scavengers of reactive oxygen species.  The rate limiting step of polyamine synthesis is also 
the first one and is accomplished through the decarboxylation of ornithine to putrescine by ODC1 
(ornithine decarboxylase) (Figure I.5).  Interestingly, just as KRAS activation and STK11 loss activate MYC, 
ODC1 is a key transcriptional target of MYC [73, 74]. Putrescine is further converted to spermidine by 
spermidine synthase (SRM) and spermidine to spermine by spermine synthase (SMS). An irreversible 
inhibitor of ODC1 has been developed called difluoromethylornithine (DFMO) and functions as an 
inhibitor of polyamine synthesis [68, 75-78]. The polyamine pathway has been strongly linked to 
immune suppression and its inhibition through DFMO has been shown to reverse this phenotype [79, 
80].  
 
Figure I.5 Polyamine pathway 
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Polyamines play a large role in translation, through the regulation of it comes as no surprise that they 
are an integral part of methionine salvage, the amino acid responsible for translational initiation.  
Through S-adenosyl-L-methionine (SAM), both spermidine and spermine are given an aminopropyl 
group through putrescine and spermidine respectively [81, 82]. SAM is largely responsible for serving as 
a methyl donor and alterations in its abundance can impact epigenetic control through DNA, histone, 
and protein methylation [83, 84]. 
Nitrogen metabolism, vitamin B6 (pyridoxal), and the urea cycle 
As the most abundant gas in our atmosphere, nitrogen plays a large role in life and especially cancer 
[85].  It is involved in nearly every aspect of biology from the synthesis of nucleic acids to amino acids. 
However, the simplest form of nitrogen is ammonia and is very toxic, especially neurologically.  Taking 
place in the liver, the urea cycle, processes ammonia and excretes it in the form of urea [86] (Figure I.6).  
Primarily, excess ammonia is formed through the utilization of amino acids as energy substrates through 
the removal of an amino group, leaving the remaining carbon backbone.  Mostly all deamination 
(removal of amino group) and transamination (transfer of amino group) reactions require vitamin B6 
(pyridoxal) as a cofactor [87].  The transfer of amino acids is catalyzed by enzymes such as alanine 
aminotransferase GPT2 and ornithine aminotransferase OAT, which help generate glutamine from 
alanine and ornithine respectively. Several enzymes play a role in the urea cycle including: arginase 
(ARG1), ornithine transcarbamylase (OTC), carbamoyl-phosphate synthase 1 (CPS1), argininosuccinate 
synthase (ASS1), and argininosuccinate lyase (ASL) [88, 89]. The first step of the urea cycle is rate-
limiting and involves the incorporation of ammonia and bicarbonate to form carbamoyl phosphate and 
is catalyzed by CPS1. The next step involves combining carbamoyl phosphate and ornithine to form 
citrulline through OTC. Citrulline then reacts with aspartate to form argininosuccinate by ASS1. 
Argininosuccinate is then converted to arginine through ASL. Finally, a hydrolysis of arginine forms urea 
and ornithine through ARG1. 
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Figure I.6 Urea and TCA cycle 
Figure from NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue 
syndrome  [90] 
GABA’s background, function, and impact on immune response 
GABA function 
GABA (gamma-amino butyric acid), is an inhibitory neurotransmitter in the brain [91].  It is essential for 
normal brain function, information processing, and even in disease response.  Medications that act on 
GABA mediated pathways help to treat withdrawals symptoms, epilepsy, anxiety, and even to induce 
sedation.  It has also been shown to protect neurons during strokes, or acute hypoxia.  In addition to 
GABA’s role in neurobiology it has also been shown to impact inflammatory response [92].  In fact, 
GABAergic agents have been shown to directly impact the function of antigen presenting cells [91, 93]. 
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Interestingly, GABAergic activity has been linked to cyclic AMP dependent signal transduction pathways 
in addition to calcium signaling [94]. GABA receptor activation also reduces cyclic AMP dependent 
phosphorylation of STK11 and impacts neuronal polarization [95].  Additionally, GABA treatment on 
CD4+ T-cells caused a decrease in proliferation, and inhibited the secretion of over 37 cytokines in a 
dose dependent manner [96, 97]. 
GABA’s synthesis from putrescine and succinate production 
In addition to GABA’s role in neurotransmission and immunomodulation, it is most commonly known for 
its synthesis from glutamate by the enzyme glutamate decarboxylase (GAD1).  However, less known 
synthesis of GABA involves the oxidation of either putrescine or n-acetyl putrescine through diamine 
oxidase (DAO) or monoamine oxidase (MAOA) respectively [98, 99].   This intermediary step produces 
GABA-aldehyde or n-acetyl GABA-aldehyde and through aldehyde dehydrogenases (ALDH3A2) can 
further be converted to GABA (Figure I.7).  The final step in the utilization of GABA involves the 
aminotransferase reaction of GABA to form succinic semi-aldehyde by the enzyme GABA amino 
transferase (GABAT).  The last step involves succinic acid semi-aldehyde dehydrogenase to form succinic 
acid, to be further used in the TCA cycle [100, 101]. 
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Figure I.7 GABA synthesis from polyamine and recycling through succinate 
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Chapter 1: Somatic Mutations and Ancestry Markers  
in Hispanic Lung Cancer Patients 
Abstract 
To address the lack of genomic data from Hispanic/Latino patients with lung cancer, the Latino Lung 
Cancer Registry was established to collect patient data and biospecimens from these patients. This 
retrospective observational study examined lung cancer tumor samples from 163 Hispanic/Latino 
patients, and tumor-derived DNA was subjected to targeted-exome sequencing (>1000 genes, including 
EGFR, KRAS, STK11, and TP53) and ancestry analysis. Mutation frequencies in this Hispanic/Latino cohort 
were compared with those in a similar cohort of non-Hispanic white (NHW) patients and were 
correlated with ancestry, sex, smoking status, and tumor histology. Among adenocarcinomas (n=120) in 
the Hispanic/Latino cohort, 31% had EGFR mutations, versus 17% in the NHW control group (p < 0.001). 
KRAS (20% vs. 38%; p=0.002) and STK11 (8% vs. 16%; p=0.065) mutations occurred at lower frequency, 
and mutations in TP53 occurred at similar frequency (46% vs. 40%; p=0.355) in Hispanic/Latino and 
NHW patients, respectively. Within the Hispanic cohort, ancestry influenced the rate of TP53 mutations 
(p=0.009) and may influence the rate of EGFR, KRAS, and STK11 mutations.  Driver mutations in 
Hispanic/Latino lung adenocarcinoma patients differ in frequency from those in NHWs   associated with 
their Indigenous American ancestry. The spectrum of driver mutations needs to be further assessed in 
the Hispanic/Latino population. 
Introduction 
The US Census Bureau projects that the US Hispanic/Latino (H/L) population will reach 119 million by 
2060.[102] However, H/Ls represent only 3% of patients characterized in the Cancer Genome Atlas and 
Indigenous Americans represent less than 0.5%.[103]  Since precision medicine is driven by data that 
18 
 
primarily represents non-Hispanic white (NHW) patients, there is a significant potential health disparity 
for under-represented groups. [104-107] Non-small cell lung cancer (NSCLC), is the leading cause of 
cancer death among H/L men and second only to breast cancer in H/L women.[104]  In NHW individuals, 
half of NSCLC cases have been shown to possess at least one of several known driver mutations, 
including alterations in KRAS, EGFR, MET, HER2, BRAF, PIK3CA, AKT1, MAP2K1, ALK, and MEK.[108]  
African Americans demonstrate a similar frequency of these mutations. [109] The frequency of EGFR 
mutations has been extensively studied for some groups and determined to be approximately 30% for 
Asian, 15% for NHW, and 19% to 21% for African American populations.[106, 110] Studies in H/L 
individuals have indicated an elevated frequency of EGFR mutations relative to NHWs. [111, 112] Other 
common mutations in lung cancer among H/Ls have not been investigated.[113, 114]  To address the 
lack of molecular data for H/Ls, our group established the Latino Lung Cancer Registry. We describe here 
our initial characterization of 163 H/L lung cancer patients. 
Results 
Patient Characteristics 
Table 1.1 summarizes the demographics of the overall cohort and by site of collection. The most 
common histology in the cohort was adenocarcinoma (120 [74%]) followed by squamous cell 
carcinomas (27 [17%]). Known females (78) out-numbered known males (66), and never-smokers (45) 
represented 36% of those with known smoking status. We subjected available samples to AIM analysis 
to define the relative contributions of European, African American, and Indigenous American ancestries 
in the cohort and in each individual patient. Overall, the cohort was primarily European (67%), followed 
by Indigenous American (21%), and then African ancestry (12%). African ancestry was enriched in the 
Puerto Rican sub-cohort, and Indigenous American ancestry was enriched in the group from Perú. 
Table 1.1 Demographics of the Cohorts, Combined and Individual Results 
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Demographic 
Total Patients (N = 
163)  
Moffitt Cohort        (N = 
93)  
PR Cohort (N= 
46)  
Perú 
Cohort  
(N = 24) 
 No. %  No. %  No. %  No. % 
Histology            
  Adenocarcinoma 120 74  65 70  31 67  24 100 
  Squamous cell 
carcinoma 27 17  15 16  12 26  0 0 
  Other* 16 10  13 14  3 7  0 0 
            
Sex            
  Male 66 46  35 38  20 63  11 58 
  Female 78 54  58 62  12 38  8 42 
  Unknown 19 NA  0 NA  14 NA  5 NA 
            
Smoking            
  Ever 80 64  60 66  17 81  3 23 
  Never 45 36  31 34  4 19  10 77 
  Unknown 38 NA  2 NA  25 NA  11 NA 
            
Ancestry            
  % European  67   79   64   63 
  % African  12   10   22   6 
  % Indigenous 
American  21   11   14   31 
*The Moffitt cohort includes 7 carcinoids; 3 non-small cell lung carcinomas, not otherwise specified; 2 
large cell carcinomas; and 1 adenosquamous carcinoma. The Puerto Rico (PR) cohort contains 3 
carcinomas, not otherwise specified, and 1 non-small cell lung carcinomas, not otherwise specified.  
NA, not available 
  
 
Prevalence of Somatic Mutations  
Figure 1.1A presents the mutation frequency in the four most common drivers in lung adenocarcinoma 
in NHWs. Within the adenocarcinoma histology, 37 (31%) had one or more EGFR variants and 17 (14%) 
had KRAS variants.  This analysis also showed a trend toward reduced rates in STK11 mutations 
(p=0.065). The mutation rate of TP53 was indistinguishable (p=0.717) between H/Ls (49%) and NHWs 
(46%).   
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The relation between driver mutations and patient characteristics was also explored. Figure 1.1B 
presents the mutation rates of EGFR, KRAS, STK11, and TP53 in male and female patients in each group. 
Notably the rate of EGFR mutations was nearly 50% in Hispanic females. Mutations in KRAS and STK11 
were reduced in Hispanic females and to a lesser extent in Hispanic males. The rate of TP53 mutations 
was similar between male and female patients.  Figure 1.1C presents a comparison between ever and 
never-smokers among H/L and NHW patients. Mutation rates in KRAS and STK11 were much higher in 
smokers for both H/L and NHW cohorts.  In fact, no STK11 mutations were observed in the 45 H/L never-
smokers. In NHWs, EGFR mutations were four times more common in never-smokers. In the H/L cohort, 
this effect was much smaller. Mutations in TP53 were not strongly associated with smoking in either 
cohort. Finally, mutations were examined as a function of smoking by sex.  Although the numbers are 
too small for statistical significance, Figure 1.1D reveals that EGFR mutations in males in the H/L cohort 
were reduced in smokers, but there was no difference detected in female smokers vs non-smokers. In 
contrast, a similar analysis in NHWs (Figure 1.1E) shows a clear increase in EGFR mutations in both male 
and female non-smokers.   
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Figure 1.1 Mutational frequency of the Hispanic cohort with respect to gender and smoking 
(A) Mutation rate comparison between 75 H/L lung adenocarcinomas and 748 NHW. Histograms of the 
4 most common mutations in NHW adenocarcinomas as indicated as percent patients with any detected 
variant. Number of mutants or number in cohort is indicated above histograms. All significantly different 
rates are indicated by Fisher exact test p values: *p <0.05, **p <0.01, ***p <0.001 (B) Mutation rate 
comparison between males/females and H/Ls/NHWs. Same analysis as in panel A, except H/Ls and 
NHWs were divided into male and females. (C) Mutation rate comparison between H/L (and NHW) ever 
and never-smokers. Although statistically insignificant, trend suggests that EGFR mutations are seen 
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more commonly in non-smokers, whereas KRAS and STK11 are more frequently mutated in smokers. 
(D) Mutation rate comparison between H/L males/females and ever/never-smokers. Although 
statistically insignificant, trend suggests that EGFR mutations are seen more commonly in non-smokers, 
whereas KRASand STK11 are more frequently mutated in smokers. (E) Mutation rate comparison 
between NHW males/females and ever/never-smokers. 
EGFR mutations are associated with Indigenous American ancestry 
In general, H/L individuals are characterized by a wide mixture of ancestries. Therefore, to explore the 
role that ancestry may play in mutation frequency in the H/L cohort, the Ward linkage method was used 
to separate the cohort into three ancestral clusters (Figure 1.2A). The mutation frequency of various 
genes was then compared between the three clusters. Figure 1.2B reveals that EGFR mutations were 
more common in the Indigenous America cluster but appear identical in the European and African 
clusters. In contrast, TP53 mutations were much less common in the Indigenous American cluster, 
whereas the frequency of TP53 mutations appeared identical in European and African clusters. KRAS 
mutations were shown to be rare in the African cluster, and STK11 mutations were rare in both the 
African and Indigenous American clusters, relative to the European cluster.  
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Figure 1.2 Mutational rate comparison by ancestry 
(A) The Ward linkage method and Euclidean distance metric were used cluster H/L patients by ancestry. 
The clusters were classified as follows: 1) Indigenous American (green cluster), 2) African (red and left 
blue cluster), 3) European (right blue cluster). (B) Mutation rate comparison between 3 ancestral 
clusters. Mutation rates of 4 common drivers within the 3 ancestral clusters reveal a statistically 
significant difference between TP53 mutations between Indigenous American and European (p=0.0087) 
and Indigenous American and African ancestral clusters (p=0.011). The same comparison for EGFR has 
a p value of 0.058 and 0.072, respectively.  
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Discussion 
In previous reports, EGFR exhibited a higher rate of mutation and KRAS was suggested to have a lower 
mutation rate in H/L patients compared with NHW patients.[104, 105, 111, 115] The data presented 
here confirm these observations overall. Among the 120 H/L adenocarcinomas that we analyzed, 37 
(31%) had EGFR mutations, compared with 17% in our TCC NHW cohort, and 17 H/L patients (14%) had 
KRAS mutations. In a published NHW cohort, 11% of lung adenocarcinomas had EGFR mutations and 
35% had KRAS mutations.[116] In addition, our data suggest that the elevation in EGFR mutations within 
our H/L cohort is driven by females, with 48% having EGFR mutations (Figure 1.1B). Our data also 
suggest altered mutation rates for other genes commonly mutated in NSCLC. Among adenocarcinoma 
patients, the frequency of KRAS and STK11 mutations were reduced in H/L patients relative to NHW 
patients.   
Smoking is the primary driver of mutations in lung cancer.  The overall percentage of non-smokers in the 
H/L cohort was 36%. In comparison, a NHW cohort showed 9% non-smokers[116] and The Cancer 
Genome Atlas lung adenocarcinoma cohort showed 7% non-smokers. Nonetheless, H/L individuals 
appear to have a similar pattern as observed in NHWs for STK11 and KRAS in that mutations in both 
genes increases with smoking in both groups (Figure 1.1C). Unlike NHWs, mutations in TP53 occurred 
with nearly equal frequency in both smoking groups in the H/L cohort and the inverse correlation 
between smoking and EGFR mutations was dampened in H/L patients. These results suggest that 
smoking status was not the primary factor explaining the high rate of EGFR mutations in H/L patients. 
The observation that KRAS and STK11 mutations are elevated in H/L smokers addresses the objection 
that H/L ever-smokers are lighter smokers than NHW individuals. There may be differences in how 
smoking influences the mutations observed in men versus women (Figure 1.1D-E). However, drawing 
this conclusion firmly will require a larger dataset.  
Finally, the role that ancestry might play in this cohort was examined by clustering patients into 
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ancestral groups based on AIM analyses (Figure 1.2A). Whereas the analysis is only statistically 
significant for the TP53 mutations, the data (Figure 1.2B) suggest that, relative to European ancestry, 
Indigenous American ancestry correlates with low rates of TP53 and STK11 mutations and high rates of 
EGFR mutations and African ancestry correlates to low rates of KRAS mutations. At this point, our 
dataset is too small to make claims with respect other mutations that are even less common than these 
four. 
There are a few notable study limitations worth addressing. One of the most significant was the lack of 
matched normal samples for each of the sequenced tumors. Likewise, we utilized various sources of 
tissue and various sequencing technologies than should considered interpreting these data. Other 
limitations include incomplete clinical data for several samples in our cohort that affected our ability to 
determine statistical significance and lack of age, tumor stage and outcome data.  Future studies will be 
necessary to provide statistical power for additional comparisons. Nonetheless, this study is the first 
addressing the lack of comprehensive genomic data in H/L lung cancer patients.  The data suggest that 
EGFR mutations in H/L lung adenocarcinoma patients are associated with their Indigenous American 
ancestry. 
Materials and Methods 
Patients and Tissues 
Three tissue sources contributed to this study (Table 1.1). Patient sex, smoking status, and tumor 
histology were collected from patient medical records, as available.  Patient age, tumor stage and 
outcome were not available for enough of the patients for analysis.  DNA sequencing and ancestry 
analysis were performed on as many samples as possible; however, DNA was limiting in some cases.  
Statistical comparisons were made on the largest subgroups possible, as indicated within each Figure or 
Table. Tissue samples designated “Moffitt” were acquired from patients diagnosed primarily with NSCLC 
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who consented to Moffitt Cancer Center’s Total Cancer CareTM (TCC) program between April 2006 and 
August 2010. The University of South Florida (Protocols 00001222 and 00011723) Institutional Review 
Board approved this study. Tissue samples designated “Puerto Rico” were acquired through the Puerto 
Rico Bio-Bank. The Ponce Health Sciences University (Protocol 080121-IF) Institutional Review Board 
approved this study. Tissue samples designated “Perú” were from untreated patients diagnosed with 
lung adenocarcinoma who had surgery during the years 2013- 2014 in Lima, Perú, where institutional 
approval was obtained locally for the collection of tumor blocks and clinical data.   
DNA isolation 
 TCCTM-provided DNAs were extracted from fresh-frozen macro-dissected tumor tissues using Qiagen 
DNeasy Blood & Tissue Kits according to the methods and consent protocols, previously described.[117]  
DNA samples acquired through the Puerto Rico BioBank (PRBB) originated from lung biopsies in the 
form of fine-needle aspiration collected in PAXgene Tissue Containers (Qiagen) or were from archived 
tissue blocks.  Samples from Perú were all from archived tissue blocks.  Candidate tissue blocks were cut, 
H&E-stained, and reviewed by the tissue procurement core pathologist to verify the diagnosis, histology, 
and the amount of tumor present.  Tumor margins were marked and each tumor specimen was excised 
in Moffitt’s Tissue Core Facility.  DNA quantity and quality were assessed using a Qubit and Tape Station, 
respectively.  
DNA sequencing 
Sequencing information across exons of 1,321 genes for an initial 28 H/Ls samples was obtained via our 
TCCTM institutional sequencing protocol.[117]  Subsequently, another 76 samples were subjected to a 
targeted Agilent panel matching the original 1321 genes of the TCCTM protocol.  Another 11 samples 
were subjected to an Illumina whole-exome sequencing panel. The processed sequencing reads were 
analyzed on Moffitt’s cluster.  Alignment and refinement was performed using BWA [118] and PICARD 
(http://picard.sourceforge.net/) against reference hs37d5 and variant calling was done using GATK 
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[119]through a BASH pipeline. The VCF file was annotated with ANNOVAR [120]and read and exported 
using Varsifter 1.8[121].  Heterozygous or homozygous variants were exported only if they resulted in a 
change in protein sequence.  Synonymous and intronic mutations were excluded from analysis.  
Additionally, since matching normal DNA samples were not available for many of the tumor samples, 25 
unmatched normal samples from healthy Puerto Rican blood donors were sequenced and used to filter 
the sequenced tumors.  Any mutation occurring in the normal samples was removed.  Quality filters 
were applied and any variant call with a VSQR Tranche score from 99.90-100.00 was removed.  To 
further account for unmatched normal samples and eliminate false positive mutation calls the Broad 
Institute EXAC database of SNP’s was downloaded. The EXAC database provides variant call frequency 
by global population frequency (AF_GLOBAL) and maximum frequency in any ethnic subpopulation 
(AF_POPMAX).  Any variant call from our cohort that exceeded a 1% AF_GLOBAL or AF_POPMAX 
frequency was removed.  Finally, to account for batch effects of multiple sequencing types, identical 
nucleotide variants that were associated with a single sequencing run and at a frequency greater than 
that of the most common canonical mutation were excluded. 
Global ancestry estimations 
A set of 106 single nucleotide polymorphisms (SNPs) that discriminate Indigenous American, African, 
and European ancestry was used to estimate the proportion of genetic ancestry. The SNPs were chosen 
to maximize information for more than one ancestral population pairing, with a large difference in allele 
frequency between ancestral populations.  They are widely spaced throughout the genome and have a 
well-balanced distribution across all 22 autosomal chromosomes. Genotyping was performed using a 
multiplex PCR coupled with single base extension methodology with allele calls using a Sequenom 
analyzer. The AIMs panel and reference populations have been described previously.[122] For each 
sample, genetic ancestry was estimated using ADMIXTURE[123]. 
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Chapter 2: Immune suppression in STK11 loss of function lung adenocarcinoma is associated with non-
canonical polyamine metabolism 
 
Abstract 
Purpose:  STK11 (LKB1) mutations are common in lung adenocarcinoma.  Recent studies demonstrate 
that immunotherapies that block programmed cell death 1 (PD-1) function are very unlikely to benefit 
patients with loss of STK11.  We sought to identify targetable STK11-mediated metabolic pathways that 
account for the lack of immune response.  
Experimental Design:  We utilized two previously described cohorts, TCGA and our own MLOS cohort, 
representing approximately 1,000 lung adenocarcinoma patients, with available mutation, gene 
expression and protein expression data, to identify metabolic pathways strongly associated with STK11 
loss.   We then subjected 126 tumors from our MLOS cohort to liquid chromatography-mass 
spectrometry (LC-MS) to validate our predictions.   
Results: Multiple gene-set enrichment analyses reveal patient tumors with predicted loss of STK11 
upregulate amino acid catabolism, the urea cycle, and polyamine synthesis.  ODC1 (ornithine 
decarboxylase 1), the rate limiting step in polyamine biosynthesis, was identified as one of the strongest 
genes associated with STK11 loss. ODC1 over expression in STK11 loss tumors was unique to human 
samples and not significantly associated with STK11 loss in commonly-used cell line, mouse, or patient-
derived xenograft models.   Untargeted LS-MS metabolomics validate the predictions based on 
gene/protein expression, demonstrating that tumors with loss of STK11 function have increased 
production of putrescine, gamma-aminobutyric acid (GABA), and pyridoxal with decreases in ornithine 
and histamine.   
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Conclusion:  These data suggest a non-canonical and neuroendocrine-like utilization of putrescine for 
GABA production, leading in turn to immune suppression.   We predict that inhibition of this ODC1-
driven pathway could restore immunotherapeutic efficacy in an otherwise unresponsive cohort.    
Introduction 
In the current age of cancer therapeutics, immunotherapy has given us significant strides towards 
increased progression free survival and even permanent remission in a small percentage of patients. 
Some of the best responses to immunotherapy have been seen in subsets of immunogenic cancers such 
as melanoma and lung cancer.  However, despite successful treatments, the response rate rarely 
exceeds 25% [36, 37]. Prediction of the patients who will benefit from immunotherapy through clinical 
biomarkers is one hurdle to overcome.  Perhaps the most difficult challenge is unraveling the 
mechanisms underlying immunocompromised non-responders [35, 38]. Increased understanding of 
these adaptations will pave the way for better personalized combination therapy. 
STK11, also known as LKB1, is a well-established mediator of stress and has been shown to be mutated 
in roughly 18% of all lung adenocarcinomas (LUAD), the most incident histology of all lung cancer [10].  
Patients harboring tumors deficient in STK11 signaling have been shown to have a reduction in the 
infiltration of cytotoxic T-cells and respond poorly to anti PD-L1 therapy [47-49, 52, 53].  Functionally, 
STK11 lies downstream of PKC (protein kinase C) and upstream of AMPK and is responsible for 
phosphorylating ~14 kinases in response to alterations in cellular energy homeostasis [40, 124]. In times 
of metabolic stress, or a high cAMP/ATP ratio, STK11 phosphorylates AMPK resulting in activation of 
catabolic pathways over anabolic ones.  This molecular switch has been displayed by the role of STK11 
on mTOR inhibition and autophagy induction.  Changes in the functional status of STK11 have been 
linked to alterations of methylation, metabolism, cellular polarity, differentiation, and apoptosis [41, 42, 
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44, 46, 67, 125].  While much is known about STK11’s role in metabolism, it is unclear at this point, what 
role altered metabolism plays in tumor suppression, particularly in regard to immune evasion.   
In this study, we use gene and protein expression data on nearly 1000 lung adenocarcinoma patients to 
identify potential metabolic alterations associated with STK11 loss of function that could explain its 
immune suppressed microenvironment.  These analyses identified ornithine decarboxylase 1, which 
converts ornithine to putrescine and is the first step in polyamine biosynthesis, as one of the most 
upregulated genes in STK11 loss tumors.   Polyamines are found in nearly every life form and are 
thought to be one of the most intricately regulated aspects of biology.  They are essential for cell 
proliferation and are known to bind DNA and minimally regulate both transcription and translation [73].  
Furthermore, polyamine upregulation has been shown to cause immunosuppression and inhibition of 
their synthesis has been shown to alleviate this phenotype [70, 71, 79, 80].  Interestingly, this 
upregulation did not occur in cell lines, mouse or patient-derived xenograft models, limiting our ability 
to validate upregulation of polyamines in STK11-loss tumors experimentally.  To circumvent this 
limitation, we obtained fresh frozen tissue from 126 lung adenocarcinoma patients and subjected them 
to liquid-chromatography-mass spectrometry to measure the levels of polyamines and other 
metabolites in tumors.   As predicted, we find that tumors with loss of STK11 function have increased 
levels of putrescine and decreased levels of its precursor ornithine. 
Results 
Gene expression patterns of STK11 mutants by DNA-sequencing 
According to TCGA’s pan-cancer study, DNA mutations of STK11 are most commonly found in large cell 
neuroendocrine lung tumors at a rate of 33% followed by LUADs at 18% (Figure 2.1).  Previously, we and 
others have reported gene expression-based classifiers that can distinguish STK11 mutated tumors from 
those with wildtype STK11 [53, 126-128]. In the present work, we extend this gene expression analysis 
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to in vivo data.  First, we sought to characterize similarities between RNA expression changes in two well 
annotated LUAD datasets: TCGA (N=515) and Moffitt’s MLOS (N=442) (Figure 2.2A).  Each of these 
datasets contains both DNA sequencing and RNA expression data on the majority of patients. The initial 
test involved determining which patients had a sequenced STK11 mutation in each dataset and 
comparing them to their (wildtype) un-mutated counterpart.  TCGA contained (76) mutant patients by 
DNA-sequencing and (409) confirmed wildtype patients while MLOS contained 68 and 374 respectively 
(Table 2.1).  In each study only the genes changing by at least +/- 1.5 Fold and with a Bonferroni 
corrected p-value of < 1e-10 by student’s t-test was further considered.  TCGA had 64 genes that 
surpassed these criteria and MLOS contained 71 genes. Taken together, 29 genes overlapped and were 
used for gene set enrichment (Figure 2.2B and Table 2.2). Upon closer examination, STK11 mutant 
patients’ tumors show a significant up-regulation of several solute transporters (SLC7A2, SLC14A2, and 
SLC16A4) (Table 2.2). SLC7A2 is known to be responsible for the membrane transport of cationic amino 
acids arginine, lysine, and ornithine.  SLC14A2 is surprisingly responsible for the transport of urea and is 
the end result of nitrogen detoxification.  SLC16A14 (MCT14) is part of the monocarboxylate transporter 
family and has been shown to be highly abundant in both the kidney and central nervous system. This 
family of transporters is known for their transfer of carboxylic acids.   In addition to these family of 
transporters we also observe a consistent upregulation of CPS1 (Carbamoyl-phosphate synthase 1), 
which has previous been associated with pathway disruption of STK11 [61, 62], and ODC1 (ornithine 
decarboxylase), which has not been previously associated with STK11. Taken together, these genes 
cooperate in the regulation of the urea cycle, with CPS1 being responsible for the initial incorporation 
and removal of both ammonia and bicarbonate and ODC1 catalyzing the rate limiting step of polyamine 
biosynthesis from ornithine, another urea cycle intermediate. Genes regulating transport suggest that 
these cells are increasing their flux of the transport of ornithine, arginine, and urea which further point 
to the enrichment of this liver-associated biological pathway.  Using the 29 genes in gene set enrichment 
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analyses (Genemania and mSigDB’s Hallmark datasets described in the Supplementary Materials) 
support the conclusion that the polyamine pathway, highlighted in Figure 2.2C, is dramatically altered in 
STK11 mutant tumors.  
 
Table 2.1 – STK11 mutant statistics and signature prediction 
MLOS WT Sig (N, (%)) Mutant Sig (N, (%)) Total (N, (%)) 
WT DNA 297 (67.2) 77 (17.4) 374 (84.6) 
Mutant DNA 0 (0) 68 (15.4) 68 (15.4) 
Total 297 (67.2) 145 (32.8) 442 (100) 
 
TCGA WT Sig (N, (%)) Mutant Sig (N, (%)) Total (N, (%)) 
WT DNA 314 (61.0) 95 (18.4) 409 (79.4) 
Mutant DNA 4 (0.80) 72 (14.0) 76 (14.8) 
Unknown 19 (3.7) 11 (2.1) 30 (5.8) 
Total 337 (65.5) 178 (34.5) 515 (100) 
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Figure 2.1 STK11 mutations most frequently occur in large cell neuroendocrine carcinoma and lung 
adenocarcinoma  
Cbioportal bargraph representing the detectable STK11 mutation frequency amongst all cancer types, 
with the most frequent histology being large cell neuroendocrine cancers followed by lung 
adenocarcinoma.  
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Figure 2.2 STK11 mutations result in transcriptional changes related to amino acid metabolism 
(a) Introduction of the cohorts we will be using for the duration of the study.  Moffitt’s Lung Overall 
Survival (MLOS) cohort contains 442 patients, with 150 of those patients on a tumor microarray for IHC 
staining, and 126 of those patients were analyzed using LC-MS untargeted metabolomics. TCGA contains 
515 LuAD tumor samples with 360 of those patients having reverse phase protein array (RPPA) data.  
These two cohorts will be used in parallel to confirm our hypotheses.  (b) Venn-Diagram displaying the 
overlap of genes changing as a result of STK11 DNA level mutations in both cohorts.  Using a Bonferroni 
corrected p-value of < 1e-10 and a linear fold change of +/- 1.5, 29 genes were found to be significantly 
altered in both studies. (c) Gene set enrichment utilizing both Genemania and mSigDB’s Hallmark 
datasets suggest disruption of the canonical polyamine metabolism pathway highlighted here. 
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Table 2.2 - STK11 DNA mutation related gene expression changes 
Gene MLOS BF p-
value 
MLOS 
FC 
MLOS 
RANK 
TCGA BF p-
value 
TCGA 
FC 
TCGA 
RANK 
Average 
Rank 
Average 
FC 
LINC00473 3.3E-32 6.70 1 1.56E-29 26.96 1 1.0 16.83 
SLC16A14 1.19E-31 6.06 2 7.95E-24 6.07 3 2.5 6.06 
PDE4D 4.63E-20 2.73 6 2.8E-26 3.74 2 4.0 3.23 
ODC1 1.42E-25 2.62 3 1.49E-20 3.59 7 5.0 3.10 
INHA 1.91E-19 4.34 7 6.59E-23 14.46 4 5.5 9.40 
SLC7A2 1.27E-22 4.50 4 1.92E-20 7.01 8 6.0 5.75 
CPS1 7.06E-19 4.88 9 5.68E-21 28.80 6 7.5 16.84 
SLC14A2 1.85E-22 4.34 5 3.52E-19 12.72 10 7.5 8.53 
DUSP4 4.21E-18 2.94 10 3.71E-18 4.10 11 10.5 3.52 
IRS2 5.08E-16 2.02 16 7.69E-23 3.29 5 10.5 2.65 
FXYD4 1.3E-17 2.41 11 2.22E-16 7.86 15 13.0 5.13 
GLTPD2 2.18E-15 2.21 17 3.96E-18 7.10 12 14.5 4.65 
INSL4 3.22E-17 5.71 14 3.01E-14 9.25 18 16.0 7.48 
BAG1 4.11E-15 1.57 20 3.22E-17 1.89 13 16.5 1.73 
FGL1 2.82E-15 6.73 18 5.32E-15 17.50 16 17.0 12.11 
HAL 6.91E-15 3.79 21 8.55E-17 6.72 14 17.5 5.26 
PPARGC1A 1.86E-16 3.14 15 3.39E-14 5.17 20 17.5 4.16 
KSR1 1.98E-19 1.92 8 2.97E-11 2.12 29 18.5 2.02 
KCNU1 5.36E-11 2.09 29 2.44E-19 4.56 9 19.0 3.32 
GALNTL6 1.85E-17 4.49 12 1.21E-11 3.36 28 20.0 3.93 
EYS 2.01E-17 2.19 13 7.95E-12 3.00 27 20.0 2.60 
CALCA 3.44E-15 7.31 19 7.95E-13 20.24 24 21.5 13.77 
TACC2 2.25E-13 2.18 24 3.18E-14 2.56 19 21.5 2.37 
ADSSL1 2.65E-11 2.06 28 1.96E-14 2.68 17 22.5 2.37 
FURIN 4.85E-14 1.65 22 3.08E-13 2.33 23 22.5 1.99 
AIM1 1.21E-13 -2.08 23 2.5E-13 -2.54 22 22.5 -2.31 
BMP6 5.95E-13 2.70 25 1.97E-13 3.82 21 23.0 3.26 
PDE3A 2.26E-11 2.47 27 8.53E-13 3.92 25 26.0 3.20 
VPS37A 1.2E-12 1.91 26 3.65E-12 1.61 26 26.0 1.76 
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Expansion and classification of patients with STK11 loss 
We hypothesized that DNA sequencing would only reveal a portion of patients with the same phenotype 
of STK11 mediated pathway disruption with chromosomal loss of 19p13, methylation of the STK11 
allele, or alterations in up or downstream pathways accounting for STK11 loss-of-function without 
mutation.  When using our 29-gene signature as a classifier for STK11 status and utilizing principal 
component analysis (PCA) in LUAD patients in both TCGA and the MLOS we discovered that nearly twice 
as many patients have gene expression patterns imitating mutations in STK11 based on the 1st principal 
component (PC1) (Figure 2.3 A-B).  Thus, we derived a signature score based on PC1 coefficients from 
TCGA and MLOS cohorts (Supplementary Methods and Supplementary Table 2.3) to reclassify patient 
STK11 loss with a signature score greater than 0 were classified as mutant and less than 0 were classified 
as wildtype.  Upon reclassification of patients into either mutant-like or wildtype, we analyzed these 
new cohorts for gene expression changes (Figure 2.3 C-D). The volcano plot of genes changing as a result 
of STK11 loss of function reveal far more upregulated genes than downregulated ones.  With many 
patient tumors harboring expression patterns imitating that of an STK11 mutation and representing 
false negatives for detection of an STK11 mutation that were classified into our initial wildtype cohort, 
our first analysis was statistically weakened.  While many of the hallmarks of STK11 pathway disruption 
remained constant in this new analysis, many others now surpassed our threshold of statistical 
significance (Supplemental File 1).  By keeping our threshold of a fold change of +/- 1.5 consistent, we 
increased our Bonferroni corrected p-value to only include genes with a value of less than 1e-15.  Even 
with this increase in stringency we observed statistically relevant changes in 451 genes in TCGA and 165 
genes in the MLOS, with 137 genes overlapping between both of these datasets (Figure 2.4A). All genes 
upon re-classification have much greater statistical significance and fold changes.  It is worth noting that 
the long non-coding RNA annotated as both LINC00473 and C6ORF176 are consistently the best marker 
of STK11 loss of function in both studies [129]. 
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Table 2.3 - STK11 signature gene PCA coefficients 
Gene TCGA PC1 MLOS PC1 Average PC1 
CPS1 0.3739 0.2756 0.3248 
CALCA 0.3737 0.2567 0.3152 
FGL1 0.3470 0.2375 0.2922 
LINC00473 0.3284 0.2099 0.2692 
INSL4 0.2224 0.1950 0.2087 
INHA 0.2620 0.1553 0.2087 
SLC14A2 0.2500 0.1491 0.1995 
SLC7A2 0.2101 0.1646 0.1874 
SLC16A14 0.1811 0.1798 0.1804 
HAL 0.1917 0.1554 0.1736 
PPARGC1A 0.1820 0.1337 0.1579 
DUSP4 0.1519 0.1396 0.1457 
FXYD4 0.2094 0.0820 0.1457 
BMP6 0.1579 0.1235 0.1407 
GLTPD2 0.1768 0.0789 0.1279 
GALNTL6 0.1103 0.1416 0.1259 
KCNU1 0.1529 0.0829 0.1179 
PDE3A 0.1303 0.1033 0.1168 
PDE4D 0.1169 0.1016 0.1092 
ODC1 0.1222 0.0959 0.1090 
IRS2 0.1113 0.0759 0.0936 
EYS 0.1092 0.0681 0.0886 
TACC2 0.0889 0.0770 0.0829 
FURIN 0.0940 0.0564 0.0752 
ADSSL1 0.0743 0.0759 0.0751 
KSR1 0.0771 0.0697 0.0734 
VPS37A 0.0519 0.0706 0.0612 
BAG1 0.0488 0.0431 0.0459 
AIM1 -0.1045 -0.0760 -0.0902 
 
Principal component 1 from both MLOS and TCGA using the 29 consensus genes. 
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Figure 2.3 Generation of a gene expression signature to predict STK11 loss of function in patients 
(a-b) Principal component analysis using the 29 genes from Figure 2.1 in the MLOS (a) and TCGA (b) 
cohorts.  Patients with detected DNA mutations in STK11 are indicated in blue and wildtype in red. (c-d) 
Volcano plot of genes changing between patients with a signature score > 0 (mutant) or < 0 (wildtype) in 
MLOS (c) and TCGA (d).  
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Predicted STK11 loss is associated with changes in nitrogen metabolism and the immune 
microenvironment 
Following expansion of the STK11 pathway disruption signature, GSEA was re-run on the 137 genes.  
This time, MSigDB’s Hallmarks revealed enrichment in Inflammatory Response (FDR = 8.77e-13), 
Interferon Gamma Response (FDR = 8.77e-13), as well as Interferon Alpha Response (FDR = 1.58e-8).  
This result is interesting because it supports the observation that disruption of the STK11 signaling 
pathway with respect to our signature involves an alteration of the inflammatory and immune response 
of the tumor microenvironment (Figure 2.4B).  It is our hypothesis that these changes in the immune 
landscape are influenced by metabolic alterations in the microenvironment resultant of an altered stress 
response. Genemania’s enrichment was in support of this altered immune reactivity with the top 
biological processes being response to virus (FDR = 1.1e-14) and response to type I interferon 
(FDR=9.17e-14) (Supplemental File 2-3). Using our own K-means enrichment algorithm described in 
Materials and Methods, we discovered that gene sets pertaining to amino acid metabolism, polyamine 
metabolism, and the urea cycle were most significantly useful in distinguishing predicted STK11 mutant 
from wildtype tumors (Figure 2.4C).  Altogether, these data suggest that upregulation of amino acid 
catabolism, nitrogen processing through the urea cycle, and polyamine metabolism could be influencing 
the immune silent microenvironment seen in patients with STK11 mediated pathway disruption.   
 
Additionally, we thought it would be interesting to take our STK11 signature and apply it to each cancer 
type in TCGA’s pan-cancer study.  Patients with a high relative STK11 pathway disruption score exist in 
lung adenocarcinoma as shown, but also in cervical cancer, kidney papillary and clear cell carcinoma, 
breast cancer, lung squamous cell carcinoma, stomach adenocarcinoma, and liver hepatocellular 
carcinoma.  Liver has the highest overall signature for STK11 loss than any other cancer by a good 
margin (Figure 2.4D). The liver is a uniquely capable of responding uniquely in times of energy 
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deprivation and utilizing amino acids and fats for energy [86].  It is also the main site of the urea cycle, 
responsible for processing most of the body’s excess nitrogen and excreting it in the form of urea. This 
observation fits the hallmark of STK11 loss very well and helps support this novel role of amino acid 
degradation.  
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Figure 2.4 Gene set enrichment and pathway prediction of STK11 loss 
(a) Venn-Diagram displaying genes changing by a Bonferroni corrected p-value of < 1e-15 and a linear 
fold change of +/- 1.5.  In both TCGA and MLOS there are now 137 genes that overlap.  (b) MsigDB’s 
Hallmark geneset overlap between the 137 genes seen in (a). (c) A novel method of gene set enrichment 
using unsupervised K-means clustering of genesets between patients with predicted STK11 loss of 
function. (d) Application of the STK11 signature to TCGA’s pan-cancer dataset by cancer type. 
 
ODC1 elevation is specific to patient tumors with STK11 loss 
We sought to determine whether elevation of ODC1 could be studied outside the context of patient 
tumors with predicted STK11 loss.  We applied the patient tumor derived STK11 signature to the 
following datasets: cell line datasets (GSE36133 and GSE68950) (Figure 2.5A), patient derived lung 
xenografts (PDX) (GSE78806) (Figure 2.5C), and patient datasets (MLOS and TCGA) (Figure 2.5D).  
Additionally, we characterized the expression of ODC1 in Cre mouse studies of primary tumors between 
KRAS and KRAS/STK11 mice (Figure 2.5B).  Similar to our patient datasets, samples with a signature 
score higher than 0 were considered mutant-like and less than 0 wildtype.  To our surprise, cell line 
datasets (p = 0.443 and 0.843), mouse models (p = 0.753), and PDX models (p=0.165) of STK11 loss 
showed no significant change in ODC1 expression despite ODC1 being a significant driver of the STK11 
signature. These data suggest the limitations of studying this biological mechanism outside of the 
patient setting with further studies being required to elucidate its patient specific conservation.   
Patients with STK11 loss have elevated levels of ODC1 protein  
We have shown that by gene expression ODC1 is significantly elevated in patients with predicted STK11 
loss of function (MLOS p = 1.9e-54 and TCGA p = 1.05e-56) (Figure 2.5D).  In order to validate whether 
or not tumors with STK11 mutations have a detectably higher level of ODC1 activity than WT tumors, we 
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ran a western blot on protein extracts from a dozen patient tumors from the MLOS cohort.  This western 
blot was done on patients with detectable DNA level STK11 mutations and validates that there is a 
strong association between the levels of mRNA and functional protein (Figure 2.5E). Further, we then 
compared ODC1 gene expression and STK11 loss signature score in these patients.   There is a clear 
correlative relationship between the STK11 loss signature, ODC1 protein, and ODC1 gene expression.   
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Figure 2.5 ODC1 elevation is specific to patient tumors 
(a) Boxplot of predicted STK11 mutant (CCLE n=24, GSE68950 n = 14) and WT(CCLE n=50, GSE68950 n = 
24) cells for ODC1. (b) Boxplot of ODC1 expression in primary lung tumors from KRAS (n=9) and 
STK11/KRAS (n=9) transgenic mice in GSE21581. (c) Boxplot of ODC1 expression in human patient 
derived xenograft models from GSE78806 based on predicted STK11 status.  (d) Boxplot of ODC1 
expression between patients with predicted STK11 loss of function and wildtype in MLOS (left) and 
TCGA (right).  (e) Western blot on patient samples based on DNA level detected mutations.   
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STK11 loss is associated with a lack of immune infiltration 
One pattern observed in the subset of patients with STK11 pathway disruption is the inverse relationship 
with immune components and inflammation [53, 65]. We suspect that the lack of immune response is 
supported by the lack of tumor PD-L1 expression because it suggests that the immune evasion is 
through a mechanism independent of PDL-L1 activity.  Several key elements of the immune response 
are notably reduced in STK11 mutant patients such as co-stimulatory molecules CD40 and CD80, antigen 
presentation in the form of MHC class I and II, immuno-inhibitory ligands PD-L1 (CD274), inflammasome 
complex formation through AIM1, and chemotactic recruitment of cytotoxic cells in the form of CX3CL1 
[130-133] (Supplemental File 1). 
 
In order to further validate this observation in coordination with our gene set enrichment results we 
compared PD-L1 abundance (CD274) on both the mRNA and protein level between mutant and wildtype 
STK11 patients.  Patients with an STK11 mutation have significantly lower amounts of PD-L1 mRNA 
(p<1e-12) and protein (p=1.04e-6) (Figure 2.6E).  We believe that this lack of PD-L1 expression is due to 
the lack of T-cell infiltration and immune reactivity.  In order to look more globally at the association 
between inflammation and STK11 status, we clustered lung adenocarcinoma patients by MsigDBs gene 
list for Interferon Signaling titled “REACTOME_INTERFERON_SIGNALING”, containing 159 gene symbols 
validated for this pathway. We used these data as a surrogate marker of immune activation in all LUAD 
patients.  We used K-means clustering to separate both TCGA LUAD (n=515) and MLOS (n=442) into 3 
distinct subpopulations (Interferon low, medium, and high) (Figure 2.6 A-B).  Both TCGA and MLOS 
clustered into similar distributions, with roughly 20% of samples falling into the Interferon Low subset 
(Table 2.4).  We used Fisher’s Exact test to analyze these populations for enrichments in DNA mutations 
(Figure 2.6 A and C). In addition, we applied the STK11 signature to these clusters and there was a 
significant difference between Interferon low and high populations in both TCGA (p=7.37e-33) and 
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MLOS (p=4.06e-33).  STK11 is the leading mutation accounting for the changes in interferon signaling 
and is inversely related to Interferon levels between IFN_Low and IFN_High (p= 4.51E-12) in TCGA and 
between IFN_Low and IFN_High (p= 4.29e-7) in MLOS.  It is interesting that mutations in EGFR and TP53 
both trend in the direction opposite of STK11 mutations.  This outcome is likely due to both of these 
mutations being mutually exclusive with STK11 suggesting preservation of the p16/TP53 signaling 
pathway in patients with STK11 loss as similar seen in large cell neuroendocrine tumors [134].  However, 
we suspect that EGFR is effecting interferon signaling through downstream kinase activity and TP53 is 
increasing neo-antigen levels and that both likely contribute to the increase in inflammatory signaling. 
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Figure 2.6 STK11 loss of function and polyamine metabolism is associated with lack of immune 
infiltration 
 (a, c) K-means clustering was used on mSigDB’s Interferon Geneset (n=159 genes) to cluster patients 
from MLOS (a top) and TCGA (c top) into 3 subsets of varying interferon response. Corresponding DNA 
Mutation rate was calculated by Fishers Exact test between subsets (a, c bottom). (b, d) The STK11 
signature was calculated in these three subsets in MLOS (b) and TCGA (d). (e) CD274  (PD-L1) expression 
was determined in MLOS (far left) TCGA (far right) and paired with IHC data in MLOS and RPPA in TCGA. 
(f, g) Pearson correlation coefficient was plotted between canonical immune markers (CD19, CD274, 
IFNG, PDCD1, CD8A)  and STK11 related biomarkers (ODC1,NKX2-1,KIT)  in MLOS (f) and TCGA (g).  
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Table 2.4 - Interferon gene-set K-means association with STK11 status 
 TCGA (N, (%)) STK11 Mutation % MLOS (N, (%)) STK11 Mutation % 
Low 100 (19.42) 35 87 (19.68) 36 
Mid 212 (41.17) 17 172 (38.91) 13 
High 203 (39.42) 3 183 (41.4) 9 
 
ODC1 and the polyamine pathway is associated with immune suppression 
Polyamines have been studied for decades and recent literature has shown the impact that polyamine 
inhibition can have on reversing tumor-associated immune suppression [70, 71, 79, 80].  In order to 
determine if there was a relationship between ODC1 activity and the loss of PD-1 and PD-L1 observed in 
STK11 mutant patients we looked at the correlation between STK11 relevant genes and common 
immune markers (Figure 2.6 F-G).  In order to answer this question in the appropriate context, only 
patients with predicted STK11 loss of function were used for the correlation, given that we have already 
shown that STK11 loss of function itself is associated with a lack of immune infiltration. By gene 
expression ODC1 has a strong inverse relationship to PD-1(PDCD1), CD8A, and PD-L1 (CD274) (Figure 2.6 
F-G). While correlation does not prove causation, this result is consistent with the relevance of ODC1 
biology to the observed decrease in both cytotoxic T-cell markers and tumor intrinsic immune 
suppression in patients with loss of STK11.  
Increased metabolite production of putrescine and GABA in patients with STK11 loss 
Following our discovery of both elevated ODC1 in patient tumors and its inverse relationship to 
inflammatory signaling, we sought to validate our hypothesis that this elevation was reshaping the 
microenvironment and could potentially explain changes in immune surveillance. In order to accomplish 
this, we subjected 126 patient samples of the TMA150 cohort to untargeted metabolite profiling using 
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LC-MS and generated datasets containing over 6,200 features. Of these features, approximately 250 
were identified by comparison to a library of metabolite standards. Using the STK11 signature in MLOS, 
we looked for differential features and metabolites as a result of predicted STK11 loss of function.  In 
support of our hypothesis, putrescine was one of the most significantly elevated metabolites supporting 
increased ODC1 activity (Figure 2.7A). To our surprise, rather than the canonical downstream 
polyamines spermidine and spermine being elevated, we observed an increase in 4-aminobutanoate, 
also known as gamma-aminobutyric acid (GABA) which had the strongest correlation to putrescine in 
our study (Figure 2.7B).  Additionally the acetylated counterparts of both putrescine and GABA were 
almost equally enriched (Table 2.5).  We also looked at the relationship of ODC1 to Putrescine and 
noticed that there is a significant positive correlation (r = .30, p=.0008) (Figure 2.7C).   
The strong relationship between Putrescine and GABA production in patients with predicted STK11 loss 
of function highlights the observed increase in amino acid catabolism through the deamination of 
putrescine.  The increased level of vitamin B6 (pyridoxal) supports this observation.  Pyridoxal is used as 
a co-factor when amino acids are utilized for energy through deamination or transamination reactions, 
in some cases both releasing ammonia and creating a carbon backbone.  Evidence of this pathway is 
seen by the increase in gene expression of alanine aminotransferase (GPT2), ornithine aminotransferase 
(OAT), and histidine ammonia-lyase (HAL) (Supplemental File 1). Complementing these 
aminotransferase reactions is the increase in urea transport through SLC14A2 and key enzymes of the 
urea cycle, such as CPS1 and ODC1, suggesting the need to release an excess of ammonia.  We 
hypothesize that GABA could potentially be used as a TCA cycle intermediate through conversion to 
succinate as succinic acid is part of the putrescine-GABA co-expression network. (Figure 2.7D). 
We then used Mummichog (http://mummichog.org/index.html) to predict pathway and network 
analysis from m/z values in our metabolomics data (Table 2.6). This software is capable of making 
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multiple calls to indistinguishable m/z values, allowing for the statistical inference of metabolic 
pathways based on enrichment.  When comparing untargeted metabolites between STK11 mutant and 
wildtype patients the most enriched pathway was arginine and proline metabolism (p=0.000945), both 
of which are precursors for the synthesis of ornithine required for polyamine metabolism.  Other 
interesting pathways include fatty acid metabolism (p=0.001832) and the urea cycle (p=0.008426).  
Combined data from the transcriptome, proteome, and metabolome all converge to highlight the 
increase in amino acid catabolism, urea cycle, and polyamine metabolism in patients lacking functional 
STK11. 
Table 2.5 - Metabolites elevated in predicted STK11 mutants 
Study Symbol P-Value Fold Change 
ETHYLMALONIC ACID(-) 4.87E-08 2.01 
4-ACETAMIDOBUTANOATE(-) 3.13E-07 2.18 
4-ACETAMIDOBUTANOATE(+) 5.65E-07 1.93 
PUTRESCINE(+) 6.90E-07 2.28 
4-AMINOBUTANOATE(+) 2.11E-06 1.81 
N-ACETYLPUTRESCINE(+) 3.33E-05 2.18 
 
Table 2.6 - Enriched pathways in predicted STK11 mutants through use of Mummichog 
Pathway Overlap Size Pathway Size P-Value 
Arginine and Proline Metabolism 19 35 0.000945 
Carnitine shuttle 13 21 0.000959 
Fatty acid activation 9 17 0.001832 
Lysine metabolism 12 27 0.002657 
Drug metabolism - other enzymes 8 16 0.002891 
Aspartate and asparagine metabolism 25 67 0.003461 
Tryptophan metabolism 23 62 0.004141 
Glycerophospholipid metabolism 17 44 0.004313 
Limonene and pinene degradation 4 6 0.004526 
Beta-Alanine metabolism 6 12 0.005374 
Vitamin B3 (nicotinate and nicotinamide) metabolism 9 21 0.00567 
De novo fatty acid biosynthesis 9 21 0.00567 
Valine, leucine and isoleucine degradation 12 31 0.007426 
Urea cycle/amino group metabolism 17 47 0.008426 
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Figure 2.7 Putrescine and GABA are elevated in patients with STK11 loss of function. 
 (a) Volcano plot of average peak heights of annotated metabolites in STK11 mutants compared to 
wildtype (left) and unannotated metabolites (right). (b) Correlation matrix displaying Pearson 
correlation coefficient between metabolites significantly altered in STK11 mutants. (c) Plotted 
correlation between ODC1 gene expression and linear peak height of Putrescine. (d) Schematic 
representing the potential mechanism by which STK11 mutants alter the GABA-Putrescine metabolic 
pathway. 
 
Discussion 
Here we provide an in vivo signature for functional loss of STK11, useful in the classification of patients.  
We believe that the evidence provided has shown that patients with loss of STK11 have elevated levels 
of ODC1 both gene and protein leading to increased production of putrescine, the product of ODC1 
activity.  It has been established that ODC1 is a target of MYC [58-60, 135]and previous literature has 
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shown that STK11 is a repressor of MYC activity.  We believe that loss of STK11 takes the brakes off of 
MYC and could be the mechanism behind the observed increase in polyamine synthesis.  Given the 
immunosuppressive nature of both MYC-driven cancers and polyamine synthesis, we believe that 
targeted inhibition of this pathway in combination with anti-PD-1/PD-L1 immunotherapy would increase 
survival in patients with loss of STK11 function.   ODC1 is targetable through the FDA approved drug 
DFMO (Difluromethylornithine), which acts as an irreversible inhibitor of ODC1 [68, 77, 78, 136]. Until 
now, DFMO has not been considered a treatment strategy for lung cancer, as it is most commonly 
associated with MYC/MYCN driven diseases such as prostate cancer or neuroblastoma respectively [68, 
78].  Taking the above mentioned associations into consideration, STK11 mutant tumors not only 
overexpress the MYC target ODC1, but also inhibition of this pathway with DFMO could be used to 
partially reverse the immunosuppressive characteristics as well as result in metabolic disruption and 
growth arrest. Unique to this cell lineage however, polyamine synthesis appears to be shunted towards 
GABA production rather than downstream polyamines spermidine and spermine.  In support of this 
observation, ornithine and urea transport is also transcriptionally upregulated in patients with loss of 
STK11 function through genes SLC7A2 and SLC14A2 respectively. 
Loss of STK11 greatly impacts cell lineage [137] and in a future publication we will discuss in further 
detail the difficulty in studying changes in STK11 mediated metabolism outside the patient setting 
(Figure 2.5)  Very clearly, STK11 mutations are associated with both the neuroendocrine and 
adenocarcinoma lineage; a majority of STK11 mutant lung adenocarcinomas mimic the large cell 
neuroendocrine characteristics of co-occurring KRAS and KEAP1 mutations, MYCN amplification, and 
expression of ASCL1 [134].  Therefore, these two cell types may share common genetic machinery that 
sets the stage for a unique metabolic phenotype resulting from STK11 loss.  Our data suggest that this 
loss results in synthesis and accumulation of the neurotransmitter, GABA, and its precursor putrescine, 
which fits the neuroendocrine cell fate [98, 99, 138]. Additionally, NKX2-1 positive type II pneumocytes, 
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which give rise to lung adenocarcinoma, contain the enzymes required for this conversion [8, 9, 20].  
Monoamine oxidase is required for the conversion of putrescine to GABA-aldehyde and ALDH3A2 is 
required for the conversion of GABA-aldehyde to GABA, both of which correlate with ODC1, putrescine, 
and GABA.  We hypothesize that GABA might be acting to depolarize immune cells along with the other 
immunosuppressive intermediates downstream of the polyamine pathway [91, 93, 96].  In addition, we 
believe that GABA can also be used as an energy substrate of the TCA cycle through GABA’s conversion 
to succinate through GABA-amino transferase, limited by the enzyme GABAT [100].  Notably, pyridoxal 
(vitamin B6) is required as a co-factor for nearly every transamination or deamination reaction and even 
for decarboxylation.  The increase in pyridoxal seen in this subset of patients only further supports this 
hypothesis.  It is worth noting that the conversion of GABA to succinate bypasses two NAD+ to NADH 
steps of the TCA cycle, isocitrate to alpha-ketoglutarate and alpha-ketoglutarate to succinate.  This 
observation could potentially guide us to metabolic vulnerabilities in STK11 deficient patients.   
 A difficulty of this study is that our pathway of interest has been shown to be one of the most intricately 
regulated of all human pathways with transcriptional and translational half-lives in the range of 5-30 
minutes [68, 69, 72, 75].  Additionally, ODC1 and polyamine metabolism does not appear to be 
upregulated in any cell line database, syngeneic mouse model, or xenograft model as a result of STK11 
loss.  However, every patient dataset shows a significant upregulation. Given the specificity of ODC1 
activity to patient tumors, this study could have captured metabolic alterations missed in other model 
systems. We believe this patient specificity to be a result of cellular plasticity and differentiation due to 
STK11 loss in cells grown outside their natural environment.  A number of other studies have alluded to 
STK11’s role in cell fate [30, 137].  Likely, various environmental stimuli and cell of origin greatly impact 
this observation. When dealing with potent regulators of metabolism such as STK11, it is important to 
study the cells in a similar metabolic environment that would be present in patients.  Xenograft models 
and tissue culture fail to recapitulate many variables that would be altered exclusively in the lung such 
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as: glucose, amino acids, fatty acids, immune cells, oxygen concentration, pH, paracrine signaling from 
stromal tissue, and many more.  While mouse models seem to be the answer to this question, gene 
expression patterns are vastly different in murine and human tumors.  We believe that since 
neuroendocrine cells and type II pneumocytes constitute such a small fraction of lung cells that deleting 
STK11 non-specifically in the lung results in a tumor of mixed histology with cell lineages pertinent to 
lung adenocarcinoma making up far less than 10% of the tumor.  
In conclusion, this paper puts forward a method by which patients with STK11 loss could be classified 
through gene expression signature and selected for combination anti-PD-1/PD-L1 immunotherapy with 
targeted inhibition of ODC1.  Given that this cohort would not otherwise respond to immunotherapy, 
the actionable and targeted inhibition of polyamine metabolism through DFMO as suggested from 
previous studies would abrogate the immunosuppressive microenvironment and potentially restore 
immunotherapy efficacy in this large subset of patients, greatly increasing patient survival and taking 
one step further towards both personalized medicine and potential elimination of a deadly disease. 
Materials and Methods 
Acquisition of publicly available genomic and proteomic datasets 
The TCGA LuAD dataset was downloaded from the Xena browser (https://xenabrowser.net/hub/) for 
gene expression (RNAseq), protein expression (RPPA), and somatic mutation. MLOS (GSE72094) has 
been previously described [53, 116, 126, 129, 139, 140].  
Statistical analysis 
Statistical analysis was performed using the Scipy python package and the function scipy.stats.ttest_ind 
for p-value between gene arrays.  Bonferroni correction was used by multiplying the p-value by the 
number of genes in the study.  Pearson correlation was calculated through the scipy.stats.pearsonr 
function.   
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Public gene-set enrichment software 
Two publically available methods of gene-set enrichment were used in this study.  Genemania 
(http://genemania.org/) available as a web-based software was used on overlaps between TCGA and 
MLOS by t-test for both the 29 and 137 length gene-sets. Similarly, Broad Institute’s Hallmark gene-sets 
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) were used with a FDR cutoff of 0.05. 
Pathway Schematics 
Pathways were generated using the PathVisio software available here https://www.pathvisio.org [141]. 
K-means clustering gene-set enrichment 
This method of gene-set enrichment is performed on two-predefined populations of samples (STK11 
mutant and wildtype).  A database of gene-sets is clustered into (k=2) populations using K-means 
clustering through the Biopython library and the Bio.Cluster.kcluster function. The average method was 
used and Euclidean distance with 100 permutations.  Upon clustering into two populations by each 
gene-set, a Fisher Exact test is used to statistically calculate how well the gene-set was able to cluster 
the patients into the predefined subsets.  The scipy.stats.fisher_exact function was used for the 
statistical test. 
Generation of signature scores 
Principal component analysis was run through the Biopython library (https://biopython.org/) using the 
Bio.Cluster pca function.  The data matrix was refined to the genes of interest prior to calculating 
component scores of each gene.  The principal component was chosen which explained the largest 
variance between STK11 mutant and wildtype patients (PC1). Component scores were averaged 
between TCGA and MLOS and used for calculating a gene expression signature in each dataset. 
Signature scores were generated by first calculating the number of standard deviations from the mean 
(z-score) for each gene for each patient.  The averaged principal component loading coefficients were 
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averaged between both TCGA and MLOS for each gene and were multiplied by the z-score.  This 
cumulative score was then divided by the number of genes in the signature to get an average score per 
gene. 
Western blotting and antibodies 
Antibodies were diluted to working concentrations in PBST with 5% milk. The ODC1 antibody 
(ab193338), a mouse monoclonal antibody from Abcam, was used at a dilution of 1:400.  The STK11 
(LKB1) antibody, a rabbit monoclonal antibody from Cell Signaling (27D10) #305, was used at a dilution 
of 1:1,000.  The β-actin antibody (SAB1305567), from Sigma-Aldrich, was used at a dilution of 1:20,000. 
The Li-COR Odyssey Fc was used to determine protein detection 
(https://www.licor.com/bio/products/imaging_systems/odyssey_fc/).  Blots were developed for 10 
minutes using the chemiluminescent channel.   
Metabolomics Analysis by LC-MS 
Frozen lung tumor samples (~10 mg) were homogenized in 40 mM ammonium formate using 1.0 mm 
zirconia beads in a BeadBeater (Biospec Products, Bartlesville, OK).  Insoluble material was pelleted and 
the protein concentration of the supernatant was used for quality control and normalization.  Stable 
isotope-labeled standards (SIS) including 1 mg/mL of D3-cysteine, 13C-alanine, 13C-methionine, 13C-
arginine, D3-serine, D3-S-(5'-adenosyl)-L-methionine (SAM) and 1 µg/mL of 13C4-putrescine, 13C5-
ornithine, D8-spermidine, and D8-spermine (Cambridge Isotope Labs, Tewksbury, MA) were added to 
each homogenate followed by 800 µL of acetonitrile:methanol:acetone (8:1:1) to precipitate proteins. .  
The supernatant containing metabolites was lyophilized, re-suspended in 50 µL water and analyzed with 
LC-MS (Vanquish UHPLC and Q Exactive HF mass spectrometer, Thermo, San Jose, CA).    For targeted 
quantification of metabolites in the polyamine pathway, peak areas were determined using Xcalibur 
QuanBrowser (v. 3.0.63) and amounts (in ng/mg total protein or mg tumor wet weight) were calculated 
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using the peak area ratio of each molecule to its respective SIS. For untargeted analysis, LC-MS data files 
were converted to mzml files and analyzed using MZmine 2.25. [142]  
Data processing steps for the other detected metabolites (not involved in the polyamine pathway and 
without matched stable isotope-labeled standards) consisted of several steps: mass detection, 
chromatogram building, smoothing, chromatogram deconvolution, grouping of isotopic peaks, peak 
alignment with m/z tolerance of 5 ppm and retention time tolerance of 0.25 min, gap filling to fill in 
missing peaks, duplicate peak removal, and peak filtering (retention time range 0.45–17.0 min, peak 
duration range 0.06–2.00 min).  
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Chapter 3: STK11 differentially impacts cell lineage switching via NKX2-1 in vivo and ex vivo with 
implications for future research  
 
Abstract 
STK11 mutations are most frequently found in adenocarcinoma and large cell neuroendocrine 
carcinoma of the lung, which arise from type II pneumocytes (ATII) and neuroendocrine cells, 
respectively.  Both of these cell types are responsible for regulating inflammatory responses. Neither the 
cell lineage nor inflammatory phenotypes are preserved in model systems of STK11 loss compared to 
patient tumors. STK11, a mediator of the stress response has been previously shown to impact cell 
polarity, inflammatory response, metabolism, and cell lineage switching. This study evaluates the 
disparate effect STK11 loss of function has on cellular differentiation in various model systems 
compared to human tumors: cell lines, mouse models, and patient derived xenografts and how these 
discrepancies impact our ability to accurately study inflammatory signaling and immunomodulatory 
pathways in the context of STK11 loss tumors.  These models of STK11 loss display decreased expression 
of the ATII marker NKX2-1 compared to STK11 loss human tumors which had no significant change. 
Using two well established lung adenocarcinoma cohorts TCGA and MLOS, we discover that not only do 
human tumors retain their cell lineage marker NKX2-1, but a subset of patient tumors with STK11 loss of 
function also express neuroendocrine lineage markers ASCL1 and CALCA.  Further analysis, based on 
gene expression, indicated that STK11 loss tumors can be classified into three distinct sub-groups; 
classical (NKX2-1+), neuroendocrine (ASCL1+, CALCA+, NKX2-1+), and negative (triple negative). We 
show that the negative subset of patient tumors with STK11 loss of function have increased PD-L1 
protein, loss of urea cycle enzyme ODC1 and transporter SLC14A2 expression, loss of NKX2-1 
transcriptional targets, increased rate of CDKN2A (p16) loss, and are no longer characterized by changes 
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in inflammatory signaling compared to STK11 wildtype tumors. Additionally, cell line and PDX models 
share similar characteristics and cluster with this classified negative subset of STK11 loss human tumors 
based on gene expression patterns while mouse models for STK11 loss share almost no resemblance to 
patient tumors.  Two public experimental studies were used to show expression patterns based on ATII 
differentiation and NKX2-1 addition. Enzymes altered by ATII differentiation and NKX2-1 
complementation correlate with NKX2-1 expression in patient tumors and are absent in the negative 
subset of STK11 loss patients.  Taken together, we uncover that of patients with STK11 loss, a subset 
lose cellular lineage through NKX2-1 and hallmarks of STK11 loss such as polyamine metabolism through 
ODC1 and show that all ex vivo models mimic these characteristics of loss of cellular identity.  This study 
highlights the potential shortcomings of our current model systems of STK11 loss and how these 
limitations need to be circumvented in order to fully understand the biology surrounding STK11 loss as it 
relates to the immune response in patient tumors. 
 
Introduction 
 As of 2019, lung cancer remains the leading cause of cancer death with adenocarcinoma being the most 
commonly occurring lung cancer histology of the most common classification of lung cancer, non-small 
cell lung cancer (NSCLC) [143]. Previously we showed that, adenocarcinoma patients with predicted loss 
of STK11 upregulate polyamine metabolism driven by the rate limiting enzyme ornithine decarboxylase 
(ODC1) [144].  While this phenotype was observed in patient tumors, it was not observed in cell culture, 
mouse models, and human xenografts.  Congruent with other studies, we noticed that loss of STK11 
resulted in changes in cellular lineage and differentiation and that this change in cell state was also 
associated with ODC1 expression in patients [30, 137]. Given that both STK11 loss [47-49, 145] and 
polyamine metabolism [70, 71, 79] are strongly linked to immune suppression, manipulating this 
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biological pathway in the appropriate context is crucial to our understanding of its impact. We therefore 
sought to further understand the complexity underlying the loss of conservation of gene expression in 
models of STK11 loss.  
STK11, also known as LKB1, is a mediator of stress signaling altered at a frequency of over 30% in lung 
large cell neuroendocrine and adenocarcinoma [40, 124].  Given that it plays a role in cell polarity, 
metabolic regulation, inflammation, DNA repair, and apoptosis, it comes as no surprise that it is also 
involved in cell lineage switching [30, 137, 146].  Previous genetically engineered mouse models have 
shown the impact of STK11 loss on an adeno to squamous lineage switch through both SOX2 mediated 
suppression [30] and epigenetic changes driven by the EZH2 polycomb recombination complex [137].  
While, these observations are relevant in mice, we notice that this same lineage switch is not present in 
patient tumors of STK11 loss, which maintain the histological identity of adenocarcinoma. 
The cell lineage that is most commonly thought to give rise to adenocarcinoma is the type II 
pneumocyte (ATII). These cells are characterized by expression of NKX2-1 (better known as TTF1, a 
master transcriptional regulator expressed in thyroid, lung, and diencephalon) and pulmonary 
surfactants, responsible for regulating gas exchange and injury/inflammatory response in the lung [8, 9, 
22] (Figure 3.1A). Given that many genetic alterations appear in cancer in a tissue specific manner 
implies the large impact cell lineage and tissue type play on cancer initiation and progression.   
Neuroendocrine cells of the pulmonary vasculature act as sensors of the lung, providing feedback and 
transmitting signals pertaining to the environment [31, 33, 34] (Figure 3.1A).  These cells exist in 
isolation or cluster into neuroepithelial bodies (NEBs) and express the lineage biomarkers ASCL1 
(Achaete-Scute Family BHLH Transcription Factor) and CALCA (Calcitonin related polypeptide alpha) 
[147, 148].   Serving as sentinels of abnormal lung activity, these cells are capable of sensing hypoxia 
among other environmental stimuli and can both communicate to other tissues in the body as well as 
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influence the local microenvironment [32]. In addition to their role in homeostatic maintenance and 
signal transduction, neuroendocrine cells produce neurotransmitters such as GABA and are thought to 
play a vital role in allergen response [34].  We have shown in a previous publication [144] that lung 
adenocarcinoma patients with predicted loss of STK11 function show increased production of GABA, and 
a decrease in inflammatory response [149, 150].  Cell lineage state is of great importance to biological 
function and should be considered when utilizing model systems. 
One of the most profound hurdles in our attempt to answer complex biological questions is the 
development of model systems capable of accurately recapturing biology as it exists in the patient.  
Attempts to conserve this biology range from the simplicity of in vitro culture all the way to syngeneic 
mouse models, with many others such as xenograft models and spheroid culture. Our observation is 
that lineage transitions not only occur in different contexts of STK11 loss, but that this difference could 
impact the immune microenvironment. We will focus this study on dissecting the differential impact 
STK11 loss has in different model systems in order to display that ex vivo models may fail to recapture 
some of the most relevant aspects of lung cancer biology. These findings indicate how the current 
limitations of surrogate in vivo research are hindering the discovery of novel therapeutic targets in the 
realm of metabolism and immunotherapy.  
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Figure 3.1  
Schematic of lung progenitor differentiation into cell lineages that give rise to various histology of lung 
cancer 
 
Results 
Datasets 
We first used published datasets to compare the impact of STK11 loss on gene expression in vivo and ex 
vivo models with an emphasis on cellular differentiation, as listed in Table 3.1.  We used our previously 
defined gene expression signature for STK11 loss to predict STK11 status for all studies except 
genetically engineered mouse models [144]. These resources include cell line datasets GSE36133 
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(Cancer Cell Line Encyclopedia or CCLE) [151], mouse models GSE21581 (MM1) [152] and GSE118246 
(MM2) [30], patient derived xenograft GSE78806 (PDX) [153], and two human datasets mentioned in 
our previous study MLOS [53, 127, 139] and TCGA.  The CCLE contains 44 annotated lung 
adenocarcinoma samples, 15 classified as STK11 mutant and 29 as wildtype.  MM1 contains 18 primary 
lung samples, 9 KRAS mutant and 9 KRAS/STK11 mutant. MM2 contains 8 KRAS/TP53 mutants, 9 STK11 
mutant SOX2 cre, 6 STK11/PTEN mutants, 8 SOX2 overexpressed STK11 mutants, and 3 normal lung. The 
PDX study contains 46 adenocarcinoma samples determined by clustering and of these 10 were 
accurately called STK11 mutant and 29 wildtype.  MLOS contains 442 patient tumors, 145 predicted 
STK11 mutants and 297 wildtype.  TCGA contains 515 lung adenocarcinoma tumors, 178 predicted 
STK11 mutants and 337 wildtype.  In addition to these datasets, we also explored two separate 
characteristics of ATII cellular identity through viral transduction of NKX2-1 into A549 cells (STK11 
mutant, NKX2-1 null) (GSE40584) and combination dexamethasone and cyclic AMP treatment of fetal 
lung epithelial cells to differentiate them into ATII cells (GSE3306).   
Table 3.1 Public dataset information 
Dataset Name GSE Description 
PDX GSE78806 Patient Derived Xenografts 
CCLE GSE36133 Cancer Cell Line Encyclopedia 
MM1 GSE21581 Mouse Model #1 
MM2 GSE118246 Mouse Model #2 
NKX2-1 GSE40584 NKX2-1 addition to A549 cells 
DCI GSE3306 ATII differentiation 
 
Ex vivo models of STK11 loss lose ATII lineage marker NKX2-1 
We characterized the expression changes of NKX2-1 in each study with respect to STK11 status, either 
determined by signature or study design, in mouse models.  STK11 mutant samples in MM1 (p = 0.131), 
MM2 (p=6.3e-05), STK11 predicted mutants in the CCLE (p=0.0037) and PDX cohorts (p = 0.00397) had 
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notable reductions in their expression of the ATII lineage marker NKX2-1 (Figure 3.2 A-B).  In MM1 a 
subset of KRAS mutant mouse models had reduced expression of NKX2-1, whereas all STK11 mutant 
tumors displayed this reduction, explaining the decreased statistical significance. A similar observation is 
made in the CCLE and PDX model, where NKX2-1 is unanimously reduced in STK11 mutant-like samples 
but selectively reduced in the wildtype (Figure 3.2 C-D).  We also explored the MLOS and TCGA cohort to 
determine if patient tumors with predicted STK11 loss also displayed reduction of NKX2-1. While a 
subset of patients had marked reduction of NKX2-1 in both the STK11 mutant-like and wildtype cohorts, 
there was no change in frequency of this reduction with respect to STK11 status in both MLOS (p = 
0.246) and TCGA (p=0.246) (Figure 3.2 E-F).  
 
Figure 3.2 STK11 loss results in loss of type II pnuemocyte identity ex vivo  
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(a-f) Log2 transformed expression of NKX2-1. (a) Mouse model (MM1) of n=9 KRAS tumors vs n=9 
KRAS/STK11 tumors. (b) Mouse model (MM2) of n=8 KRAS/TP53 tumors and n=6 STK11/PTEN tumors. 
(c) Cell Line Encyclopedia lung adenocarcinoma cell lines predicted with the STK11 loss signature cutoff 
WT (n = 29) < 0 > Mutant (n = 15). (d) Patient derived xenograft models predicted with the STK11 loss 
signature with a cutoff of WT (n=29) < 0, Mutant (n =10) > 0.1. (e) MLOS lung adenocarcinoma patient 
tumors predicted for STK11 status with WT (n=297) and Mutant (n=145). (f) TCGA lung adenocarcinoma 
patient tumors predicted for STK11 status with WT (n=337) and Mutant (n=178).  
A subset of tumors with predicted STK11 loss from MLOS and TCGA also show reduced NKX2-1 
expression, similar to the phenotype of all non-patient models (Figure 3.2 E-F).  This provides us with an 
opportunity to assess the impact of STK11 loss in the context of NKX2-1 expression both within patient 
tumors and between in and ex vivo models.  Previously we reported that patient tumors with predicted 
STK11 loss  upregulate amino acid catabolism, polyamine metabolism, and the urea cycle while 
downregulating interferon mediated immune response and inflammation [144].  Remarkably, patient 
tumors with both STK11 loss and decreased NKX2-1 expression lose these hallmarks as denoted by their 
loss of key regulatory genes SLC14A2 and ODC1.  Specifically, the urea transporter SLC14A2, a hallmark 
gene of the urea cycle pathway highly correlates with NKX2-1 expression only in tumors with STK11 loss 
(Figure 3.3A).  Cell lines, mouse models, and PDX models of STK11 loss similarly lack NKX2-1 and also 
lack upregulation of these genes (Figure 3.3B).   
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Figure 3.3 Cell lineage impacts the urea cycle and polyamine pathway 
(a) Correlation of the expression of the urea transporter SLC14A2 and NKX2-1 in TCGA.  (b) Fold change 
of ODC1 expression in each study. 
 
Classification of STK11 loss tumors into neuroendocrine, classical, and negative subtypes  
Interestingly, we noticed that a fraction of patient tumors with STK11 loss upregulated lineage 
markers of neuroendocrine carcinoma such as ASCL1 (TCGA p = 8.38e-31 MLOS p = 2.19e-16) 
and CALCA (TCGA p = 1.13e-54 MLOS p = 3.78e-41) (Figure 3.4).  Coincident with an increase in 
the abundance of the neurotransmitter GABA in tumors with STK11 loss [144], this suggests 
that pathologically classified lung adenocarcinoma with STK11 loss could undergo partial 
lineage switching to neuroendocrine carcinoma.  
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Figure 3.4 A subset of patients with STK11 loss express neuroendocrine markers 
Gene expression of neuroendocrine markers ASCL1 and CALCA in TCGA (left) and MLOS (right). 
We further classified patient tumors with predicted STK11 loss based on their expression 
patterns of neuroendocrine markers ASCL1 and CALCA and the ATII marker NKX2-1 through K-
means clustering. We annotated tumors in MLOS and TCGA with high expression of ASCL1, 
CALCA, and NKX2-1 as “neuroendocrine”, high expression of NKX2-1 and low ASCL1/CALCA as 
“classical”, and “negative” as low expression of all these markers. In TCGA, patients clustered 
into these 3 subtypes with 84 classical tumors, 68 neuroendocrine, and 26 negative (Figure 
3.5A).  MLOS contained 91 classical, 44 neuroendocrine, and 10 negative tumors (Figure 3.5B).   
The negative cohort similarly to STK11 WT cells lacks both ODC1 and SLC14A2 expression 
compared to the classical and neuroendocrine subtypes (Figure 3.5 C-D). 
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Figure 3.5 Classification of STK11 loss patient tumors into neuroendocrine, classical, and negative 
subsets 
(a-b) K-means clustering of STK11 mutant patients in TCGA (a) and MLOS (b) into negative, classical, and 
neuroendocrine subsets based on the markers NKX2-1, ASCL1, and CALCA. (c-d) Expression of ODC1 (c) 
and SLC14A2 (d) in negative, classical, neuroendocrine, and STK11 WT patients in TCGA. 
Molecular profiling of STK11 mutant subtypes  
We characterized these cohorts by defining molecular characteristics. We analyzed gene expression, 
protein expression, DNA mutations, and copy number alterations using data from the TCGA cohort and 
gene expression, survival, and clinical data from both TCGA and MLOS.   
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Clinical data  
Clinically, there were only few notable characteristics distinguishing the 3 clusters.  The negative cluster 
displayed characteristics of a more aggressive disease state in TCGA.  Compared to the classical and 
neuroendocrine cohorts they displayed a higher T3-4 to T1-2 ratio (negative = 0.368, classical = 0.137, 
neuroendocrine = 0.097) and N2 to N0 ratio (negative = 0.67, classical = 0.20, neuroendocrine = 0.21) 
(Figure 3.6 A-B).  No significant clinical characteristics separated the classical from neuroendocrine 
cohorts.   
 
Figure 3.6 Clinical data of STK11 loss subtypes 
(a) N staging in the three STK11 loss subtypes in TCGA. (b) T staging in the three STK11 loss subtypes in 
TCGA 
Survival 
Overall survival was assessed at 3 years (1095 days or 36 months) in the 3 subtypes through Kaplan 
Meyer analysis and log-rank test (Figure 3.7 A-B). The negative cohort displayed the worst survival 
compared to both the classical (TCGA p = 0.019, MLOS p = 0.00087) and neuroendocrine (TCGA p = 
0.00074, MLOS p = 5.24e-7) cohorts with a median survival of less than 700 days.  There was no 
significant difference between the classical and neuroendocrine cohort in TCGA (p = 0.103) but the 
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neuroendocrine subset had a slightly better prognosis in MLOS (p = 0.022).  These data suggest that de-
differentiation and loss of cell identity is strongly associated with poor patient prognosis. 
 
Figure 3.7 Survival curves of STK11 loss subtypes 
(a-b) Kaplan Meier curves of 3 year survival in TCGA (a) and MLOS (b) based on the STK11 loss subtypes 
Gene expression 
We analyzed differences in gene expression patterns in both MLOS and TCGA based on our 
reclassification of patients, utilizing fold changes in one vs rest and one vs one between cohorts (Figure 
3.8 A).  The classical cohort was characterized by elevated levels of SFTPD, ALDH3A1, HHLA2, and 
SCGB3A2 with decreases in FGB and PAH. The negative cohort displayed elevated levels of DKK1, CPS1, 
KYNU, SMOX, NTS, and FGA with decreases in PGC, SFTA3, NKX2-1, PRMT8, LPL, MAOA, ALDH3A2, HOPX, 
ODC1, SLC14A2 and FOXA2. The negative cohort loses lineage markers associated with ATII biology, 
including genes necessary for urea transport (SLC14A2) , polyamine metabolism (ODC1), and synthesis of 
GABA from putrescine (MAOA, ALDH3A2). In the negative cohort there is also marked increase of the 
neurotransmitter neurotensin (NTS) and polyamine catabolism in spermine oxidase (SMOX). A potent 
biomarker of ex vivo STK11 loss, carbamoyl phosphate synthase 1 (CPS1), is elevated in this subset of 
patients [61, 62].  The neuroendocrine cohort had elevated RET, DLL3, NEUROD1, SOX2, DDC, MYCN, 
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and MYCL1 with decreases in KRT6A and INSL4, which has recently been reported to sustain growth and 
viability in STK11 mutants ex vivo [154].  
The most drastic changes in gene expression were associated with the negative vs classical and negative 
vs neuroendocrine comparisons as the classical and neuroendocrine cohorts as more similar (Figure 
3.8A).  Unexpectedly, within the classical cohort is a shift in expression patterns towards characteristics 
of the negative cohort, congruent with decreasing NKX2-1 expression, suggesting that de-differentiation 
is a continuous process and results in changes in both transcriptional regulation and tumor 
aggressiveness.    
Protein 
Through use of TCGA’s RPPA protein expression data we profiled the three STK11 mutant subtypes for 
defining characteristics (Figure 3.8 B).  In the classical cohort there was a significant reduction in cyclin 
B1 (CCNB1), glutamine dependent asparagine synthetase (ASNS), caspase 7 cleavage, and 
immunosuppressive programmed cell death 1 ligand 1 (PD-L1).  There was a significant increase in 
napsin A which is involved in the processing of surfactants, HER3, and YAP pS127 which lies downstream 
of AMPK activation and is activated during high cellular density. The negative cohort had significant 
increases in glucose-6-phosphate dehydrogenase G6PD and hallmark of NRF2 activation, TFRC, cyclinE1 
and had the highest levels of both PD-1 and PD-L1 expression. There was a reduction in TTF1 (NKX2-1), 
c-KIT, and IGFBP2. Through both gene and protein expression there is a remarkable correlation of KIT to 
NKX2-1 levels.  KIT is highly mutated in gastrointestinal cancers [155], is highly associated with STK11 
loss and may be related to gastrointestinal signaling mediated through NKX2-1 otherwise repressed by 
STK11 [28].  The neuroendocrine cohort was characterized by elevated IGFBP2, XRCC1, BCL2, acetyl-a-
tublin lys40 with decreases in YAP pS127.   
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Figure 3.8 Gene expression and protein expression of STK11 loss subtypes 
(a-b) Heatmap of Z-score (scale -3 to 3) transformed gene expression (a) and protein RPPA (b) changes 
in TCGA in the three STK11 loss subtypes.  
Mutations 
The three subtypes did not have drastic alterations in mutational profiles (Figure 3.9A).  However, TP53 
and SMARCA4 [156-158]mutations were more prominently associated with the negative cohort. KRAS 
mutations were seen in both the classical and neuroendocrine subsets at increased rates relative to the 
negative cohort. SMARCA4 (BRG1) is known for its role in Rb signaling and chromatin remodeling and is 
found at the same chromosomal locus as both KEAP1 and STK11 (19p13), which is commonly lost in lung 
adenocarcinoma.   Interestingly, conservation of TP53 and p16 signaling have both been associated with 
neuroendocrine characteristics [147] and NKX2-1 signaling [27, 67]. The neuroendocrine cohort had 
increases in ATM mutations and decreases in NRF2 activating mutations of KEAP1/NFE2L2, which are 
seen in high statistical co-occurrence with STK11 mutant tumors [52]. 
Copy number 
Gene copy number profiles showed very interesting lineage specific amplifications (Figure 3.9B).  The 
neuroendocrine cohort displayed copy number amplifications of the NKX2-1/FOXA1 locus, suggesting 
that amplification of NKX2-1 may have an oncogenic role in this subset.  NKX2-1 and FOXA1 have been 
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shown to have opposite roles in the regulation of differentiation and lung cancer progression [28, 29].  
CDKN2A (p16), had an increased rate of deletion in the negative cohort, followed by the classical, and 
much less so in the neuroendocrine subset.  While MYC was amplified in each cohort, it was most 
commonly amplified in the neuroendocrine subset.  
 
Figure 3.9 Mutational frequency and copy number alterations of STK11 loss subtypes 
(a) Mutational frequency of canonical mutations in lung adenocarcinoma between the three STK11 loss 
subtypes and STK11 wildtype patient tumors. (b) Heatmap of Z-score transformed copy number changes 
(scale -3 to 3) between the three STK11 loss subtypes. 
GSEA of STK11 loss subtypes reveals role of cell lineage on immune response 
Gene set enrichment was performed on each subtype compared to STK11 WT tumors in both MLOS and 
TCGA.  Genes changing by +/- 1.5 fold with a p-value of less than 1e-10 were kept; except for in the 
negative vs WT comparison of MLOS as a p-value of less than 1e-7 was used due to sample size 
limitations.  The classical cohort contained 335 genes in MLOS and 734 genes in TCGA with 218 of these 
genes overlapping. GSEA analysis on these 218 genes revealed the top hallmarks of interferon alpha 
75 
 
response (FDR = 4.73e-8), interferon gamma response (FDR = 1.1e-6), fatty acid metabolism (FDR = 
1.16e-6), and inflammatory response (FDR = 6.41e-6) (Figure 3.10A).  The neuroendocrine cohort 
contained 426 genes in MLOS and 1399 with 315 overlaps. GSEA analysis resulted again in interferon 
gamma (FDR = 1.41e-13) and alpha response (FDR = 7.11e-11), inflammatory response (FDR = 1.54e-8) 
as well as late estrogen response (1.54e-8) (Figure 3.10B). Finally, the negative cohort contained 364 
genes in MLOS and 901 in TCGA with 155 overlaps. Hallmarks for the negative cohort are vastly different 
than the others, as seen through hallmarks of xenobiotic metabolism (FDR = 1.92e-4) and coagulation 
(FDR = 1.92e-4) (Figure 3.10C) being the top pathways altered.  Only 14 genes out of a total of 688 
overlap between the 3 cohorts (2.03%) with the most unique cohort being negative, overlapping with 
classical in 15 out of 373 (4.02%) genes and neuroendocrine with 9 out of 470 (1.91%).  Neuroendocrine 
and classical subtypes overlap with 78 out of 533 (14.6%) genes, displaying that their biology is more 
readily conserved between them (Figure 3.10D).  As expected, the negative cohort loses inflammatory 
and interferon signaling, partially elucidating the role of cell lineage in the immune suppressive 
phenotype of STK11 loss.  
Two gene expression signatures explain the changes between lineage states 
In order to describe the variance in expression patterns seen between subtypes we performed principal 
component analysis on the most variant genes.  Two principal components sufficiently explain this 
variance with PC-1 describing neuroendocrine features and PC-2 describing features of NKX2-1 loss 
(Figure 3.10E). Loading coefficients of genes most significantly contributing to PC-1 include CALCA, 
ASCL1, KLK12, PCP4, CTNND2, RET, and NEUROD1. Top coefficients of PC-2 include PCSK2, GKN2, 
C16ORF89 (LINC00473), SLC14A2, NAPSA, NKX2-1, LPL, and HOPX. 
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Figure 3.10 ATII cell lineage loss results in loss of inflammatory signaling 
(a-c) MSigDB GSEA of (classical (a), neuroendocrine (b), and negative(c)) vs WT consensus genes. (d) 3-
way Venn diagram of consensus gene expression changes in both MLOS and TCGA of each STK11 loss 
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subtype compared to STK11 WT. (e) Scatter plot of PC-1 and PC-2 of Principal component analysis 
performed on 544 genes describing variance of STK11 loss subtypes. 
ATII differentiation upregulates surfactants and neuroendocrine enzymes 
In order to distinguish the changes that take place as a result of type II pneumocyte differentiation we 
explored a public dataset in which human fetal lung epithelial cells were differentiated into type II 
pneumocytes through treatment with dexamethasone and cyclic AMP [159].  Since many characteristics 
of type II pneumocytes are lost in ex vivo studies as well as in a subset of patients, it is important to see 
what genes are directly regulated through the differentiation.  A student’s t-test was performed on the 
dataset comparing the 5 treated samples to untreated and changing genes were displayed through 
volcano plot (Figure 3.11A).  In the treated cohort, significant upregulation was seen in ALDH3A2, SFTPC, 
SFTPB, CIT, CALCA, HOPX, NR4A2, LPL, PGC, and MAOA. Reductions in PLAU, GABBR1, TP63, HLA-DRB4, 
SLC7A2, and PTGS2 were also observed.  Many of these genes upregulated during ATII differentiation 
play critical roles in ATII cell biology and are seen in neither ex vivo models nor the negative cohort of 
patients with STK11 loss.  GSEA was performed on significantly changing genes and resulted in the 
hallmarks of late (FDR = 2.16e-12) and early (FDR = 5.34e-8) estrogen response, KRAS signaling (FDR = 
2.32e-11), apical junction (FDR = 5.34e-8), and TNFa signaling via NFKB (FDR = 5.34e-8) (Figure 3.11C).  
Given that cells were treated with a corticosteroid (dexamethasone), estrogen response was not 
surprising.  However, KRAS signaling and inflammatory pathways are observed to change upon ATII 
differentiation and describe the function of type II pneumocytes to repair upon injury and mediate lung 
inflammation.   
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Figure 3.11 ATII differentiation and NKX2-1 addition share transcriptional changes associated with 
STK11 signaling 
(a) Volcano plot of gene expression changes as a result of type II pneumocyte differentiation. (b) 
Volcano plot of gene expression changes as a result of NKX2-1 addition to A549 cells. (c-d) GSEA of 
genes changing as result of ATII differentiation (c) and NKX2-1 addition (d). 
 
Overexpression of NKX2-1 in A549 cells partially restores in vivo phenotype 
A previous publication used a lentivirus to overexpress NKX2-1 in NKX2-1 null A549 cells [160].  This cell 
line was derived from lung adenocarcinoma and is used as a model of alveolar type II cells. They have 
been shown to have loss of function of STK11 by DNA-sequencing and gene expression patterns with an 
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activating mutation in KRAS.  While these characteristics mimic that of a common patient tumor lacking 
STK11, these cells are negative for the type II marker NKX2-1, making them an interesting candidate for 
the complementation of its expression.  Student’s t-test was performed on the gene expression of this 
dataset to explain the variance between these A549 cells determinate of NKX2-1 status (Figure 3.11B). 
Notable increases in gene expression include: CD274 (PD-L1), KIT, SFTPB. ODC1 was also slightly 
upregulated upon treatment. Decreases in PTGS2 (COX2), FGA, and HLA-DMB was observed.  The 
complementation of NKX2-1 to A549 cells restored a subset the observed patterns of gene expression 
seen in patients with STK11 loss including increases in KIT and decreases in class II HLA’s. Unexpectedly 
there is a remarkable increase in PD-L1 expression, opposite to the patient phenotype of STK11 loss.  
Recently, a study suggested that the anti-sense transcript of NKX2-1 is responsible for the repression of 
CD274 [161].   Perhaps the regulation of PD-L1 lies on a balance between NKX2-1 and its anti-sense 
transcript (NKX2-1-AS1), of which is not transcribed from the lentiviral construct.  This dataset displays 
the role that the NKX2-1 transcription factors plays in the context of STK11 loss and highlights its 
importance in regulating the expression of several genes lost in ex vivo studies.   
Differentially expressed genes from this study were filtered by a p-value of less than 1e-5 with an 
absolute fold change of more than 1.5.  The remaining 360 genes were used for gene set enrichment 
(Figure 3.11D).  Complementation of NKX2-1 revealed an increase in epithelial to mesenchymal 
transition (FDR = 1.16e-29), hypoxia (FDR = 9.42e-26), TNFa signaling via NFKB (FDR = 1.39e-20), 
upregulation of KRAS signaling (FDR = 6.37e-17), and inflammatory response (FDR = 6.37e-17).  These 
hallmarks display the significant impact that NKX2-1 plays in metastasis, sensing of oxidative stress, and 
immune responses that are lacking in ex vivo models of STK11 loss.  
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STK11 loss subtype signatures are altered in both NKX2-1 addition and ATII differentiation 
We applied the principal component derived signatures explaining the variance between subtypes of 
STK11 loss to the studies of both NKX2-1 addition to A549 cells and ATII differentiation. In both the 
NKX2-1 study (p=0.244) and ATII differentiation study (p=0.200) PC-1 was not significantly altered. PC-2, 
the component lost in the negative cohort of STK11 loss tumors, was significantly increased in both the 
A549-NKX2-1 (p=0.00079) and differentiation study (p=1.45e-6) (Figure 3.12 A-B). This displays that 
NKX2-1 associated transcriptional activity conserved in a majority of patients is upregulated upon either 
the restoration of NKX2-1 expression in NKX2-1 null A549 cells or the differentiation of lung fetal 
epithelial cells to ATII cells. Further, a large number of gene expression changes are conserved between 
both studies with a fold change exceeding +/- 1.5 and p-value of less than 0.001, suggesting that NKX2-1 
plays significant role in ATII differentiation (Figure 3.12C). 
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Figure 3.12 Component scores in ATII and NKX2-1 studies 
(a) Boxplot of PC-1 (left) and PC-2 (right) in NKX2-1 addition study. (b) Venn diagram of genes changing 
between ATII differentiation and NKX2-1 addition. (c) Correlation matrix of genes altered between 
STK11 subtypes in TCGA. 
 
STK11 negative cohort clusters with ex vivo models 
We characterized gene expression patterns conserved between studies, represented by the 5-way Venn 
diagram displaying overlaps of genes changing by either +/- 1.5 fold (Figure 3.13A).  Using the log2 gene 
expression changes in each public dataset used in this study, a matrix was created for every gene that 
had expression data.  In both MLOS and TCGA, we added the relative fold change from the classical, 
neuroendocrine, and negative cohort compared to STK11 WT patients along with the average for all 
patient tumors with predicted STK11 loss vs WT.  Each study was hierarchically clustered based on genes 
that were used to the describe subtype variance in PC-1 and PC-2 The neuroendocrine, average, and 
classical cohort all cluster together from each study while the negative cohorts cluster with both PDX 
and CCLE models of STK11 loss (Figure 3.13B).  More surprising is that mouse models of STK11 loss 
exhibit the least resemblance to STK11 mutant patient tumors and cluster alongside the experimental 
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studies.  Genes consistently lost in ex vivo models are ones with overlapping characteristics of both 
neuroepithelial cells as well as type II pneumocytes such as: dopamine decarboxylase (DDC), ornithine 
decarboxylase (ODC1), calcitonin related peptide alpha (CALCA), monoamine oxidase (MAOA), thyroid 
transcription factor (TTF1) NKX2-1, surfactants A-D, lipoprotein lipase (LPL), and progastricsin (PGC). The 
similarity of cell line and PDX models of STK11 loss to patients with loss of cell lineage displays that ex 
vivo models of STK11 loss fail to maintain cellular identity as seen in a majority of patients. 
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Figure 3.13 Ex vivo models of STK11 loss cluster with and mimic the negative subset of STK11 mutant 
patients lacking inflammatory signaling. 
(a) 5-way Venn diagram of average STK11 loss vs WT, cell lines (CCLE), patient derived xenografts (PDX), 
and mouse models (MM1 and MM2). (b) Hierarchical clustering of gene expression fold changes of each 
study. TCGA and MLOS were further divided into fold changes of subtype vs WT and average vs WT.  
Genes selected were used for PCA signature generation. 
Discussion 
Here we show that STK11 loss of function results in changes in cell lineage markers unanimously in 
model systems and that these cell lineage transitions influence immunomodulatory signaling.  We first 
profiled several known in vivo and ex vivo datasets in the context of STK11 loss.  We showed the specific 
loss of cellular identity in ex vivo models of STK11 loss through NKX2-1 expression, while revealing that a 
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majority of patient tumors retained this identity. In addition, we observed the enrichment of 
predominant neuroendocrine characteristics in a subset of in vivo STK11 loss tumors through expression 
of ASCL1 and CALCA.  We clustered patients into 3 subsets dependent upon their expression of lineage 
markers into ATII-like (classical), ASCL1/ CALCA positive (neuroendocrine), and loss of lineage (negative). 
These cohorts were then analyzed for recurrent changes in copy number alterations, protein expression, 
mRNA expression, DNA mutation profiles, and overall survival.  Negative cohorts displayed loss of ATII 
identity and subsequently other hallmarks of STK11 loss via urea cycle utilization, polyamine 
metabolism, and an increase in inflammatory response. An additional two datasets were used to 
confirm the impact of NKX2-1 in the context of STK11 loss and genes modified by ATII differentiation via 
dexamethasone and cyclic AMP treatment. The negative patient cohort displayed gene expression 
patterns most similar to cell line and PDX models of STK11 loss and clustered separately from the 
neuroendocrine and classical cohorts.  
It is important to understand the differences in the nature of each of these models.  The total tumor 
distribution of each of the observed subtypes of STK11 loss has not been determined.  It is possible that 
these diverse genetic subpopulations exist in regions of the tumor; contributing to intra-tumor 
heterogeneity. They could even collaborate with one another or rather they could exist as a more 
homogenous and universally dispersed cell type.  Cell lines, mouse models, and PDX models are much 
more homogenous than most human tumors with a much quicker initiation in the case of PDX and 
mouse models.  Being a mediator of energy sensing and metabolic stress, STK11 loss in environments 
with vastly altered resource and nutrient availability likely contribute to the significant alterations in 
both cellular differentiation and gene expression seen in in vitro culture. Culture conditions most 
commonly provide an excess of amino acids and sugar and are grown at normoxia (20% O2), all of which 
are significantly different from in vivo models. Most surprising is how far mouse models miss the mark 
of recapturing patterns of human gene expression changes. In this setting, most environmental stressors 
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such as oxygen availability, immune response, and lung specific signaling should remain intact. It is 
possible that studies that do not specifically target NKX2-1 positive cells with the induction of STK11 loss 
could result in a tumor with mixed histology given the low frequency of ATII cells to other cell types.  
Mouse models differ significantly in tumor initiation from that of patient tumors, which undergo a much 
more stringent and elaborate adaptive process in disease progression. Further, another explanation of 
the discrepancy of cell line and PDX models is a selection for the most aggressive phenotype of STK11 
loss, which happens to be cells lacking ATII identity.   
One critical factor missing from these studies is that nearly all patients with STK11 loss also have a 
history of smoking [162, 163].  It is possible that environmental stress mixed with chronic tobacco 
inhalation is significantly contributing to the variance of patient tumors compared to the ex vivo models. 
Nicotine serves as an agonist to the stimulatory nicotinic acetylcholine receptors and plays a role in 
neurological function [164, 165]. Given that we observe a significant increase of neuroendocrine like 
features in patients with STK11 loss, smoking is a likely a missing piece to this puzzle. Chronic tobacco 
use would result in chronic inflammation in the lung [166, 167], creating a selective pressure to not only 
overcome this inflammation but to process many of the neurotoxic and ammonia containing reagents in 
tobacco. Gene expression patterns allude to this selective demand through the upregulation of both 
urea cycle enzymes ODC1 and CPS1 and the urea transporter SLC14A2.  STK11 mutations are found in 
large cell neuroendocrine and adenocarcinoma at a frequency that far surpasses other cancer types. 
These observations suggest that STK11 loss may fit a very unique niche of selective adaptation to 
tobacco distinct to cellular lineage. Both neuroendocrine and ATII cells modulate the inflammatory 
response of the lung and have been linked to conditions such as chronic obstructive pulmonary disease, 
allergy, and asthma [168-170]. These two cell types are also the ones responsible for the initiation of 
large cell neuroendocrine and adenocarcinoma respectively.  
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An interesting observation made is that ATII differentiation greatly upregulates enzymes required for 
GABA synthesis from putrescine, another neuroendocrine-like feature.  These enzymes include 
monoamine oxidase (MAOA), required for the conversion of n-acetyl putrescine to n-acetyl GABA-
aldehyde and aldehyde dehydrogenase (ALDH3A2) required for the conversion of n-acetyl GABA-
aldehyde to n-acetyl GABA [96, 100]. The precursor substrate for this pathway is the synthesis of 
putrescine from ornithine through ODC1, seen to be elevated only in tumors with STK11 loss that 
preserve their ATII phenotype.  Further, GABA has been linked to be an immunomodulatory and 
suppressive agent in many studies and could explain the differences in inflammatory response seen 
between STK11 loss subtypes [91, 93, 94, 96, 97].  
Previous studies of STK11 loss claimed that neutrophils modulate the immune microenvironment and 
result in lack of immunotherapy efficacy through an increase in proinflammatory cytokines CXCL7, G-
CSF, and IL-6 [145].  While these observations are true of mouse models, these same markers are not 
seen to be elevated in patient studies nor do we observe any significant changes in myeloid cell 
populations through gene expression patterns. Flow cytometry of patient tumors with STK11 loss 
revealed that of all basic immune cell populations, t-cells were the most significantly reduced cell 
population [48].  This study was carried out in mice with genetic backgrounds of KRAS/TP53 and 
KRAS/TP53/STK11.  We observed that TP53 mutations were enriched in the negative cohort of patients 
with STK11 loss (Figure 3.9A) and previous publications have shown the dichotomy of NKX2-1 signaling 
dependent on TP53 status and STK11 loss [27, 67]. Additionally, it has been shown that TP53 and p16 
alterations are exclusive for subsets of large cell neuroendocrine carcinoma with dual KRAS/STK11 
mutation [134]. TP53 mutations are exclusively associated with both KRAS and STK11 mutations in lung 
adenocarcinoma and this could play a role in the maintenance of both cell state and subsequently 
inflammatory signaling. 
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NKX2-1 has historically been associated with lung adenocarcinoma and is commonly used as a clinical 
marker [21]. What is most fascinating is its duality of both an oncogene and tumor suppressor 
dependent on context [22].  Loss of NKX2-1 is associated with a poor prognosis and more aggressive 
disease state.  However, in our neuroendocrine cohort we observed amplification of the chr14q13 locus 
where NKX2-1 resides. This further supports the role of NKX2-1 as an oncogene and tumor suppressor 
dependent on cell lineage.  We notice a strong association between NKX2-1 and loss of PD-L1 (CD274) 
expression.  In A549 cells, when NKX2-1 is added back, PD-L1 is one of the most significantly elevated 
genes.  However, the opposite trend remains true of patients with STK11 loss, in which PD-L1 is 
significantly lower than tumors of other genetic background.  Recently, a study determined that the 
anti-sense strand of NKX2-1 (NKX2-1-AS1) is responsible for repressing PD-L1.  Likely, STK11 plays a key 
role in signaling both up and downstream of NKX2-1 and is determined by the equilibrium of NKX2-1 and 
NKX2-1-AS1.   
Model systems are created with the purpose of deepening our understanding of patient biology and 
thus providing a mechanism towards discovering therapies to be used in our fight against cancer.  This 
study highlights the importance of having model systems that are not only capable of manipulation, but 
also ones that accurately recapitulate patient biology, especially in the context of immunotherapy. 
Understanding the limitations of such systems will help to not only keep an open mind to previous failed 
treatments but also to improve our current models in a way that accurately depicts the disease we are 
attempting to eliminate. Tissue specificity influences the frequency of genomic aberrations, as 
confirmed from the diverse landscape of genomic alterations in specific cancer types.  With respect to 
lung cancer and STK11 loss, we hope that this consideration will drastically alter the ways in which we 
study this unique genetic abnormality and provide insight into the lack of immune response in this 
cohort.   
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Materials and Methods 
Acquisition of public datasets  
Public datasets were acquired through NCBI GEO DataSets (https://www.ncbi.nlm.nih.gov/gds/) and 
series matrix files were downloaded.  Datasets that contained linear gene expression were log2 
transformed. The individual datasets with GSE numbers are provided in Table 4.1.  TCGA data was 
downloaded from the Xena browser (https://xenabrowser.net/hub/) for gene expression (RNA-seq), 
protein expression (RPPA), copy number variants and somatic mutation. MLOS (GSE72094) has been 
previously described [53]. 
Hierarchical Clustering 
Hierarchical Clustering was performed using the Python programming language.  The gene expression 
matrix was first Z-score transformed for each gene. Distance was calculated through 
scipy.spacial.distance.pdist using the Euclidean distance metric.  Linkage was then calculated through 
scipy.cluster.hierarchy.linkage using Ward linkage. Dendrograms were created for the clustering of both 
samples and genes and represented using scipy.cluster.hierarchy.dendrogram. Heatmaps were 
displayed on a color bar scale by Z-score from -3 to 3. 
Principal component analysis and signatures 
Principal component analysis was run through the Biopython library (https://biopython.org/) using the 
Bio.Cluster pca function.  The data matrix was refined to the genes of interest prior to calculating 
component scores of each gene. Signature scores were generated by first calculating the number of 
standard deviations from the mean (z-score) for each gene for each patient.  The averaged principal 
component loading coefficients were multiplied by the z-score for that same gene.  This cumulative 
score was then divided by the number of genes in the signature to get an average score per sample. 
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K-Means clustering 
K-means clustering was used to classify the three STK11 loss subtypes through the Biopython library and 
the Bio.Cluster.kcluster function was utilized to generate (k=3) clusters. The average method was used 
and Euclidean distance with 100 permutations.  
GSEA 
Gene Set Enrichment Analysis was performed by using Broad Institute’s Hallmark gene-sets 
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) with a FDR cutoff of 0.05. 
Venn diagrams 
Venn diagrams were generated using (http://www.interactivenn.net/) as referenced [171]. 
Kaplan Meier curves 
Kaplan Meier survival curves were generated using pythons lifelines library 
(https://lifelines.readthedocs.io/en/latest/). The KaplanMeierFitter was called and passed vital status 
information as (alive = 0) and (death = 1) and respective survival duration. Log-rank assessment was 
performed using the logrank_test in the lifelines library. 
Statistical Tests 
Statistical analysis was performed using the Scipy python package and the function scipy.stats.ttest_ind 
for p-value between arrays. Pearson correlation was calculated through the scipy.stats.pearsonr 
function. The scipy.stats.fisher_exact function was used for the statistical test determining the 
significance between mutations occurring in each STK11 loss subset compared to STK11 WT. 
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Chapter 4: Biomarkers, vulnerabilities and molecular characterization of STK11 loss  
 
Abstract 
STK11 loss occurs in 30% of lung adenocarcinoma patients.  Being able to identify patients with this 
genetic abnormality as well as understand its role in tumor progression is of great importance.  In this 
study we add STK11 back to cell lines with STK11 loss of function: A549, NCIH1437, and NCIH1944.  We 
attempt to recapture increases in expression of ODC1 as a result of STK11 loss.  We determine that this 
hallmark of STK11 loss biology is not sufficiently captured in vitro.  Additionally, we discover that STK11 
loss in vitro provides resistance to hypoxic signaling through cobalt chloride treatment, sensitivity to 
immune response through interferon gamma, and impacts the sensing and uptake of nutrients glucose 
and glutamine.  We additionally explored siRNA of STK11 in STK11 wildtype cell lines maintaining ATII 
identity as well as mouse xenograft models of A549 EV and 50kD wildtype cells.  Neither of these models 
were capable of recapturing gene expression changes as they occur in vivo. Finally, through IHC we 
confirm that KIT is a biomarker of STK11 loss in vivo and could have clinical use in the detection of 
patients with STK11 loss of function. 
Introduction 
STK11 loss of function occurs in over a third of lung adenocarcinoma patients.  With such a high 
prevalence it is important that we uncover vulnerabilities resulting from its absence.  Mutations in 
STK11 are associated with lack of immune infiltration and response to immunotherapy [47-49, 65, 66, 
172]. One of the pathways altered by STK11 and suspected to mediate this lack of immune response is 
the polyamine pathway driven through the rate limiting enzyme ornithine decarboxylase I (ODC1).  
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Oddly, only in patient tumors does ODC1 remain elevated as a result of STK11 loss, making it difficult to 
study and manipulate outside the human body.  This study focuses on attempts at restoring the STK11 
loss phenotype of polyamine metabolism in vitro while uncovering potential vulnerabilities of STK11 
loss.  In order to accomplish this we successfully cloned STK11 and ODC1. Throughout this study we use 
qPCR, western blotting, viability assays, and Seahorse metabolic flux assays to determine the impact of 
various treatments and conditions on our genetically modified cell lines.  
Utilizing the following STK11 mutant cell lines: A549, NCI-H1437, and NCI-H1944, we added back wild 
type STK11 and used these as direct controls.  Since STK11 loss has such a strong role in metabolic 
regulation, we believe that changes in culture conditions could explain the discrepancies between 
patient tumors and cell lines.  We modified glucose, amino acid, fetal bovine serum (FBS), and oxygen 
concentrations in attempts to recapture the in vivo phenotype of polyamine biosynthesis and amino 
acid catabolism. Given that polyamine metabolism overlaps with the methionine salvage pathway [98, 
173] and methylation [83] we manipulated methionine and cysteine levels individually and combined 
with glutamine availability to determine if this would shift metabolic flux through the polyamine 
pathway. Other experiments focused on prolonged fasting, glucose deprivation, and amino acid 
starvation in the context of STK11 loss.  
In addition to modifications to cellular nutrient availability we explored a myriad of drugs capable of 
recapturing in vivo biology such as: interferon gamma, dexamethasone, and cobalt chloride. Interferon 
gamma, is a pleiotropic molecular that has been shown to have apoptopic, antiproliferative, and 
antitumor effects [174, 175]. It is released by immune cells during periods of cytotoxic and 
proinflammatory response and is significantly decreased in STK11 mutant tumors. Cobalt chloride is a 
synthetic stabilizer of HIF1A and inducer of hypoxia [176, 177]. Dexamethasone is a corticosteroid and 
has been associated with cellular differentiation of type II pneumocytes in the lung [178, 179].   Finally, 
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we identify novel biomarkers capable of predicting in vivo STK11 loss and attempt to explore these 
biomarkers in vitro.   
Results 
Cloning of STK11 and ODC1 
In order to modulate the expression of our genes of interest, we cloned cDNA sequences of STK11 and 
ODC1 into lentiviral vector with expression driven through the cytomegalovirus (CMV) promoter.  This 
construct was further transduced into A549 cells to generate 4 unique cell lines, A549 STK11 (50kD WT), 
A549 STK11 (42kD) lacking a kinase domain, A549 Empty Vector (EV), and A549 ODC1. We validated 
successful cloning through western blot of A549 cells with both STK11 and ODC1 running at roughly 
50kD as expected (Figure 4.1). The A549 STK11 42kD was not used further in experimentation. 
 
Figure 4.1 Validation of cloning of STK11 and ODC1 in A549 cells     
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A549 cells transduced with empty vector (EV), ODC1, STK11 42kD lacking a kinase domain, and STK11 
50kD wildtype protein. 
STK11 alone doesn’t influence ODC1 expression in A549 cells 
One of our first observations was that stable transduction of STK11 mutant cell lines with wild type 
STK11 did not result in gene expression changes seen in patient tumors, most notably in ODC1.  
Likewise, biomarkers such as LINC00473 were drastically reduced through expression of wild type STK11 
(Figure 4.2).  We validated this lack of gene expression change through western blotting and discovered 
that ODC1 protein levels did not increase as a result of STK11 loss and were slightly elevated in the wild 
type.  Since STK11 is a mediator of metabolism and the stress response, we explored various stressors in 
order to recapture and study this patient phenotype.      
 
Figure 4.2 STK11 addition to mutant cell lines does not restore patient phenotype 
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Diminished nutrients does not alter ODC1 expression in vitro 
Given that STK11 is a sensor of low energy, we hypothesized that prolonged growth in tissue culture 
medium, diminished amino acid availability, glucose levels, or fetal bovine serum could explain 
differences in ODC1 expression.  Since tissue culture media such as RPMI or DMEM contain much higher 
levels of nutrients than those seen in a tumor, we explored the impact that different nutrients could 
have in STK11 dependent regulation of expression. To our surprise, prolonged growth in unchanged 
tissue culture media for up to two weeks did not result in changes in ODC1 expression in an STK11 
dependent manner in NCIH1437 cells (Figure 4.3).  Glucose, amino acid levels, and fetal bovine serum 
were also not sufficient to recapture ODC1 overexpression seen in patient tumors. KIT, a common 
marker of STK11 loss was also assessed as it was also not increased in cell lines as a result of STK11 loss. 
 
Figure 4.3 Fasting does not restore patient phenotype in cell line constructs 
 
STK11 loss sensitizes cells to interferon gamma treatment 
We treated A549 cells with interferon gamma to assess the impact on cell viability, gene expression 
changes and protein changes of ODC1. First, dose response curves were generated by measuring 
changes in total cell count, using the Celigo for counting of viable cells.  From 5ng/mL upwards there is a 
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significant reduction in both the A549 EV and ODC1 constructs relative to the 50kD STK11 in total viable 
cells relative to control. There was fairly consistently a difference of 20% in cell viability at all 
concentrations exceeding 5ng/mL of interferon gamma at both 48 and 96 hours (Figure 4.4A-B).   
 
Figure 4.4 Sensitivity of A549 cells to Interferon gamma at 48h  
(a-b) A549 cells (EV, STK11 (50kD), and ODC1) treated with varying concentrations of interferon gamma 
at 48 hours (a) and 96 hours (b)  
 
Interferon gamma increases ODC1 expression but not protein in STK11 loss cells 
Using the viability assay we determined a functional concentration of interferon gamma that displayed 
changes between A549 EV (mutant) and STK11 (50kD wildtype). We then treated the cells for 48 hours 
with 25ng/mL interferon gamma and isolated both protein and RNA.  We ran western blots and qPCR to 
test for changes in ODC1 protein and gene expression.  In addition to interferon gamma, we explored 
the impact that DFMO, an irreversible inhibitor of ODC1, would have on its expression in either single or 
combination treatment with interferon gamma.  Interestingly, interferon gamma caused an increase in 
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ODC1 gene expression in the STK11 mutant A549 EV, but a significant reduction in protein expression 
relative to the wild type (Figure 4.5A-B). As expected, DFMO caused a feedback response of an increase 
in ODC1 protein (Figure 4.5A).  LINC00473 was used to validate STK11 function in vivo as seen in Figure 
4.5B.   
 
Figure 4.5 Interferon gamma increases ODC1 gene expression but not protein in STK11 loss A549 cells 
(a) Western blot of A549 variants treated with 25ng/mL interferon gamma, DFMO, and combination of 
both (b) qPCR of A549 cells treated with 25ng/mL interferon gamma at 48hours 
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STK11 loss provides resistance to hypoxic signaling 
We sought to explore the possibility that the induction of hypoxic response could be a factor 
distinguishing in vivo models from those in vitro.  Cobalt chloride is used to stabilize HIF1A and induce a 
hypoxic response. We hypothesized that since atmospheric oxygen is at a concentration of nearly 20% 
while tumors range from 1-5% that this change could result in changes to oxidative stress response 
pathways such as polyamine metabolism.  We treated both A549 and NCIH1944 cells with (1x = 500uM) 
Cobalt chloride for 48 hours at concentrations varying by 3 fold and 2 fold respectively.  In both 
instances, the mutant empty vector had a significant increase in viability relative to the STK11 wildtype 
(Figure 4.6A-B).    
 
Figure 4.6 STK11 loss provides resistance to hypoxic signaling through cobalt chloride 
(a-b) A549 (a) and 1944 (b) cells at 48hours treated with cobalt chloride  
 
Glutamine is required for ODC1 protein expression dependent of STK11 loss 
Glutamine is an amino acid essential for cellular growth in vivo, and is also the precursor of ornithine 
synthesis through the enzyme ornithine aminotransferase (OAT). We hypothesized that perhaps the 
increased ODC1 levels seen in patients was due to the scarcity of precursors of either polyamine 
metabolism or methionine salvage through methionine and cysteine.  In order to further dissect the 
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impact of these metabolites, we cultured A549 cells in dialyzed FBS with media lacking glutamine, 
methionine, and cysteine.  We added back each of these metabolites and grew cells for 48 hours.  
Shockingly, in media conditions lacking methionine and cysteine but with added glutamine, ODC1 
protein expression was elevated in the mutant EV cells but not in the wildtype (Figure 4.7).  Upon 
removal of glutamine, ODC1 protein was also reduced in the EV cells. 
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Figure 4.7 Glutamine in the absence of methionine and cysteine increases ODC1 protein in A549 cells 
with STK11 loss 
(a) Western blot of A549 cell variants EV and 50kD STK11 wildtype 48 hours following the above nutrient 
conditions (b) qPCR of the RNA harvested from the same conditions in (a) 
 
STK11 loss impacts glutamine sensitivity 
To further study the relevance of glutamine sensitivity in the context of STK11 loss, we subjected A549 
cell line variants to seahorse assays to determine the impact of glutamine on oxygen consumption and 
metabolic capacity.  Glutamine injections increase the relative oxygen consumption of A549 EV cells at a 
much more rapid rate than cells with wildtype STK11 (Figure 4.8).  This suggests that STK11 loss either 
allows for the more rapid consumption of glutamine or heightens the cells sensitivity to its withdrawal.  
 
Figure 4.8 STK11 loss increases glutamine uptake and dependence 
Seahorse assay with the injection of glutamine to a final concentration of 1mM in A549 EV and 50kD 
STK11 wildtype cells 
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STK11 loss impacts nutrient sensing 
We next wanted to determine whether or not STK11 loss had an impact on the sensing and uptake of 
available nutrients from the environment.  In order to answer this question, we serially diluted both 
glutamine and glucose levels in a 96 well plate for both the STK11 EV mutant and 50kD wildtype A549 
cell lines.  Both cell lines had decreased cellular growth upon diminishment of either glucose or 
glutamine.  However, what was remarkable was the rate at which the 50kD wildtype cell line was able to 
properly sense nutrients at a lower concentration (Figure 4.9 A-B).  This suggests that STK11 loss hinders 
a cells ability to detect low levels of nutrients and instead allows them to grow at an optimum rate as 
long as they are above a minimum threshold.  This could partially explain the increase in oxygen 
consumption seen earlier through glutamine injection, as STK11 loss could serve to lift inhibitory 
mechanisms of metabolic capacity.    
 
Figure 4.9 STK11 loss impairs low concentration sensing of glucose and glutamine 
(a-b) Relative viable cells compared to control at 48 hours with altered glutamine concentrations and 
glucose concentrations relative to normal media in A549 EV cells (a) and STK11 wildtype (b) 
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siRNA of STK11, KEAP1, and NKX2-1 in H441 cells 
In order to circumvent the cell lineage loss mentioned in chapter 3, we identified a cell line (NCIH441) 
that maintained cellular identity through NKX2-1.  This cell line was wildtype for STK11 and had a known 
mutation in TP53.  We utilized a siRNA for both STK11 and KEAP1 to determine whether knockdown of 
STK11 in a cell line that maintained ATII identity would increase ODC1 expression (Figure 4.10).  KEAP1 
siRNA was used as a control to elucidate the role of STK11 loss, given that these two mutations have 
high co-occurrence in lung adenocarcinoma.  Cell pellets were harvested at 24, 48, 72, and 96 hours 
following siRNA treatment.  At 96 hours, STK11 was almost undetectable by western blot.  However, 
there was no increase in ODC1 or KIT, both of which are biomarkers of STK11 loss in vivo.  There was no 
notable change in NKX2-1 expression following knockdown of STK11.  Knockdown of KEAP1 resulted in 
partial reduction of NKX2-1.  We conclude that knockdown of STK11 through siRNA is either not capable 
of mimicking the STK11 loss phenotype or that this model system still falls short of recapturing patient 
biology. 
 
Figure 4.10 siRNA of NCIH441 cells for STK11 and KEAP1 
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Xenografts of EV and STK11 wildtype A549 cells 
NSG mice were used as hosts for the flank injection of EV and STK11 50kD wildtype cell line variants of 
A549 cells.  Following tumor extraction, RNA was harvested and tested for changes in genes known to 
be altered through STK11 loss in vivo.  As expected, LINC00473 was extremely significantly elevated.  
However, ODC1 expression was not significantly elevated (Log2 change of 0.25) (Figure 4.11). This data 
suggests that xenograft models and the tumor microenvironment are not sufficient to induce the same 
expression patterns seen in patient samples.   
 
Figure 4.11 Xenografts do not restore patient phenotype of STK11 loss 
A549 EV (blue) and 50kD STK11 WT (red) xenograft tumors harvested from NSG mice 
 
c-KIT is a biomarker of STK11 loss in vivo 
Biomarkers for STK11 loss are highly relevant, as only 50% of patients with STK11 loss are actually 
detected through DNA sequencing alone (Chapter 2). Clinically, biopsy material is subjected to 
measurement to aid diagnosis, prognosis, and to predict response to therapy. We first observed that c-
KIT expression was highly associated with STK11 loss through analysis of TCGA’s reverse phase protein 
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array (RPPA) (Figure 4.12 A-B) with our signature for STK11 loss (p=1.14e-24). In validation of this result 
we stained our tissue microarray of 150 patients (TMA150) with a c-KIT antibody and calculated percent 
pixel positivity (Figure 4.12 C) (p=2.53e-10). KIT, or c-KIT, is a proto-oncogene and receptor tyrosine 
kinase that has been shown to result in oncogenic growth upon its over-expression in melanoma, lung 
cancer, and gastrointestinal cancers.  A noteworthy observation is that KIT is most commonly associated 
with GIST (Gastrointestinal stromal tumors) and activating mutations in KIT account for more than 85% 
of all GIST tumors [180].  This is striking because STK11 germline mutations result in a condition known 
as Peutz-Jeghers syndrome (PJS), a disease characterized by a predisposition for the development of 
hamartomatous polyps in the gastrointestinal tract [50, 51]. Elevated both transcriptionally and 
translationally, c-KIT is one of the best single clinical biomarkers for STK11 loss of function (Figure 4.12 
A-B).  It is uncertain whether or not c-KIT is functionally relevant in the context of STK11 deficient lung 
adenocarcinoma but provides prognostic value in classification of patients and potentially response to 
immunotherapy. 
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Figure 4.12 KIT is a biomarker of STK11 loss 
Discussion 
In this study we transduced wildtype STK11 into cell lines with STK11 loss: A549, NCIH1437, and 
NCIH1944.  We describe that in vitro ODC1 expression is not altered through modulation of STK11 
expression or through various conditions of metabolic stress.  We discovered conferred resistance to 
hypoxic response through cobalt chloride and sensitivity to interferon gamma as a result of STK11 loss.  
STK11 loss was shown to increase glutamine sensitivity and consumption while hindering the utilization 
of low concentrations of both glucose and glutamine.  Finally, we conclude that KIT is a viable biomarker 
of STK11 loss in vivo.   
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A remarkable aspect of reconstitution of STK11 expression in mutant cell lines was how selective its 
uptake was.  Cell lines (NCIH: 1395, 2126) without a potent oncogenic driver such as KRAS or TP53 were 
incapable of surviving STK11 addition. Both A549 and NCIH1944 contain mutations in STK11 and KRAS 
while NCIH1437 has a mutation in both STK11 and TP53.  Cell lines that managed to express STK11 and 
survive had notable changes in their morphology as they were much more mesenchymal and elongated. 
In addition to interferon gamma and cobalt chloride, we tested many other compounds for changes in 
ODC1 expression and overall cell growth.  Metformin (an activator of AMPK), resveratrol, protein kinase 
C agonists (PKC) (upstream of STK11), 5-azacytidine (demethylating agent), dexamethasone, calcium and 
potassium, glucose, atmospheric oxygen concentration, and essential amino acids had no impact on 
ODC1 expression or cell viability with respect to STK11 status.  These results further bring us to the 
conclusion that in vitro cultures of STK11 loss undergo cell lineage differentiation that is no longer 
comparable to in vivo patient tumor biology.   
It is interesting that STK11 loss results in sensitivity to interferon gamma.  Taken together with the lack 
of immune infiltration seen in STK11 mutant patients and lack of response to immunotherapy, these 
tumors could be extremely sensitive to the restoration of an anti-tumor immune response.  Originally, 
we hypothesized that methylation change and epigenetic silence could influence the expression of ODC1 
expression.  Treatment with 5-azacytidine had no impact on its expression (data not shown), suggesting 
that this regulatory mechanism of gene expression is far more complex.  In order to rule out the 
possibility that other downstream pathways independent of STK11 could be contributing to ODC1 
expression we treated cell lines with activators of PKC, AMPK, and CAMK.  We also hypothesized that 
ODC1 upregulation could be in response to diminished methionine levels that would otherwise be 
restored through the methionine salvage pathway.  Methionine deprivation alone had no impact on 
ODC1 levels with respect to STK11 status.  Finally, we tested whether amino acid catabolism and the 
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urea cycle could be a result of a starvation response in the tumor as a result of decrease nutrient 
availability.  Serum, glucose, or amino acid deprivation in any combination did not result in the 
restoration of the patient phenotype of ODC1 upregulation.  
STK11 loss also impacted cellular growth and division at varying concentrations of glucose and 
glutamine.  At low concentrations A549 cells with STK11 loss grew as though there were no nutrients at 
all while STK11 wildtype variants were able to slow cellular division in accordance to nutrient availability.  
STK11 loss results in very polarized cell growth that may be advantageous above a certain threshold of 
nutrient concentration but detrimental at ones below that.  Given that patient tumors with STK11 loss 
show upregulation of amino acid catabolism (Chapter 2) suggests that these tumors may be tapping into 
starvation induced response while ignoring negative effects of slowed proliferation and apoptosis.   
In conclusion, our attempts at studying the impact of STK11 loss on ODC1 function display the 
limitations of in vitro work, especially in the context of metabolism. While STK11 loss spans many 
biological functions and aids in tumor progression, certain aspects of STK11 loss appear to be specific to 
cellular lineage (Chapter 3).  Further studies should be performed from fresh patient tumor samples in 
order to more accurately depict patient biology.    
Materials and Methods 
Molecular cloning 
STK11 
WT STK11 was ordered from Addgene (pcDNA3-FLAG-LKB1, Plasmid #8590) and constructs were made 
for both 42kDa mutant and 50kDa WT isoforms. To produce the 42kDa mutant isoform of STK11, a 
forward (GACTGGATCCGACGCC) and reverse (GGCCGCGAATTC) primer were used for PCR. The isolated 
product was then sub-cloned into pENTR1A destination vector. The resulting plasmid was then 
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recombined into pLenti-CMV-Puro and virus was produced. To produce the 50kDa WT STK11 isoform, 
the WT sequence was sub-cloned into pENTR1a. This plasmid was then recombined into pLenti-CMV-
Puro and virus was produced. 
ODC1 
ODC1 ORF Vector (Human) (pORF) was ordered from abmgood (cat# ORF007352, lot#ML8154). The 
ODC1 insert was sub-cloned into pENTR1A destination vector. This plasmid was recombined into pLenti-
CMV-Puro and virus was produced.  
qPCR 
For mRNA quantification, equal amounts of cDNA were synthesized from extracted total RNA samples 
using a Bio-Rad iScript cDNA Synthesis Kit (1708890). The cDNA was combined with 2x PerfeCTa SYBR 
Green SuperMix (Quantabio), respective forward and reverse primer, and loaded onto Bio-Rad 
Multiplate PCR Plates (Cat. #MLL9601). 18S was amplified in each sample for loading control and 
standardization. 
 
qPCR Primers 
Target Forward Sequence Reverse Sequence 
CX3CL1 ACCACGGTGTGACGAAATG TGTTGATAGTGGATGAGCAAAGC 
GPT2 TCCTTCCACTCCACCTCCAA TCAGGGTGCAGGTTGATCAC 
LINC00473 AGGCGGTTCCACCTTCTAAT CAGCTACTTGCCAACAACCA 
ODC1 AGATCACCGGCGTAATCAAC CGGGCTCAGCTATGATTCTC 
18S GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
 
IHC staining 
Slides were stained using a Leica Bond RX automated system (Leica Biosytems, Buffalo Grove, IL) per the 
manufacturer's protocol with proprietary reagents. Briefly, slides were deparaffinized on the automated 
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system with Dewax Solution (Leica).  Heat induced antigen retrieval was performed using Epitope 
Retrieval Solution 2. The rabbit primary antibody that reacts to CD117 (#117R-14, Cell Marque, Rocklin, 
CA) was used at a 1:100 concentration in Dako diluent (Carpenteria, CA) and incubated for 25 min. The 
Leica Bond Polymer Refine Detection System was used.  Post primary was incubated for 8 min.  Polymer 
was used for 8 min.    Slides were then counterstained with Hematoxylin.  Slides were dehydrated and 
cover slipped per normal laboratory protocol. 
Scoring of tissue microarray (TMA) slides was accomplished by using Leica Biosystems Aperio eSlide 
Manager online software.  Each core of the TMA was segmented and used to calculate percentage of 
positive pixels for the respective stain, as we have previously described [116].   
Interferon gamma and cobalt chloride 
Interferon gamma was ordered from Thermo Scientific (Lot #SK2477231) and diluted in tissue culture 
purified water to a concentration of 100µg/mL.  Cells were treated with various concentrations of 
interferon gamma in a 96 well plate. Cobalt chloride was ordered from MP Biomedicals, LLC                 
(CAS #7791-13-1) and diluted in tissue culture purified water to a concentration of 100mM. 
Tissue culture and cell lines 
The following cell lines were acquired from the Moffitt Cancer Center cell line repository: A549, 
NCIH1437, and NCIH1944. Cells were grown in standard RPMI with 10% fetal bovine serum (FBS) unless 
amino acid or glucose levels were altered in which case dialysed FBS (dFBS) was used in order to avoid 
supplementing the nutrients we were removing. Cells were grown in a tissue culture incubator at 5% 
CO2 for the allotted time points.   
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Seahorse assays 
The seahorse XF96 analyzer was used for this experiment (https://www.agilent.com/en/products/cell-
analysis/seahorse-analyzers/seahorse-xfe96-analyzer). A549 cells were plated at a density of 5,000 cells 
per well of seahorse XF 96 well cell culture microplate and allowed to adhere overnight for 24 hours. 
Seahorse XF calibrant solution was added to each well of the 96 well sensor cartridge and placed in a 
non CO2 incubator overnight. One hour prior to the experiment, the media was replaced with Seahorse 
XF RPMI medium and injection ports were loaded at a 10x concentration.  Seahorse Wave software was 
used for the analysis of the results.   
Celigo image analysis 
The Celigo imaging cytometer (https://www.nexcelom.com/nexcelom-products/cellometer-and-celigo-
image-cytometers/celigo-imaging-cytometer/) was used to count cells stained with a final concentration 
of 1uM Hoechst. Cells were plated at a concentration of 5,000 cells per well of a 96 well plate. 
RNA extraction 
For harvesting, cells were trypsinized, spun down for 5 minutes at 1,500 RPM (4˚C), and resuspended in 
RLT Buffer (Qiagen, Lot #160019989) supplemented with β-mercaptoethanol (Sigma-Aldrich, Lot 
#79296HMV). A Qiagen RNeasy Mini Kit (Cat. #74104) was used for total RNA extraction. 
Protein extraction 
A cell scraper was used to harvest cells. The cells were spun down for 5 minutes at 1,500 RPM (4˚C) to 
make cell pellet. A total protein lysate was extracted by resuspending cell pellet in RIPA Buffer            
(Cell Biolabs, INC. AKR-191) + Protease and Phosphatase Inhibitor Cocktail (Sigma-Aldrich, Lot# 
117M4185V), incubated on ice for 20 minutes and vortexed 4-5 times regularly, and centrifuged for 20 
minutes at 14,000 RPM (4˚C). 
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Chapter 5: Transcriptional, proteomic and metabolic characterization of lung adenocarcinoma 
 
Abstract 
Lung adenocarcinoma is the most common histological subtype of lung cancers.  In this study, we 
characterize a cohort of 123 lung adenocarcinoma patients.  We associate gender, smoking, survival and 
common driver mutations (EGFR, KEAP1, KRAS, STK11, and TP53) with comprehensive gene expression, 
proteomic and metabolic measurements.  Additionally, we classify patients based on interferon and 
inflammatory signaling and further characterize these cohorts.  From the metabolite, protein, and gene 
expression datasets we used principal component analysis (PCA) to transform the data into the top ten 
components and assessed these transformations in each of the predefined cohorts. These components 
were described using Gene Set Enrichment Analysis (GSEA) for both mRNAs and proteins and a Python 
based metabolic pipeline (mummichog) for metabolites. There were significant relationships between 
genetic drivers, immune signatures, and our generated components. This study uncovers novel 
molecular associations between multi-dimensional molecular data with the potential for hypotheses 
that could ultimately lead to targeted therapeutic interventions. One of the most fascinating discoveries 
in this study is uniqueness of EGFR mutations compared to others.  Patients with EGFR mutations had 
significantly increased frequency in female gender over male, better prognosis, and were metabolically 
characterized by histidine metabolism and histamine production.  Furthermore, heightened 
inflammatory response predicted from gene expression was significantly enriched for pyrimidine 
metabolism and displayed elevated levels of pyridine-2,3-dicarboxylate, nicotinate, kynurenine, and 
putrescine. We conclude this study by generating prognostic signatures from the metabolomics and 
proteomics dataset. 
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Introduction 
Constitutive activation or amplification of oncogenes KRAS and EGFR are a hallmark of lung 
adenocarcinoma [181-183], while deletions and inactivation of tumors suppressors TP53, STK11, and 
KEAP1 are also commonly seen [10, 184-186]. A majority of patient tumors has at least one of these 
genetic abnormalities, while others either have no identifiable genetic abnormality or ones that are far 
less common such as: FRAS, BRAF, ALK, BRG1, CDKN2A and others. Up until now, the most 
comprehensive analysis of these genes corresponding to tumor initiation and progression has involved 
changes in gene expression through measurement of the abundance of mRNA transcripts.  Other studies 
such as TCGA have constructed cohorts of various tumor histology that contain a myriad of genetic 
information such as next generation DNA and RNA sequencing, copy number, methylation, and protein 
data.  While these studies have pioneered the field of multi-omics characterization, they have several 
limitations including: limited protein information (<300) through utilization of reverse phase protein 
arrays and a lack of metabolomics. 
We have previously described a cohort of approximately 150 lung adenocarcinoma patients (referred to 
as MLCom [116, 139], Moffitt Lung Complete) that includes clinical metadata, limited protein[116, 187, 
188] and LINC00473[129] expression data derived from a tissue microarray, driver mutation data in the 
form of Sanger sequencing and Affymetrix-based gene expression data [116, 126, 129, 139, 140, 187-
189].  Herein, we expand 123 patients of this cohort to also contain 6285 metabolite features and 5834 
proteins through use of liquid chromatography mass spectrometry (LS-MC). This unique cohort allows 
for the multi-omics analysis of gene expression, protein, and metabolite in the context of DNA 
mutations of TP53, KRAS, EGFR, and STK11 identified through Sanger sequencing. Additionally, 
alterations in STK11 and KEAP1 are much more accurately identified through gene expression 
signatures, which we will use in this study. To our knowledge, this is the largest cohort of lung 
adenocarcinoma that has been extensively profiled using LC-MS for proteins and identified metabolite 
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features. In this study we extend our understanding of lung adenocarcinoma through the analysis of 
gene expression, protein, and metabolite data with comprehensive and integrated analysis of DNA 
mutations, gender, smoking and overall survival. Using these methods, we detect novel proteins and 
metabolites associated with both genetic background and immune surveillance.  
Results 
Description of the dataset 
Clinical data 
Of the 123 patients, there were only 9 (7.32%) that reported to have never smoked while 94 (76.42%) 
had a history of prior smoking.  Gender was equally represented with 62 (50.40%) males and 61 
(49.60%) females.  Most tumors were early staged by pathology: stage 1 (52.03%), stage 2(17.07%), 
stage 3 (16.26%), stage 4 (5.69%), and unknown (8.94%). Sanger sequencing identified the following 
mutations: KRAS (43.08%), TP53 (33.33%), STK11 (28.45%), and EGFR (9.75%). Only 13 patients (10.57%) 
had no identifiable driver mutation. Through gene expression signature there were 51 (41.46%) patients 
with predicted STK11 and 38 (30.89%) with KEAP1 mutation (Figure 5.1A). The median follow-up time 
was 31.1 months of the 80 patients alive at the time of the last follow up, 40 patients had died with a 
median survival of 16.8 months.     
Metabolome 
Using LC-MS, 6285 metabolite features were extracted, 3151 as negative ions and 3134 as positive ions.  
Of these, 259 metabolite features were identified from our annotated library with 193 unique 
metabolites; the remaining 6026 features were analyzed as mass to charge (m/z) ratios (Figure 5.1B).  
Proteome 
Through LC-MS, we profiled 5834 proteins (Figure 5.1C).  Of the 5834 proteins, 2533 (43.4%) had 75-
100% coverage, 925 (15.6%) had 50-75% coverage, 1128 (19.3%) had 25-50% coverage, and 1247 
(21.3%) had 0-25% coverage (Figure 5.1D). Total coverage was seen for 831 proteins (14.2%).   
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Figure 5.1 The MLOS cohort of 123 patients with gene, protein and metabolite data 
(a) Explanation of the information available in the cohort with provided mutational frequencies (b) 
Metabolite peak height and variation across 6285 features (c) Protein expression and variation across 
5824 proteins (d) Coverage of proteins separated into bins by 10% 
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Clinical associations by mutation 
By gender, EGFR mutations were considerably more likely to be female (82.35%) than male (17.65%, 
p=0.0061). On the other hand, both STK11 mutations were enriched in males (66.66%) compared to 
females (33.34%, p=0.02, Figure 5.2A).  Mutational co-occurrence displayed that KEAP1 and STK11 
mutations were commonly found in the same patient (Figure 5.2B). EGFR mutations had the highest 
rate of co-occurring TP53 mutation while STK11 and KEAP1 were more likely to be TP53 wild type.  
Analysis of smoking status by mutation revealed an increased rate of EGFR mutations amongst non-
smokers (29.41%, p=1.0e-4), with no significant variation between the other characterized mutations 
(70-86%, Figure 5.2C).  There was a significantly better prognosis amongst patients who had an EGFR 
mutation compared to any other (p = 0.22, Figure 5.2D). 
 
Figure 5.2 Clinical features with respect to mutational frequency 
(a) Gender frequency by mutation (b) Mutational co-occurrence (c) Smoking history by mutation (d) 
Overall survival at 3 years by mutation 
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Molecular characterization by mutation 
In the sections that follow, each mutation whether identified through sequencing (EGFR, KRAS, and 
TP53) or gene expression signature (STK11 and KEAP1) was characterized by changes in gene expression, 
protein expression, and metabolite abundance.  The top 150 unique genes or proteins that changed the 
most were then enriched against MSigDB’s hallmark geneset while mummichog[190] was used to 
identify enriched metabolic pathways. Results of each analysis are tabulated, with gene set enrichment 
annotated by rank and metabolite by pathway associated p-value.   
TP53 
TP53 had the least significant changes to gene expression among the five mutations by p-value despite 
the large percentage of TP53 mutations in the cohort.  Top gene sets by gene expression included: E2F 
targets (FDR = 4.16e-56) and G2M checkpoints (FDR = 2.15e-54) (Table 5.1).  Proteins followed a similar 
pattern as gene expression as there was very minimal significance to their expression patterns.  Top 
changing proteins were enriched for E2F targets (FDR = 8.66e-8) and hypoxia (FDR = 7.18e-7) (Table 5.2).  
Metabolites were enriched in the pathways for the carnitine shuttle (p = 0.00011), fatty acid activation 
(p = 0.00576), and de novo fatty acid biosynthesis (p = 0.00938) (Table 5.3). 
EGFR 
EGFR had no significant gene sets that were enriched amongst its most significantly altered genes (Table 
5.1).  By protein, expression fatty acid metabolism (FDR = 2.7e-6), complement pathway (FDR = 1.06e-4), 
and coagulation (1.06e-4) were amongst the most enriched (Table 5.2). Notable changing proteins 
include a decrease in DSG2, NAMPT, CFL1, GOT1, and NNMT.  There was a significant increase in the 
proteins CTSH, ACAD8, and class II HLA molecules (DRA and DPA1) (Table 5.4A). Metabolically EGFR 
mutations were strongly associated with the TCA cycle (p = 0.105), histidine metabolism (p = 0.117), 
lysine metabolism (p = 0.0178), and caffeine metabolism (p = 0.0178) (Table 5.3). Altered metabolites 
include an increase in l-carnitine, pyridoxine, propionate, and histamine (Table 5.4B) 
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KRAS 
KRAS had a lower level of statistical significance to gene expression changes by raw p-value with most 
altered genes in the range of greater than 1e-10.  Top gene sets include coagulation (FDR = 3.69e-2) and 
apical junction (FDR = 3.69e-2) (Table 5.1).  By protein, apical junction was also enriched (FDR = 2.91e-3) 
and separately cholesterol homeostasis (FDR = 2.91e-3) (Table 5.2).  Metabolically, KRAS status was 
associated with arginine and proline metabolism (p = 0.128), n-glycan biosynthesis (p = 0.020), heparin 
sulfate degradation (p = 0.025), and glyocosphingolipid biosynthesis (p = 0.049) (Table 5.3). Due to the 
low significance of molecular characteristics we did not include them in a table. 
STK11 
STK11 had very strong gene, protein, and metabolite signatures.  By gene set enrichment, inflammatory 
response was the most significantly altered pathway (FDR = 1.04e-9) followed by early estrogen 
response (FDR = 3.65e-5) (Table 5.1).  Protein expression changes were enriched for xenobiotic 
metabolism (FDR = 7.9e-14) and interferon gamma response (FDR = 4.78e-11) (Table 5.2). Noteworthy 
increasing proteins include ASAH1, PGC, CPS1, ANXA1, and SFTPB (Table 5.5A). Metabolite enrichment 
revealed a significant alteration in the carnitine shuttle (p = 0.002), fatty acid metabolism (p = 0.025), 
glycosphingolipid metabolism (0.037), and arginine and proline metabolism (p = 0.044) (Table 5.3). 
Metabolites increased as a result of STK11 loss include increases in ethylmalonic acid, n-acetyl-GABA, 
putrescine, GABA and n-acetyl putrescine (Table 5.5B).  
KEAP1 
KEAP1 had the strongest gene and protein expression patterns.  Gene expression enrichment revealed 
changes to xenobiotic metabolism (FDR = 2.38e-16) and the reactive oxygen species pathway (FDR = 
1.14e-14) (Table 5.1).  Proteins were enriched for the exact same pathways: xenobiotic metabolism (FDR 
= 7.39e-21) and the reactive oxygen species pathway (1.64e-18) (Table 5.2). Notable increases in 
proteins include AKR1C1 and 2, UGDH, NQO1, and G6PD (Table 5.6A).  Metabolites shows the most 
drastic changes to aspartate and asparagine metabolism (p = 0.069) and glutathione metabolism (p = 
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0.062) (Table 5.3). Given that nearly 80% of patients with a KEAP1 mutation also have STK11 loss, there 
is a notable increase in STK11 related metabolites.  Taking this into consideration, there is an increase in 
hypotaurine and taurine and a decrease in creatine levels (Table 5.6B). 
Table 5.1 - Gene set enrichment of Hallmarks by Mutation  
Pathways EGFR KEAP1 KRAS STK11 TP53 
Xenobiotic Metabolism - 1 - - - 
Reactive Oxygen Species - 2 - - - 
Fatty Acid Metabolism - 3 - - - 
MTOR Signaling - 4 - - - 
Glycolysis - 5 - - - 
Coagulation - - 1 - - 
Apical Junction - - 2 - - 
Myogenesis - - 3 - - 
TNFa signaling via NFKB - - 4 - - 
Inflammatory Reponse - - - 1 - 
Estrogen Response Early - - - 2 - 
IL2 STAT5 Signaling - - - 3 - 
Estrogen Response Late - - - 4 - 
Interferon Gamma Response - - - 5 - 
E2F Targets - - - - 1 
G2M Checkpoint - - - - 2 
Mitotic Spindle - - - - 3 
MYC Targets - - - - 4 
Spermatogenesis - - - - 5 
 
 
 
Table 5.2 - Protein set enrichment of Hallmarks by Mutation 
Pathways EGFR KEAP1 KRAS STK11 TP53 
Fatty Acid Metabolism 1 3 3 3 - 
Complement 2 - - - - 
Coagulation 3 - - - - 
Heme Metabolism 4 - - - - 
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MTOR Signaling 5 4 - 4 4 
Xenobiotic Metabolism - 1 - 1 - 
Reactive Oxygen Species - 2 - - - 
Glycolysis - 5 - - 3 
Apical Junction - - 1 - - 
Cholesterol Homeostasis - - 2 - - 
Protein Secretion - - 4 - - 
Unfolded Protein Response - - 5 - - 
Interferon Gamma Response - - - 2 - 
Interferon Alpha Response - - - 5 - 
E2F Targets - - - - 1 
 
Table 5.3 - Metabolic pathway enrichment by Mutation  
Pathways EGFR KEAP1 KRAS STK11 TP53 
TCA cycle 0.010547 0.350359 0.920227 0.852334 0.77431 
Histidine metabolism 0.011656 0.953568 0.993766 0.777195 0.959729 
Caffeine metabolism 0.017714 0.57737 0.391382 1 0.922912 
Lysine metabolism 0.017876 0.522299 0.124584 0.579914 0.76307 
Arginine and Proline Metabolism 0.064527 0.276891 0.012836 0.044627 0.24803 
Ascorbate and Aldarate Metabolism 0.091962 0.71747 0.683127 1 0.059395 
N-Glycan Degradation 0.162159 0.058939 0.128265 0.081248 0.406833 
Prostaglandin formation 0.162159 0.058939 0.128265 0.308533 1 
Fatty acid activation 0.220325 0.559385 0.544902 0.024852 0.005764 
De novo fatty acid biosynthesis 0.239734 0.963917 0.517662 0.178018 0.009384 
Carnitine shuttle 0.414751 0.580907 0.72206 0.002084 0.000106 
Glycosphingolipid biosynthesis 0.461507 0.310984 0.049598 0.579019 0.922912 
Aspartate and asparagine metabolism 0.601609 0.069876 0.141304 0.15978 0.442367 
Chondroitin sulfate degradation 0.816377 0.228423 0.024698 0.308533 0.131982 
Heparan sulfate degradation 0.816377 0.228423 0.024698 0.308533 0.131982 
N-Glycan biosynthesis 0.893793 0.182565 0.020323 0.764047 0.972508 
Glycosphingolipid metabolism 0.914322 0.645735 0.353905 0.037157 0.366433 
Glutathione Metabolism 1 0.061886 0.938117 0.333762 0.747941 
 
Table 5.4A - Top 20 EGFR related proteins by p-value 
Protein Description Log 2 change p-value 
DSG2 desmoglein 2 -2.02 2.55E-07 
NAMPT nicotinamide phosphoribosyltransferase -1.64 2.50E-06 
CTSH cathepsin H 1.66 3.73E-06 
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CFL1 cofilin 1 (non-muscle) -0.62 9.43E-06 
ACAD8 acyl-CoA dehydrogenase family member 8 1.95 1.17E-05 
EEF1B2 eukaryotic translation elongation factor 1 beta 2 -1.03 1.77E-05 
HLA-DRA major histocompatibility complex, class II, DR alpha 1.59 2.48E-05 
BCCIP BRCA2 and CDKN1A interacting protein -1.50 3.32E-05 
GOT1 glutamic-oxaloacetic transaminase 1, soluble -0.85 3.47E-05 
EEF1G eukaryotic translation elongation factor 1 gamma -0.87 3.63E-05 
MAPK8IP3 SPAG9  1.00 4.30E-05 
PPA1 pyrophosphatase (inorganic) 1 -0.69 4.40E-05 
NARS asparaginyl-tRNA synthetase -0.78 5.13E-05 
NNMT nicotinamide N-methyltransferase -1.52 6.42E-05 
HLA-DPA1 
major histocompatibility complex, class II, DP alpha 
1 
1.69 6.78E-05 
HSD17B8 hydroxysteroid (17-beta) dehydrogenase 8 1.51 8.03E-05 
PGM3 phosphoglucomutase 3 -1.09 8.71E-05 
ASNS asparagine synthetase (glutamine-hydrolyzing) -2.07 8.91E-05 
ZC3HC1 zinc finger, C3HC-type containing 1 2.25 9.97E-05 
NME1 NME/NM23 nucleoside diphosphate kinase 1 -0.94 0.000105 
 
Table 5.4B - Top 10 EGFR related annotated metabolites by p-value 
Metabolite Log2 change p-value 
L-CARNITINE 0.95 5.19E-06 
PYRIDOXINE 1.55 2.32E-05 
PROPIONATE 1.02 2.43E-05 
PUTRESCINE -1.41 5.23E-05 
BENZYLAMINE 1.41 5.44E-05 
HISTAMINE 2.31 8.16E-05 
D-FRUCTOSE 0.99 0.000277 
GLYOXYLIC ACID 1.19 0.000563 
D-SACCHARIC ACID;GALACTARATE 1.15 0.000658 
3-HYDROXYBENZYL ALCOHOL -0.07 0.000663 
 
 
Table 5.5A - Top 20 STK11 related proteins 
Protein Description Change p-value 
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 1.19 1.44E-08 
AKR1C1 aldo-keto reductase family 1, member C1 2.70 5.54E-08 
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PIR pirin 2.10 4.95E-07 
AKR1C2 aldo-keto reductase family 1, member C2 3.12 7.78E-07 
FASN DCXR-DT  1.23 7.93E-07 
DPYD dihydropyrimidine dehydrogenase -1.25 1.21E-06 
PPP1R18 protein phosphatase 1 regulatory subunit 18 -0.98 1.26E-06 
CPS1 carbamoyl-phosphate synthase 1 2.13 3.36E-06 
NAXE apolipoprotein A-I-Binding Protein 0.86 4.48E-06 
ANXA1 annexin A1 -1.01 4.61E-06 
PGC progastricsin (pepsinogen C) 3.96 5.31E-06 
GORASP2 golgi reassembly stacking protein 2 0.83 6.50E-06 
S100P S100 calcium binding protein P 2.34 6.66E-06 
COTL1 coactosin-like F-actin binding protein 1 -0.94 6.82E-06 
ACADVL acyl-CoA dehydrogenase, very long chain 0.88 9.20E-06 
UGDH UDP-glucose 6-dehydrogenase 1.15 1.04E-05 
PSMB9 proteasome subunit beta 9 -0.76 1.30E-05 
AKR1D1 aldo-keto reductase family 1, member D1 2.14 1.41E-05 
TACC2 transforming, acidic coiled-coil containing protein 2 1.23 1.45E-05 
SFTPB surfactant protein B 2.16 1.47E-05 
 
Table 5.5B - Top 10 STK11 related annotated metabolites 
Metabolite Log2 change p-value 
ETHYLMALONIC ACID 1.00 4.87E-08 
4-ACETAMIDOBUTANOATE 1.12 3.13E-07 
4-ACETAMIDOBUTANOATE 0.95 5.65E-07 
PUTRESCINE 1.19 6.90E-07 
4-AMINOBUTANOATE 0.85 2.11E-06 
N-ACETYLPUTRESCINE 1.12 3.33E-05 
URIDINE 0.66 9.02E-05 
URIDINE 0.60 0.00013 
2,6-DIHYDROXYPYRIDINE 0.49 0.00017 
PALMITATE 0.49 0.000263 
 
 
Table 5.6A - Top 20 KEAP1 related proteins 
Protein Description Log2 change p-value 
AKR1C1 aldo-keto reductase family 1, member C1 4.55 2.59E-22 
AKR1C2 aldo-keto reductase family 1, member C2 5.36 2.75E-19 
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UGDH UDP-glucose 6-dehydrogenase 2.15 6.19E-18 
AKR1D1 aldo-keto reductase family 1, member D1 3.78 1.30E-16 
NQO1 NAD(P)H dehydrogenase, quinone 1 3.49 1.54E-13 
CBR1 carbonyl reductase 1 1.97 1.22E-12 
G6PD glucose-6-phosphate dehydrogenase 1.69 1.30E-11 
GCLC glutamate-cysteine ligase, catalytic subunit 2.20 1.73E-11 
TXNRD1 thioredoxin reductase 1 1.86 2.32E-11 
ALDH3A1 aldehyde dehydrogenase 3 family member A1 4.13 2.39E-10 
TALDO1 transaldolase 1 0.81 3.23E-10 
AKR1B10 aldo-keto reductase family 1, member B10  4.52 8.19E-10 
PIR pirin 2.60 8.40E-10 
ME1 malic enzyme 1, NADP(+)-dependent, cytosolic 1.48 9.32E-09 
---  2.26 1.20E-08 
PPP1R18 protein phosphatase 1 regulatory subunit 18 -1.17 2.82E-08 
FASN DCXR-DT  1.44 3.97E-08 
IDH1 isocitrate dehydrogenase 1 (NADP+) 0.71 6.41E-08 
AKR1C3 aldo-keto reductase family 1, member C3 2.45 7.72E-08 
VAPA VAMP associated protein A 1.10 1.05E-07 
 
Table 5.6B - Top 10 KEAP1 related annotated metabolites 
Metabolite Log2 change p-value 
HYPOTAURINE 0.75 4.96E-05 
4-ACETAMIDOBUTANOATE 0.86 0.000361 
HYPOTAURINE 0.70 0.000579 
PUTRESCINE 0.89 0.000674 
4-ACETAMIDOBUTANOATE 0.69 0.000825 
4-METHYL-2-OXOVALERIC ACID 0.94 0.001009 
ETHYLMALONIC ACID 0.64 0.001603 
3-METHYL-2-OXOVALERIC ACID 0.69 0.003869 
TAURINE 0.24 0.00503 
CREATINE -0.49 0.018545 
 
Immune Signatures 
We used gene sets describing immune related signaling from MSigDB’s hallmark geneset.  Both 
inflammatory response and interferon gamma response gene sets contained 200 genes, with only 37 
genes overlapping between each pathway.  
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Interferon Gamma response 
Patients were clustered by gene expression into two distinct populations representing extremes of 
expression: interferon gamma low (n = 52) and high (n = 71) (Figure 5.3A).  Patients were further 
analyzed for changes in metabolite and protein abundance.  As expected proteins were enriched in 
interferon gamma (FDR = 2.09e-16) and alpha (FDR = 1.95e-12) response (data not shown). There was 
an increase in STAT1, GBP1 and 2, and PYCARD with a decrease in ALDH3A1 and AKR1C1 protein 
expression (Table 5.7A).  Butanoate metabolism (p = 0.0017) was the leading altered metabolic pathway 
(Table 5.9).  Followed by: lysine (p = 0.0035), tryptophan (p = 0.0176), and aspartate and asparagine (p = 
0.025) metabolism.   Interestingly, there was a significant increase in pyridine-2,3-dicarboxylate, 
nicotinate, kynurenine and betaine in patients with high interferon response (Table 5.7B). 
 
 
 
 
 
 
 
Table 5.7A - Top 20 proteins as a result of interferon gamma signaling high vs low 
Protein Description Log2 Change p-value 
GBP1 guanylate binding protein 1, interferon-inducible 1.73 2E-09 
HSPA1A HSPA1B heat shock protein family A/B (Hsp70) member 1A/B -0.56 6.08E-08 
GBP2 guanylate binding protein 2, interferon-inducible 1.41 9.2E-08 
STAT1 signal transducer and activator of transcription 1 1.34 1.21E-07 
PYCARD PYD and CARD domain containing 0.98 7.59E-07 
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LAP3 leucine aminopeptidase 3 0.64 9.07E-07 
EFHD2 EF-hand domain family member D2 0.98 9.86E-07 
PSME2 proteasome activator subunit 2 0.93 1.78E-06 
CBR1 carbonyl reductase 1 -1.29 2.45E-06 
ALDH3A1 aldehyde dehydrogenase 3 family member A1 -2.90 3.96E-06 
WARS tryptophanyl-tRNA synthetase 0.84 4.82E-06 
PSMB9 proteasome subunit beta 9 0.79 6.47E-06 
SAMHD1 SAM domain and HD domain 1 0.84 7.79E-06 
AKR1C1 aldo-keto reductase family 1, member C1 -2.25 8.37E-06 
CASP1 caspase 1 1.01 9.23E-06 
ALDH6A1 aldehyde dehydrogenase 6 family member A1 -1.23 9.27E-06 
PSME1 proteasome activator subunit 1 0.61 1.11E-05 
AKR1C2 aldo-keto reductase family 1, member C2 -2.81 1.16E-05 
LCP1 lymphocyte cytosolic protein 1 (L-plastin) 0.83 1.89E-05 
PTRHD1 peptidyl-tRNA hydrolase domain containing 1 -0.78 1.98E-05 
 
Table 5.7B - Top 14 metabolites as a result of interferon gamma signaling high vs low 
Metabolite Log2 change p-value 
PYRIDINE-2,3-DICARBOXYLATE 2.64 6.30E-08 
NICOTINATE 1.36 7.57E-07 
DL-KYNURENINE 1.39 6.05E-05 
BETAINE 0.55 0.002089 
TRANS-4-HYDROXYPROLINE 0.43 0.003047 
5,6-DIHYDROURACIL 0.59 0.003083 
3-HYDROXY-3-METHYLGLUTARATE 0.36 0.003874 
DEOXYCARNITINE 0.79 0.004679 
URACIL 0.62 0.00545 
SPHINGANINE 0.33 0.008811 
N(PAI)-METHYL-L-HISTIDINE 0.39 0.009837 
XANTHOSINE 0.43 0.010345 
L-GLUTAMIC ACID 0.36 0.012294 
THIAMINE 0.38 0.012406 
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Figure 5.3 Characterization and prognosis of immune signatures 
(a) Clustering of patients into interferon low (n = 52) (left) and high (n = 71) (right) (b) Clustering of 
patients into inflammatory low (n = 25) (left) mid (n = 47) (middle) and high (n = 45) (right) (c) Overall 
survival at 3 years for each of the 5 clusters mentioned previously 
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Inflammatory Response 
Likewise, the hallmark gene set for inflammatory response was also used to cluster patients.  This time, 
patients were clustered into 3 distinct populations: inflammatory low (n = 25), middle (n = 47), and high 
(n = 51) (Figure 5.3B).  Enrichment was further run on the proteins and metabolites altered between low 
and high subsets.  Hallmarks for proteins were again enriched in interferon gamma (FDR = 1.24e-12) and 
alpha pathways (FDR = 1.16e-9). Protein expression changes were very similar to interferon gamma 
response (Table 5.8A). Mummichog analysis of metabolites resulted in enrichment of pyrimidine 
metabolism (p = 0.0035), aspartate and asparagine metabolism (p = 0.064), and the urea cycle (p = 
0.067) (Table 5.9).  Many metabolites were changing similarly to interferon gamma response with key 
exceptions being a decrease in both putrescine and GABA (Table 5.8B).  Histamine and d-ornithine were 
also seen to be increased in patients with high levels of inflammation.   
Prognostic significance of immune signatures 
Surprisingly, amongst the two signatures for interferon response, low interferon signaling had a slightly 
better prognosis than high although not significant (p = 0.44) (Figure 5.3C).  Inflammatory signaling had 
a significant increase in survival amongst the patients who clustered in the “middle” cohort (p < 0.006) 
while both low and high inflammatory signaling resulted in a poor prognosis (Figure 5.3C). 
 
 
 
 
 
 
127 
 
Table 5.8A - Top 20 proteins as a result of inflammatory signaling high vs low 
Protein Description Log2 change p-value 
SAMHD1 SAM domain and HD domain 1 1.54 1.85E-08 
PSMB9 proteasome subunit beta 9 1.44 2.29E-08 
GBP1 guanylate binding protein 1, interferon-inducible 2.30 8.54E-08 
AKR1C2 aldo-keto reductase family 1, member C2 -4.81 8.73E-08 
PPP1R18 protein phosphatase 1 regulatory subunit 18 1.57 1.06E-07 
GBP2 guanylate binding protein 2, interferon-inducible 1.88 1.18E-07 
COTL1 coactosin-like F-actin binding protein 1 1.48 1.31E-07 
AKR1C1 aldo-keto reductase family 1, member C1 -3.66 3.02E-07 
SERPINB9 serpin peptidase inhibitor, clade B, member 9 1.19 5.86E-07 
LSP1 lymphocyte-specific protein 1 1.45 7.02E-07 
RAC2 ras-related C3 botulinum toxin substrate 2  1.62 8.33E-07 
ARHGAP25 Rho GTPase activating protein 25 1.63 8.51E-07 
EFHD2 EF-hand domain family member D2 1.37 2.22E-06 
OPTN optineurin 1.60 2.26E-06 
PYCARD PYD and CARD domain containing 1.36 2.46E-06 
CORO1A coronin, actin binding protein, 1A 1.34 2.52E-06 
AKR1D1 aldo-keto reductase family 1, member D1 -3.20 2.67E-06 
LAP3 leucine aminopeptidase 3 0.90 2.67E-06 
HSPA1A HSPA1B heat shock protein family A/B (Hsp70) member 1A/B -0.70 2.90E-06 
ALDH3A1 aldehyde dehydrogenase 3 family member A1 -3.88 3.09E-06 
 
Table 5.8B - Top 14 metabolites as a result of inflammatory signaling high vs low 
Metabolite Log2 change p-value 
PYRIDINE-2,3-DICARBOXYLATE 2.64 3.54E-07 
NICOTINATE 1.36 6.98E-05 
DL-KYNURENINE 1.37 0.000568 
PUTRESCINE -1.18 0.00058 
ETHYLMALONIC ACID -0.77 0.007168 
BETAINE 0.55 0.00895 
4-AMINOBUTANOATE -0.68 0.009208 
TRANS-4-HYDROXYPROLINE 0.43 0.010195 
DEOXYCARNITINE 0.79 0.013385 
L-ASPARAGINE 0.46 0.015596 
N-ACETYLPUTRESCINE -0.95 0.01624 
L-GLUTAMIC ACID 0.36 0.018254 
HISTAMINE 1.26 0.021956 
URACIL 0.62 0.026331 
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Table 5.9 - Metabolic pathways enriched through immune signatures 
Pathway IFNG Inflammatory 
Arginine and Proline Metabolism 0.048 0.157 
Aspartate and asparagine metabolism 0.025 0.064 
Butanoate metabolism 0.002 0.556 
Chondroitin sulfate degradation 0.043 0.479 
Glutathione Metabolism 0.041 0.769 
Heparan sulfate degradation 0.043 0.479 
Lysine metabolism 0.003 0.125 
Purine metabolism 0.596 0.070 
Pyrimidine metabolism 0.042 0.034 
Tryptophan metabolism 0.018 0.138 
Urea cycle/amino group metabolism 0.458 0.066 
 
Decomposition of metabolites, proteins, and gene expression 
To reduce the complexity of these datasets we utilized principal component analysis on the 
metabolomics, proteomics, and gene expression matrices.  Each dataset was reduced to the top 10 
principal components, which were further used to relate changes of each series of molecular data to 
one other.  Average principal component scores for each dataset were calculated between the 
molecular subtypes mentioned above. By gene expression, EGFR had a low expression of signature 1 and 
6. STK11 mutation was described through signature 6, and KEAP1 through signature 3 and 4 (Figure 
5.4A). KRAS and TP53 were not described well through the top 10 principal components by gene 
expression, as might be expected from the results of Table 5.1.  The protein components also described 
a variety of mutations.  EGFR had low signature 1 and 5, STK11 was high for signature 5, and KEAP1 was 
described through signature 3 (Figure 5.4B).  KRAS was described through a reduction in signature 2 
while signature 1 and 4 described TP5 status partially.  Metabolites were not as descriptive through 
principal component decomposition with component 1 and 2 describing EGFR mutations and STK11 
mutations partially (Figure 5.4C).  Gene expression component 2 accurately described both 
inflammation and interferon gamma response (Figure 5.4 A-B).  A variety of protein signatures were 
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altered by these same clusters (Figure 5.5 C-D).  Metabolic signatures 1 and 2 partially explained the 
inflammatory signaling (Figure 5.5E), while none sufficiently described interferon response (Figure 5.5F). 
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Figure 5.4  Component scores by mutation 
(a-c) Component scores by mutation for genes (a), proteins (b), and metabolites (c) 
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Figure 5.5  Component scores by immune signature 
(a-f) Component scores of genes (a-b), proteins (c-d), and metabolites (e-f) for both the 
inflammatory response clusters (a,c,e) and interferon gamma response clusters (b,d,f) 
Relationship and identification of components 
The top components were classified through gene set enrichment for both proteins and genes while 
metabolites were analyzed through mummichog.  The top 75 proteins and 300 genes by absolute 
principal component coefficients were analyzed for enrichment to the hallmark gene set used earlier 
(Table 5.10 and 11).  Metabolites were analyzed in a manner corresponding to their principal 
component score for pathway analysis (Table 5.12). The correlation matrix of the top 10 principal 
components of each dataset helps simplify the complex relationship between them (Figure 5.6A).  The 
strongest connectivity between components was seen between proteins and metabolites followed by 
genes and proteins.  The smallest correlations were seen between genes and metabolites. The most 
related gene components were component 1 with protein component 1 and gene component 8 with 
metabolite component 9.  Protein component 1 was highly associated with metabolite component 2.   
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Table 5.10 - Gene set enrichment of principal components 
Pathways PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 
PC1
0 
E2F  TARGETS 1 - - 3 - - - - 2 2 
G2M  CHECKPOINT 2 - 5 2 1 - - - 5 1 
MITOTIC  SPINDLE 3 - 1 1 - - - 4 4 - 
MYC TARGETS 4 - 2 4 - - - - 1 3 
MTORC1 SIGNALING 5 - - - - - - - - - 
ALLOGRAFT REJECTION - 1 - - - 1 1 - - - 
EPITHELIAL MESENCHYMAL 
TRANSINSITION 
- 2 - - - - 3 - - - 
INFLAMMATORY RESPONSE - 3 - - - 2 4 - - - 
COMPLEMENT - 4 - - - - - - - - 
INTERFERON GAMMA 
RESPONSE 
- 5 - - - 4 2 - - - 
TGF BETA SIGNALING - - 3 - - - - - - - 
PROTEIN SECRETION - - 4 - - - - - - - 
P53 PATHWAY - - - - 2 - - - - - 
APICAL JUNCTION - - - - - 3 - 1 - - 
KRAS SIGNALING - - - - - 5 - 3 - - 
TNFA SIGNALING VIA NFKB - - - - - - 4 - - - 
UV RESPONSE - - - - - - 5 5 - - 
APOPTOSIS - - - - - - 5 - - - 
XENOBIOTIC METABOLISM - - - - - - - 2 - - 
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Table 5.11 - Protein set enrichment 
Pathways 
PC_
1 
PC_
2 
PC_
3 
PC_
4 
PC_
5 
PC_
6 
PC_
7 
PC_
8 
PC_
9 
PC_1
0 
Coagulation 1       2           
Complement 2 4       4   
MYC Targets 3 1   3 1 1   1 1 2 
Heme Metabolism 4           
Xenobiotic Metabolism 5   4     4         
Glycolysis  2 5  3    5   
MTOR Signaling   3   1     4   2 5 
Epithelial Mesinchymal 
Transition 
 5      3    
Adipogenesis     1         2 3 4 
Fatty Acid Metabolism   2       1 
Oxidative Phosphorylation     3       5     3 
Interferon Gamma Response    2   2     
Interferon Alpha Response       4             
PI3K_AKT_MTOR Signaling    5        
Mitotic Spindle         4     4     
Reactive Oxygen Species     5       
E2F Targets           2         
G2M Checkpoint      3      
Androgen Response           5         
Protein Secretion       1     
IL2 STAT5 Signaling             3       
Unfolded Protein Response               5     
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Table 5.12- Metabolic pathways by principal component 
Pathway PC1 PC2 PC3 PC4 PC5 PC6 PC7 PC8 PC9 PC10 
Aminosugars metabolism 0.76 0.36 0.89 0.94 0.16 0.82 0.92 0.37 0.09 0.99 
Ascorbateand Aldarate Metabolism 0.35 0.01 1.00 0.13 1.00 0.73 0.61 0.01 0.96 0.03 
Aspartate and asparagine metabolism 0.10 0.00 1.00 0.00 0.01 0.98 0.00 0.78 0.36 0.87 
Bile acid biosynthesis 0.96 1.00 0.04 0.96 0.08 0.98 1.00 1.00 0.84 1.00 
Butanoate metabolism 0.04 0.00 0.93 0.08 0.02 0.62 0.29 0.87 0.57 0.80 
C5-Branched dibasic acid metabolism 1.00 0.54 1.00 1.00 1.00 1.00 0.05 1.00 0.70 0.32 
Carbon fixation 0.98 0.75 1.00 1.00 0.14 1.00 0.86 0.76 0.11 0.90 
Carnitine shuttle 1.00 1.00 0.67 1.00 0.00 1.00 0.99 0.02 0.48 1.00 
Chondroitin sulfate degradation 0.94 0.60 1.00 0.27 1.00 0.13 0.09 0.61 0.12 0.79 
De novo fatty acid biosynthesis 0.98 0.83 0.39 1.00 0.00 1.00 0.39 0.83 1.00 1.00 
Dynorphin metabolism 1.00 1.00 0.09 1.00 1.00 0.08 1.00 0.54 1.00 0.32 
Glycerophospholipid metabolism 0.45 0.90 0.51 0.47 0.00 0.41 0.35 0.30 0.34 1.00 
Glycine, serine, alanine and threonine 
metabolism 
0.14 0.23 0.94 0.01 0.27 0.81 0.49 0.82 0.96 1.00 
Glyoxylate and Dicarboxylate 
Metabolism 
0.90 0.75 1.00 0.01 0.14 0.64 0.08 1.00 0.61 1.00 
Heparan sulfate degradation 0.94 0.60 1.00 0.27 1.00 0.13 0.09 0.61 0.12 0.79 
Histidine metabolism 0.70 0.01 0.91 0.89 0.06 1.00 0.61 0.83 0.69 0.97 
Limonene and pinene degradation 0.71 0.21 1.00 0.01 1.00 0.41 0.73 0.04 0.38 0.00 
Linoleate metabolism 0.91 0.56 0.90 0.44 0.05 0.01 0.18 0.00 0.44 0.49 
Lysine metabolism 0.01 0.34 0.80 0.49 0.18 0.60 0.63 0.92 0.99 0.99 
Methionine and cysteine metabolism 0.06 0.03 0.98 0.15 0.00 0.87 0.44 0.06 0.71 0.28 
Mono-unsaturated fatty acid beta-
oxidation 
0.84 0.46 0.06 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Omega-3 fatty acid metabolism 1.00 0.71 0.21 0.77 1.00 0.08 0.83 1.00 1.00 1.00 
Phytanic acid peroxisomal oxidation 0.26 0.15 0.09 1.00 1.00 1.00 0.66 0.54 1.00 0.72 
Porphyrin metabolism 0.93 0.83 0.91 0.13 1.00 1.00 0.21 0.60 0.86 0.18 
Purine metabolism 0.83 0.18 0.95 0.64 0.35 1.00 0.44 0.59 0.05 0.67 
Pyrimidine metabolism 0.35 0.12 0.76 0.39 0.13 1.00 0.30 0.83 0.11 1.00 
Saturated fatty acids beta-oxidation 0.70 1.00 0.06 1.00 1.00 0.90 0.55 0.76 0.89 0.90 
TCA cycle 0.02 0.22 0.27 0.57 0.49 0.78 0.23 0.01 0.51 0.17 
Tryptophan metabolism 0.23 0.90 1.00 0.08 0.00 0.78 0.32 0.40 0.97 0.56 
Tyrosine metabolism 0.04 0.01 1.00 0.26 0.27 0.50 0.41 0.44 0.50 0.02 
Urea cycle/amino group metabolism 0.10 0.00 0.97 0.70 0.53 0.93 0.84 0.69 0.43 0.97 
Valine, leucine and isoleucine 
degradation 
0.03 0.02 0.86 0.14 0.30 0.74 0.76 0.68 0.83 1.00 
Vitamin B3 metabolism 0.53 0.60 0.91 1.00 0.01 0.89 0.39 0.07 0.06 0.74 
Vitamin K metabolism 0.60 1.00 0.01 1.00 1.00 1.00 1.00 1.00 0.38 1.00 
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Figure 5.6  Interconnectivity of the top 10 principal components of each dataset 
(a) Correlation matrix of the top 10 principal components from gene, protein, and metabolite datasets 
 
Prognostic classifiers from metabolomics and proteomic data 
Each protein and metabolite was tested for prognostic significance based on the top quarter, third, and 
half of expression.  The top 100 metabolites were clustered through K-means clustering to best classify 
patients (Figure 5.7A).  The two patient cohorts had an extreme difference in prognosis based on this 
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new classification (p = 1.59e-5) (Figure 5.7B). Proteins with a maximum log rank p-value of .05 between 
these three tests were used.  After this filter, 186 proteins remained and those with complete (100% 
coverage) were used to cluster patients (Figure 5.7C). While this prognostic signature was not as 
significant as the metabolite data, it still had significant difference in overall survival (p = 0.003) (Figure 
5.7D). 
 
Figure 5.7 Prognostic signatures from metabolites and proteins 
(a) Cluster of the top metabolites prognostically into a high and low risk subset (b) Overall survival of 
patients clustered in (a) (c) Cluster of the top proteins prognostically into a high and low risk subset (d) 
Overall survival of patients clustered in (c) 
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Discussion 
In this study we characterize a dataset of lung adenocarcinoma through gene expression microarray, LC-
MS metabolomics and proteomics, and clinical data containing overall survival. We emphasized analysis 
of canonical mutations throughout this study: EGFR, KEAP1, KRAS, STK11, and TP53. Additionally, we 
evaluated the dataset in the context of immune signatures for interferon gamma and inflammatory 
signaling.  The most drastic differences in clinical features resulted from EGFR status. Patients with EGFR 
mutations had significantly increased frequency in female gender over male, better prognosis, and were 
metabolically characterized by histidine metabolism and histamine production.  Furthermore, 
heightened inflammatory response predicted from gene expression was significantly enriched for 
pyrimidine metabolism and displayed elevated levels of pyridine-2,3-dicarboxylate, nicotinate, 
kynurenine, and putrescine. The top 10 unique signatures from principal components of each dataset 
were quantified amongst each mutational subtype and immune signature. These signatures were then 
correlated to help view the relationship between gene, protein, and metabolite.  Finally, from the 
proteomics and metabolomics data we generated a prognostic signature.  Both were capable of 
predicting outcome but the signature from metabolites was superior to that of the protein.    
This dataset could be used to generate a number of hypotheses.  Individual gene, protein, and 
metabolites were not analyzed but rather the decomposition of their matrices through principal 
component analysis.  The principal component method of matrix decomposition did not capture all the 
co-expression networks in this study but rather explained the most variance within the matrix itself. 
Future studies could utilize this dataset in order to better understand specific gene-protein-metabolite 
relationships or to look for any number of associations. Additionally, post translational modifications of 
proteins would add great value to this study should it be performed in the future.  
Generation of multi-dimensional molecular data will help us to uncover the complexity that exists within 
the development of cancer. Better understanding potential vulnerabilities or ways in which the tumor 
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could be influencing the microenvironment can help pave the way for novel therapeutic intervention.  
This study helps to analyze lung adenocarcinoma through use of gene, protein, and metabolite data and 
allows for the generation of hypotheses worthy of studying further in the lab.   
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Chapter 6: Final conclusions and future work 
 
Final conclusions 
Lung cancer remains to be the most lethal of any cancer. This work has all been motivated by the sincere 
desire to help those affected by this terrible disease, in hopes that through our increase in knowledge 
we may one day find a cure. 
In this dissertation we display the sheer complexity in the molecular adaptations that occur in cancer 
initiation and progression.  Various environmental factors, inherited traits, and risk factors all influence 
the histology and molecular subtype of cancer as suggested by our study in Chapter 1.  However, what is 
often overlooked or perhaps blissfully ignored is the difficulty in studying a heterogeneous, adaptive, 
and chaotic system in an elaborate environment such as the human body with countless extrinsic 
variables.  We illustrate in Chapter 2 - 4 the difficulty in studying a single mutation (STK11) outside the 
context of the human body.   
Classification of STK11 loss in the patient setting is limited by DNA sequencing as only half of all patients 
with functional loss are detected as shown in Chapter 2.  We developed a novel gene expression based 
signature of STK11 loss of function that was validated in two large datasets that can be applied clinically.  
Additionally, we provide evidence that KIT could be used as a standalone IHC biomarker of STK11 loss in 
Chapter 4.  Since KIT is highly associated with NKX2-1 and cell lineage preservation it may also serve as a 
more specific marker for lack of immunotherapy response. 
STK11 is a prime example of how intricate and interconnected cell state, metabolism, and immune 
surveillance are.  STK11 loss contributes to stress response and impacts nearly every cancer hallmark. 
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STK11 mutations are most commonly found in lung adenocarcinoma and large cell neuroendocrine 
carcinoma and are likely due to cell specific function highlighted in Chapter 3.  We have shown that 
STK11 is associated with increased polyamine metabolism and expression of its rate limiting enzyme 
ODC1, a pathway that has been strongly linked to immune suppression seen in Chapter 2.  We believe 
that STK11 loss in the patient tumor is contributing to immune evasion through the cell lineage specific 
conversion of putrescine to GABA through the enzymes MAOA and ALDH3A2 and that this immune 
suppression could be partially if not completely eliminated through ODC1 inhibition by DFMO.   
In Chapter 5 we relate untargeted LS-MC proteomic and metabolic data to gene expression microarray, 
providing novel insight to the relationship that each of these have to one another.  We also discover 
novel prognostic markers in this cohort that could be useful in a clinical setting. This data will be very 
useful for hypothesis generation and even uncovering vulnerabilities or dependencies related to a 
genetic phenotype.   
I hope that this work allows for the continuation and expansion of our understanding into the molecular 
complexity of lung adenocarcinoma.  With immunotherapy providing remarkable responses in the small 
few that reap its benefit, I hope that this work may increase the number of those that respond even 
further.  This dissertation has highlighted the great need for personalized medicine in a disease that has 
taken so many lives.  Cancer is constantly adapting and evolving and so must our technology and 
understanding of how to combat it. Through countless decades of research and the collaboration of the 
brightest minds may we one day put an end to this disease once and for all. 
Future work 
This dissertation helped to characterize various aspects of lung adenocarcinoma biology, including the 
impact that STK11 loss has on metabolism, immune surveillance, and cell lineage transition. While these 
are all very important it generates even more questions left to be answered.  
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One interesting experiment that would circumvent the lack of model system would be to deal directly 
with fresh patient tumor surgical resections. These tumors could be analyzed using flow cytometry for 
the distinguishing markers seen in vivo such as: NKX2-1, KIT, CALCA, ASCL1, and PD-L1. One interesting 
question would be to quantify the heterogeneity that exists within a patient tumor and to determine 
which cell type was contributing to changes in metabolism and gene expression through LC-MS and 
RNA-seq respectively. Patient tumors could be profiled additionally for immune cell infiltrates to 
characterize the immune cell populations that exist within each tumor and their respective expression 
patterns.  Tumor cells with STK11 loss could be sorted into classical, neuroendocrine, and negative 
subsets as described in Chapter 3.  The sorted cell populations could be further divided to profile 
intracellular metabolites and gene expression. This information would provide much greater insight into 
the heterogeneity within patient tumors and the contribution of distinct cell populations.  
While this aspect of studying patient tumors is vital, it limits our ability to manipulate various aspects of 
tumor biology through experimentation.  Given the known limitation of cell line, patient derived 
xenograft, and mouse models of STK11 loss future studies should focus on directly targeting NKX2-1 
positive type II pneumocytes for Cre induced STK11 deletion. Untargeted STK11 deletion of lung cells 
resulted in tumors that were of squamous lineage [30, 152].  In addition, mice should be exposed to 
chronic tobacco smoke in order to recapture the environmental conditions present in the initiation of 
human lung adenocarcinoma.  Assuming that this model accurately mimicked patient tumor biology, it 
would be fascinating to give mice labeled ornithine and measure the respective metabolites produced 
downstream.  If GABA and succinate are labeled, it would prove that ornithine is being used as a 
precursor for GABA synthesis and TCA cycle intermediates.   
Another area of future research would be to assess the impact that metabolites associated with STK11 
loss have on various immune cell populations.  Distinct immune cells such as antigen presenting 
dendritic cells, cytotoxic t-cells, and others should be screened by a library of STK11 associated 
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metabolites. Antigen presentation, anti-tumor response, viability, motility, and cytokine secretion 
should be measured through varying assays with this library.  This information would provide novel 
insight into the impact that metabolites have on distinct mechanisms of immune biology and could 
result in the generation of inhibitors targeting their synthesis. 
Additional work should also be performed in assessing the impact that ODC1 inhibition through DFMO 
treatment has with combination immunotherapy in patients with STK11 loss.  These patients currently 
do not respond to immunotherapy and have no targeted mechanism for their treatment.  We know 
about the immunosuppressive nature of the polyamine pathway, the increased production of polyamine 
related metabolites in tumors with STK11 loss, and the minimal toxicity associated with DFMO.  Given 
this evidence, a clinical trial should be initiated to assess the efficacy of this treatment to the current 
standard of care.   
The final area of work that could be done is the successful cloning of NKX2-1 into cell line constructs 
with the co-transduction of STK11 (Chapter 4).  STK11 appears to have a very intricate relationship to 
NKX2-1 and its signaling pathway, which also has neurological roots and has been shown to influence 
GABAergic signaling [26, 30, 67, 191].  We had noticed in previous work that the cell line NCIH1437 had 
a very distinct pattern of SFTPB protein expression that was dependent on STK11 status.  Further 
experimentation into the molecular mechanisms explaining the crosstalk between STK11 and NKX2-1 
should be explored.  It is likely that NKX2-1 influences hypoxic signaling and the oxidative stress 
response given that it is present in both the brain and lung, two organs that depend on very well 
regulated oxygen levels.  Not only this, but in data not shown NKX2-1 expression is highly associated 
with VHL mutations in kidney cancer, suggesting that it plays a role in HIF1A stabilization. Previous 
literature has highlighted the role of both AMPK and STK11 on hypoxia and oxygen sensing [192-194].  
This could shed light on the unanimous loss of NKX2-1 in ex vivo models of STK11 loss. 
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